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2. Summary 
 
The transcriptional regulation of developmental genes expression patterns in time, 
space and levels, is governed by cis-regulatory modules (CRMs). The activity of CRMs 
is controlled by transcription factor complexes that act as downstream mediators of 
signaling inputs. CRMs are associated with their target genes in chromatin domains 
with enhanced contact frequency, the so-called topologically associating domains 
(TADs). The incoming signaling cues are integrated into specific transcriptional 
outputs, which orchestrate development and differentiation. Limb bud development is 
one of the main molecular and cellular paradigms to study the roles of gene expression 
regulation during embryonic development. Limbs are external organs, easily 
accessible, largely dispensable for embryonic and postnatal survival and have 
adapted to numerous specific functions during vertebrate evolution, resulting in the 
high level of morphological diversity among vertebrates.  
 
The molecular pathways and morphogenetic events that govern limb patterning are 
largely conserved, reflecting their crucial roles in gene regulation during limb 
development. Our group previously identified and functionally analyzed the 
SHH/GREM1/AER-FGF epithelial-mesenchymal (e-m) self-regulatory signaling 
system that controls early limb bud outgrowth and patterning. The BMP antagonist 
Gremlin1 (Grem1) is one of the functionally most essential nodes in this system. Its 
spatio-temporal expression is regulated by the converging trans-acting inputs of the 
major limb bud signaling pathways. These inputs are integrated into the dynamic 
regulation of Grem1 expression by its 310 kb cis-regulatory landscape.  
 
For my Ph.D. research, I used the mouse Grem1 cis-regulatory landscape as a 
paradigm to study gene transcriptional regulation in the context of embryonic limb bud 
development. I identified and genetically analyzed the functionally relevant Grem1-
associated CRMs. To this end, I initially used reporter assays in transgenic mouse 
embryos to assess their potential enhancer activity. CRMs with established enhancer 
activities were then functionally studied by generating CRISPR/Cas9-engineered loss 
of enhancer function mutant mice. This, in combination with molecular analysis, was 
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used to assess their role(s) in the Grem1 transcriptional regulation. In addition, I used 
4C-seq assays to study the physical interactions among CRMs and the Grem1 
promoter, in wild-type and mutant mouse limb buds. I also addressed the question of 
the downstream consequences of enhancer deletions on limb bud development by 
tracking apoptosis and quantifying limb buds’ cellular proliferation. 
 
My studies revealed that the enhancer redundancy and diversity that regulates the 
Grem1 expression dynamics during mouse limb bud development was much more 
complex than the one-to-one correlation often described by others. None of the CRMs 
characterized was essential on its own for limb development. The transcriptional 
activities of different CRMs were additive in levels and partially redundant in regulating 
the spatial and temporal dynamics of the Grem1 expression. The spatio-temporal 
changes in Grem1 expression levels, caused by the loss of different enhancers alone, 
were not sufficient to explain the observed phenotypes. Therefore, additional mouse 
strains lacking several CRMs were generated and analyzed. In light of these results, I 
performed a comparative molecular analysis of key genes in the self-regulatory 
SHH/GREM1/AER-FGF signaling system, which provided a better molecular 
understanding of how these cis-regulatory alterations affect the limb bud outgrowth 
and patterning. This analysis showed that the cis-regulatory alterations affecting levels 
and spatio-temporal kinetics of the Grem1 expression are accompanied by specific 
changes in the self-regulatory feedback loops in mutant limb buds. In addition, I 
investigated potential effects on the structure of the Grem1 TAD and revealed that 
alterations in the interactions among CRMs and the Grem1 promoter contributed to 
the transcriptional regulation of Grem1 expression. 
 
This extensive genetic analysis led to the following major conclusion: the control of 
transcript levels by the Grem1-associated CRMs is additive, while they function in a 
cooperative manner to regulate the spatial dynamics of the Grem1 expression in 
mouse limb buds. In particular, deleting several of the CRMs that regulate spatial 
aspects of the Grem1 expression disrupts this cooperativity. This, in turn, weakens the 
robustness of the limb patterning system and results in the loss of pentadactyly. It 
appears that the observed limb skeletal deformity phenotypes strongly correlate with 
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reduced cell proliferation. Structural analyses reveal that intra-TAD rearrangements 
play a major role in the robustness of the Grem1 expression.  
 
 
In summary, my research provides novel insights into the transcriptional 
regulation of the Grem1 gene expression, both at the cis-regulatory and at the 
signaling systems level. 
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3. List of Abbreviations 
 
 
 
4C Circular Chromatin Conformation Capture hr hour 
AER Apical Ectodermal Ridge HR Homologous recombination 
AP Antero-posterior Id Inhibitor of Differentiation  
ArhGap11a Rho GTPase Activating Protein 11A Ihh  Indian hedgehog 
ATAC Assay for transposase-accessible chromatin kb kilobase 
BA  Branchial arches KO Knock out 
BAC Bacterial artificial chromosome LacZ Beta galactosidase coding gene 
BMP Bone morphogenetic protein LB  Lucia Broth 
bp base pair LCR Locus control region 
BSA Bovine serum albumin ld Limb deformity 
C-L Cenani-Lenz LIF Leukemia Inhibitory Factor 
Cas CRISPR-associated protein LMP Limb mesenchymal progenitor 
cDNA Complementary DNA LOF Loss of function 
ChIP Chromatin immunoprecipitation M-phase Mitotic phase 
Chr chromosome Mb Megabase 
CLM  Congenital limb malformations MEF Mouse embryonic fibroblast 
Cq Quantification cycle min minute 
CRC colorectal carcinoma n number 
CRM cis-regulatory module NRE Negative regulatory element 
CTCF CCCTC-binding Factor O/N overnight 
DIG Digoxygenin ORF Open reading frame 
DMEM Dulbecco's modified Eagle medium PAM 
Protospacer adjacent 
motif  
DNA Deoxyribonucleic acid PBS Phosphate Buffered Saline 
DV Dorso-ventral PBT PBS-0.1% Tween 20 
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e-m epithelial-mesenchymal  PD Proximo-distal 
EC Enhancer cluster PFA Paraformaldehyde 
ECh Enhancer chain PIC Pre-initiation complex  
EDTA  Ethylenediaminetetraacetic acid polyA  Polyadenylation 
Eff. Efficiency ref. Reference(s) 
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EGTA  ethylene glycol-bis (β-amino ethyl ether)-N,N,N',N'-tetra acetic acid RNA Ribonucleic acid 
EMT Epithelial-to-mesenchymal transition Rpl19 Ribosomal Protein L19 
ERCE Early replication control elements rpm Revolutions per minute 
ESC Embryonic stem cell RT Room Temperature 
EUCOMM European Conditional Mouse Mutagenesis Program  
RT-qPCR Real-time quantitative PCR 
FBS Fetal bovine serum S-phase Synthesis phase 
FGF Fibroblast growth factor Scg5 Secretogranin V 
FL forelimb SDS Sodium Dodecyl Sulfate 
Fmn1 Formin1 SE Super enhancer 
G1-phase Gap phase 1 SEM Standard error of the mean  
GBR GLI binding region sgRNA Single guide RNA 
GCR Global control region Shh Sonic hedgehog 
Gli GLI-Kruppel family member Smad Small Mothers Against Decapentaplegic 
GOF Gain of function Smoc1 Secreted modular calcium-binding protein 1  
GRE1 Gli responsive element 1 Sox9 Sex determining region Y box 9 
Grem1 Gremlin 1 TAD Topologically associated domain 
GRN Gene regulatory network Tbx2 T-box transcription factor 2 
GRS1 Gremlin1 regulatory sequence 1 TF Transcription factor 
GTF General transcription factor Tmco5 Transmembrane and Coiled-Coil Domains 5A 
H3K27ac Histone 3 lysine 27 acetylation TSS Transcription Start Site 
H3K4me1 Histone 3 lysine 4 monomethylation UCSC 
University of California 
Santa Cruz 
H3K4me3 Histone 3 lysine 4 trimethylation UTR untranslated region 
Hi-C High-throughput Chromosome Conformation Capture (Hi-C) WISH 
Whole-mount in situ 
Hybridization 
HL Hindlimb Wnt Wingless-type MMTV integration site 
HMBS Hydromethylbilane synthase WT Wild-type 
HMCO Human mouse chicken oppossum Xgal 
5-bromo-4-chloro-3-
indolyl-beta-D-
galactopyranoside  
HMPS Hereditary mixed polyposis syndrome  ZPA Zone of polarizing activity 
  ZRS ZPA regulatory sequence 
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4. Introduction 
 
4.1. Promoter and cis-regulatory modules (CRMs) 
communication 
 
4.1.1. CRMs are the cornerstones for the integration of 
signaling inputs to generate a transcriptional output 
 
4.1.1.1. Basic concepts: what are CRMs? 
 
During embryonic development, a unicellular zygote will follow genetic instructions and 
go through a series of cellular divisions to give rise to the various cell-types that 
comprise functional tissues and organs. While every single cell of a multicellular 
organism possesses the exact same genome, they regulate gene expression in 
disparate and cell type-specific spatio-temporal programs that control development 
and cellular differentiation. Such diversity in gene expression is supported by essential 
short non-coding DNA elements that activate, refine or prevent gene transcription 
(Alexander et al., 2019; Bartman et al., 2016; Benabdallah et al., 2019; Bolt and 
Duboule, 2020; Bulger and Groudine, 1999; Furlong and Levine, 2018; Gaszner and 
Felsenfeld, 2006; Gerstein et al., 2010; Levine, 2010; Ong and Corces, 2014; 
Petrykowska et al., 2008; Rusche et al., 2003; Sandelin et al., 2004; Schoenfelder and 
Fraser, 2019; Stathopoulos and Levine, 2005). Although transcription initiates at 
promoters, where the basal transcriptional machinery is recruited, promoters have little 
to no part in transcriptional regulation (Banerji et al., 1981). Promoters can be 
considered as a specific type of CRMs. They rely on other categories of CRMs that 
are in charge of the transcriptional control of gene expression in time, space and levels 
during development. CRMs are key regulators of cell fate decisions. Identifying and 
understanding CRM functions is essential to expand our knowledge of the complexity 
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in transcriptional coordination of developmental genes. CRMs – excluding promoters 
– belong to three categories: transcriptional enhancers, transcriptional silencers and 
structural insulator elements.  
 
 
 
Figure 1. Schematic of a cis-regulatory module (CRM)-Promoter synergy in gene 
transcriptional regulation. RNA polymerase II (Pol II) and general transcription 
factors (GTFs) form a complex, the pre-initiation complex (PIC), that is recruited at the 
core promoter and under the control of CRMs that locally bind transcription factors 
(TFs) and convey regulatory cues to the PIC, modulating gene expression in precise 
spatio-temporal pattern and levels. Adapted from Haberle et al. (2018). 
 
 
4.1.1.2. Basic concepts: how to identify CRMs 
 
Functional CRMs correspond to open chromatin regions that are bound by 
transcription factor (TF) complexes (Felsenfeld, 1996; Krebs et al., 2017; Thurman et 
al., 2012). TFs are the nuclear mediators relaying cell-intrinsic and cell-extrinsic 
signaling cues to modulate gene transcription (Hardison and Taylor, 2012; Long et al., 
2016). The first indication to identify putative CRMs is to look for open chromatin loci. 
Open chromatin regions are sensitive to DNases (Gross and Garrard, 1988) and 
transposases (Buenrostro et al., 2013). DNase hypersensitivity footprints (Consortium 
et al., 2007; Lu et al., 2011) or assay for transposase-accessible chromatin followed 
by deep sequencing (ATAC-seq, Buenrostro et al., 2013) have been commonly used 
to detect open and accessible chromatin regions. Although promoters and structural 
elements also overlap with chromatin accessible regions (Boyle et al., 2008; 
Felsenfeld and Groudine, 2003; Gross and Garrard, 1988; Stalder et al., 1980), they 
are not involved in the tissue-specific transcriptional control of developmental genes 
and can be removed from the analyses. To refine the selection, chromatin immune 
precipitation (ChIP) followed by deep sequencing is commonly performed. ChIP-seq 
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experiments performed in vivo, targeting the TFs regulating the transcription of 
gene(s) of interest, provide other criteria to identify CRMs. Those experiments have to 
be performed in vivo because in vitro assays will identify TF binding motifs and 
therefore millions of DNA loci while in vivo only about 1 in 500 motifs interact with the 
corresponding TFs (Zang et al., 2009; Zhang et al., 2008). In addition to binding TFs, 
CRMs can recruit histone-modifying enzymes that decorate histones with different 
marks. Detectable with ChIP-seq, those marks form a “code” that helps to predict the 
chromatin state. Active CRMs are decorated with monoacetylation on histone 3 lysine 
27 (H3K27ac) and monomethylation of histone 3 on lysine 4 (H3K4me1, Creyghton et 
al., 2010; Rada-Iglesias et al., 2011; Shlyueva et al., 2014; Zentner et al., 2011, Figure 
2). Poised enhancers overlap with the H3K4me1 mark only (Bonn et al., 2012, Figure 
2). Promoters are recognized by the presence of H3K27ac and the trimethylation of 
histone 3 on lysine 4 (H3K4me3, Heintzman et al., 2007, Figure 2). The trimethylation 
of histone 3 on lysine 27 (H3K27me3) is characteristic of an inactive or repressed state 
of the chromatin (Bernstein et al., 2006; Schuettengruber et al., 2007). Chromatin 
epigenetic profiling is a reliable method to identify different classes of putative CRMs. 
ChIP-seq targeting known insulator proteins such as the CCCTC-binding factor 
(CTCF, Dekker and Mirny, 2016; Nichols and Corces, 2018) are used to separate them 
from the putative CRMs that actively regulate transcription in space, time and levels 
(Phillips-Cremins et al., 2013; Rao et al., 2014; Sanyal et al., 2012, Figure 2). It is 
important to perform these experiments in the organ/tissue of interest and at the 
developmental stage and time where the genes of interest are expressed as CRMs 
activity depends on their cell-specific genomic environment. An active CMR in a 
specific organ may be inactive and undetectable in another organ and different 
environmental conditions. 
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Figure 2. Schematic representation of CRM identification strategy. Putative 
CRMs (blue ovals) map with open chromatin regions uncovered by ATAC-seq assays. 
ChIP-seq experiments show that they bind at least one transcription factor (TF) and 
are enriched in monoacetylated histone 3 on its lysine 27 for the active ones 
(H3K27ac, vertical blue bars) and in monomethylated histone 3 on lysine 4 for the 
poised ones (H3K4me1, vertical grey bars). The trimethylation of histone 3 on lysine 
4 (H3K4me3) allows the discrimination between promoters (red ovals, vertical red 
bars) and CRMs. A ChIP-seq experiment targeting a structural insulator (in purple) 
identifies an open chromatin region that is not a CRM. Dashed arrows show the 
possible regulatory connections between CRMs and their associated gene(s).  
 
 
Another remarkable property of developmental CRMs is their high level of sequence 
and/or ancestral function conservation throughout evolution (Bhatia et al., 2016; 
Boffelli et al., 2004; Harmston et al., 2013; Long et al., 2016; Navratilova et al., 2009; 
Rada-Iglesias et al., 2011; Shen et al., 2012), even though sequence conservation 
does not always correlate with CRM functions (Nelson and Wardle, 2013). CRMs with 
silencing functions have not been studied systematically (Petrykowska et al., 2008) 
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but even poised enhancers (Banerji et al., 1981) have been able to drive a cell-type 
and stage-specific reporter expression despite poor sequence conservation from one 
species to another one (Rada-Iglesias et al., 2011; Ritter et al., 2010). Transient or 
transgenic reporter assays represent a quick and robust strategy to functionally 
characterize enhancers as their activity is known to overlap with that of their 
associated gene (Kvon, 2015; Levine, 2010; Stanojevic et al., 1991; Visel et al., 
2009b). 
After identifying putative CRMs, one has to be able to associate them with their 
corresponding gene(s). The linear distance (nucleotide count) between a promoter 
and its enhancers is not a criterion as many studies have reported that CRMs can be 
found in inter- or intragenic regions, in the vicinity of their associated promoter or at 
great linear distances, even up to 3 Mb away from their associated gene (Krivega and 
Dean, 2012; Lettice et al., 2003; Zeller and Zuniga, 2007; Zuniga et al., 2012a; Zuniga 
et al., 2004). Vakoc and colleagues have demonstrated that promoter and enhancer 
overcome linear distances as they are brought in close proximity through chromatin 
looping (Vakoc et al., 2005). Enhancers can be associated with genes far away in 
linear distances forming so-called “long-range” interactions (Lettice et al., 2003; 
Montavon et al., 2011; Sagai et al., 2005). Impressive technological progress in the 
molecular methods based on proximity ligation (Chromatin Conformation Capture- 
(3C-) based technology) have been made this past ten years (Dekker et al., 2002).  
 
4.1.2. Developmental genes are organized into Topologically 
Associated Domains (TADs)  
 
In 2012, the establishment of DNA-DNA interaction profiles with High-throughput 
Chromosome Conformation Capture (Hi-C) has uncovered the existence of chromatin 
domains with a high frequency of internal physical interaction: the Topologically 
Associating Domains (TADs, Dixon et al., 2012; Nora et al., 2012; Sexton et al., 2012). 
TADs are chromatin domains found in eukaryotes that exhibit increased probability of 
internal physical interactions (Dixon et al., 2012; Nora et al., 2012; Rao et al., 2014; 
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Sexton et al., 2012; Stam et al., 2019) and are delimited by boundary loci (i.e. 
insulators) occupied, in most cases, by CTCF (Dekker and Mirny, 2016; Nichols and 
Corces, 2018). CRM activities seem to be directed toward the gene(s) present within 
the same TAD, with limited contacts with genes or CRMs outside of these domains 
(Dixon et al., 2016; Dixon et al., 2012, Figure 3). According to the theory supporting 
the contact model (Fulco et al., 2019), physical contacts between CRM-TF complexes 
and the promoter-pre-initiation complexes (PICs) are a prerequisite to CRMs 
functions. HiC-seq with high-resolution (Barutcu et al., 2018) but also Circular 
Chromosome Conformation Capture followed by high throughput sequencing (4C-seq, 
Simonis et al., 2006) are appropriate methods to identify putative CRMs within cis-
regulatory landscapes when compared with chromatin profiling. 4C-seq is an assay 
enabling the identification of all contacts with a promoter when it is set as the 
viewpoint. Nevertheless, 4C-seq, unlike HiC-seq, lacks the ability to identify TAD 
boundaries. However, knowing that CTCF-binding sites in converging orientation often 
surround chromatin regions with high contact frequencies (Dixon et al., 2012; Rao et 
al., 2014), while the boundaries between two adjacent TADs are characterized by 
divergent CTCF-motifs (Gomez-Marin et al., 2015), one can approximate cis-
regulatory landscapes thanks to publicly available datasets (Figure 3).  
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Figure 3. Schematic representation of the organization of chromatin into 
Topologically Associated Domains (TADs). (A) Visualization of chromatin 
compartmentalization into TADs with Hi-C heatmaps, interaction frequencies are 
represented in triangular blocks of increased color intensity. (B) CRMs influence is 
limited within TAD boundaries that also restrict the spread of chromatin modifications. 
The TAD boundary loci are associated with CTCF binding sites. TAD1 and TAD2 
include actively transcribed genes while TAD3 is transcriptionally inactive. Adapted 
from Long et al. (2016a). 
 
 
There is no established causal effect between TAD structures and enhancer-promoter 
interactions (Mir et al., 2019). When TAD formation is disrupted by depletion of its 
boundary-establishing protein, CTCF or cohesin, only a limited subset of genes activity 
is affected (Haarhuis et al., 2017; Nora et al., 2017; Rao et al., 2017; Schwarzer et al., 
2017; Sofueva et al., 2013; Wutz et al., 2017). Although genomic rearrangements that 
suppress or shuffle TAD boundaries have more impressive phenotypes and can lead 
to “TADopathies” in mice and humans (Harmston et al., 2017; Lupianez et al., 2015; 
Matharu and Ahituv, 2015; Rao et al., 2014; Symmons et al., 2014), the relative 
importance of TADs for gene expression regulation remains ambiguous (Mir et al., 
2019). Indeed, some transcribed loci do not present a TAD organization and multiple 
studies have uncovered mild consequences of TAD disruption (Despang et al., 2019; 
Ghavi-Helm et al., 2019; Kragesteen et al., 2018; Rodriguez-Carballo et al., 2019; 
Williamson et al., 2019, Figure 4). Besides, TADs rearrangements can be highly 
dynamic, resulting in great cell to cell heterogeneity (Cattoni et al., 2017; Finn et al., 
2019; Flyamer et al., 2017; Nagano et al., 2013; Stevens et al., 2017).  
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Figure 4. The functional relevance of TAD in gene transcriptional regulation is 
open for debate. Left panel on top: schematic of a reporter assay exposing the activity 
of randomly integrated CRMs in genomic loci (Symmons et al., 2016; Symmons et al., 
2014). Left panel on the bottom: some published cases of boundary disruption leading 
to developmental issues. Right panel on top: schematic of uneventful TAD CTCF 
boundaries perturbation for the Shh gene during mouse embryonic development 
(Paliou et al., 2019; Williamson et al., 2019). Right panel on the bottom: schematic 
representation of the relatively mild transcriptional changes measured after cohesin 
depletion, rPKM, reads per kilobase per million mapped reads (Rao et al., 2017; 
Schwarzer et al., 2017). Adapted from Beagan and Phillips-Cremins (2020). 
 
 
Nevertheless, the observation that CRMs appear to confine their activity toward the 
genes present in the same TAD and that TAD coordinates are often a good estimation 
of regulatory landscapes – a defined genomic region including all CRMs and their 
associated genes that are transcriptionally regulated in a coordinated fashion 
(Grosveld et al., 1987; Spitz et al., 2003) – is commonly observed for most studied 
developmental genes (Bolt and Duboule, 2020; Harmston et al., 2017; Lupianez et al., 
2015; Rao et al., 2014; Symmons et al., 2014). CRMs within the same TAD and 
regulating the same genes have overlapping activities (Symmons et al., 2016; 
Symmons et al., 2014, Figure 3, Figure 4). 
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4.1.3. Overview of the current state of the knowledge about 
CRMs function in gene transcriptional regulation  
 
4.1.3.1. Insulator functions 
 
Insulators, or boundary elements, inhibit inappropriate contacts between adjacent 
TADs (Gaszner and Felsenfeld, 2006; Petrykowska et al., 2008; Valenzuela and 
Kamakaka, 2006; Wallace and Felsenfeld, 2007). The most studied protein associated 
with insulator regions so far are the CTCFs (Bell et al., 1999; Hark et al., 2000). CTCF 
proteins together with upstream stimulatory factors recruit histone-modifying enzymes 
and prevent the spread of repressive heterochromatin state (Huang et al., 2007). They 
also limit irrelevant action of enhancers (“enhancer blockers” role) or silencers 
(“barriers” role, Valenzuela et al., 2008; Wallace and Felsenfeld, 2007). Additionally, 
CTCFs associate with cohesins at boundary regions (Wendt et al., 2008) and shape 
chromatin into TADs. CTCF/cohesin dynamics are the foundation for polymer 
simulations and genomic analyses proposing the loop extrusion model as the 
mechanism allowing TADs formation (Fudenberg et al., 2016). CTCFs protect 
cohesins from chromatin release factors and stop their linear diffusion. Cohesin 
complexes extrude chromatin forming loops. Cohesins can get trapped at CTCF 
binding sites. A steady loop domain, a TAD, happens when flanked by CTCFs, cohesin 
proteins cannot extrude or release chromatin anymore, creating stable TAD 
boundaries (Li et al., 2020, Figure 5). Besides, structural complexes such as 
CTCFs/cohesin or Mediator/cohesin (Berlivet et al., 2013; Kagey et al., 2010) help to 
connect regulatory sequences to their associated promoters (Majumder and Boss, 
2010; Ong and Corces, 2014; Sanyal et al., 2012) ensuing intra-TAD looping. 
Nevertheless, so far, they have not been described as functional modulators of 
transcription levels or dynamics.  
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Figure 5. Schematic of the interphase loop extrusion model. Dashed lines 
represent a TAD region, bordered by converging CTCF binding sites, established 
because of a loop extrusion mechanism. Adapted from Fudenberg et al. (2016). 
 
 
4.1.3.2. Enhancer and silencer functions 
 
Enhancers (Banerji et al., 1981; Fromm and Berg, 1983; Gillies et al., 1983) and 
silencers (Rusche et al., 2003) are defined by their positive or negative effects on gene 
transcriptional regulation. Their activities are often tested with reporter assays as they 
can act independently of their orientation or even position in the genome. Enhancer 
and silencer activities depend on their trans-environment. One module can assume a 
positive or negative function depending on the TF complexes they recruit (Istrail and 
Davidson, 2005; Jing et al., 2008; Li et al., 2014; Martowicz et al., 2005).  
Enhancers form the CRM category considered as a key player in the spatio-temporal 
control of gene expression during embryonic development (Bolt and Duboule, 2020; 
Long et al., 2016). The first described example of long-distance gene regulation by 
enhancers is the ß-globin locus (Carter et al., 2002; Tolhuis et al., 2002). A Locus 
Control Region (LCR) containing six DNaseI hypersensitive sites was identified more 
than 60 kb upstream of the ß-globin locus in humans (Grosveld et al., 1987) and in 
mice (Moon and Ley, 1990). The LCR is required for high-level transcription of the ß-
globin genes (Bender et al., 2000; Bulger and Groudine, 1999; Epner et al., 1998; Reik 
et al., 1998; Schubeler et al., 2001). These studies proposed an “active chromatin hub” 
concept in which close physical proximity with an associated gene was a prerequisite 
for enhancer functions (Carter et al., 2002; Tolhuis et al., 2002). The stage- and tissue-
specific expression of developmental genes can rely on the activity of multiple CRMs, 
but this is not true for all genes. During limb bud development, the Sonic hedgehog 
gene (Shh) transcription is entirely regulated by a single enhancer the Zone of 
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polarizing activity Regulatory Sequence (ZRS, Lettice et al., 2003). The ZRS is located 
within another gene (Lmbr1) 1 Mb upstream of Shh, both present at the opposite ends 
of the same TAD. The ZRS deletion phenocopies the Shh loss of function (LOF) limb 
phenotype, demonstrating the importance of this single enhancer for gene expression 
(Lettice et al., 2003; Sagai et al., 2005). Only few other studies have described the 
predominance of a single enhancer over several tissues/time-specific ones in the 
regulation of a developmental gene (loss of one enhancer function followed by partially 
penetrant phenotypes) but none were as striking as the removal of the ZRS (Gonen 
et al., 2017; Kragesteen et al., 2019; Kragesteen et al., 2018). These studies revolving 
around one single enhancer dominance seem to be the exception and not the rule as 
many more studies present instances where one single gene is under the control of 
multiple enhancers with various regulatory crosstalk. 
Enhancers can cooperate in an additive and simultaneous manner (Osterwalder et al., 
2018; Will et al., 2017, Figure 6a). In such contexts, the transcriptional levels of a gene 
are equal to the sum of each enhancer activity within the same cis-regulatory 
landscape. Thus, the number of transcripts and severity of phenotypes scales to the 
number of enhancers present in the cis-regulatory landscape. Synergistic interactions 
have also been documented. Two or more enhancers work in synergy whereby their 
combined action is stronger than the sum of their individual ones (Maekawa et al., 
1989; Stine et al., 2011, Figure 6b). When enhancers working in an additive or 
cooperative fashion are genetically altered without major changes in gene expression, 
functional redundancy between enhancers has been proposed as an explanation 
(Ahituv et al., 2007; Dickel et al., 2018; Lam et al., 2015; Osterwalder et al., 2018). 
Functional redundancy has been extensively studied, in particular by Mark Levine and 
colleagues who introduced the concept of shadow enhancers (Hong et al., 2008). They 
described shadow enhancers as “remote secondary enhancers mapping far from the 
target gene and mediating activities overlapping with the primary enhancer”. Shadow 
enhancers have overlapping patterns of activity. They bind the same TFs as the 
primary enhancer but may assume different roles in the spatio-temporal fine-tuning of 
gene expression (Barolo, 2012). They may not be essential in normal context but when 
the “primary” enhancer is inactivated, they could compensate and ensure the 
robustness of gene expression (Barolo, 2012; Frankel et al., 2010). This mechanism 
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could be the consequence of competitive interactions between enhancers (Bothma et 
al., 2015; El-Sherif and Levine, 2016, Figure 6c). Enhancer associations with 
promoters can prevent the association of other enhancers to the same promoter. In 
competitive situations, one enhancer could only reach its full potential in the absence 
of its competitor(s). Hierarchical regulations between enhancers are a non-additive 
regulatory crosstalk between one essential enhancer activating gene expression on 
its own and other(s), under the control of the main enhancer, that can bring a specific 
trait to gene expression (e.g. tissue specificity, Iampietro et al., 2010; Leddin et al., 
2011; Maeda and Karch, 2011; Mihaly et al., 2006, Figure 6d).  
 
 
 
Figure 6. Schematic of known regulatory crosstalk between enhancers. (a-d) 
Possible enhancer interactions and resulting transcriptional output in wild-type or 
mutant contexts. Adapted from Long et al. (2016a). 
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When numerous active enhancers associated with the same gene(s) are found in 
restricted chromatin region (in linear nucleotide distance) they can be referred to 
super-enhancers (Hnisz et al., 2013; Whyte et al., 2013). When enhancers are spread 
across large linear distances in a gene desert, they can be identified as a regulatory 
archipelago (Bhatia et al., 2014; Montavon et al., 2011). During limb bud development, 
the HoxD locus is regulated by an archipelago of enhancers forming a global control 
region (GCR) whose activity depends on their TAD structure and intra-TAD 
interactions (Montavon et al., 2011; Spitz et al., 2003). Enhancers located at the 3′ of 
the landscape drive proximal limb expression while the ones located at the 5′ drive 
distal limb expression, reflecting the Hox gene collinearity.  
Silencers are poorly understood modules repressing enhancer activity (Li and Arnosti, 
2011; Li et al., 2014; Petrykowska et al., 2008; Stathopoulos and Levine, 2005; Vokes 
et al., 2008). Silencers have been described as essential to prevent ectopic gene 
expression (Dunipace et al., 2011; Marinic et al., 2013; Perry et al., 2011). As a result, 
they are essential for the fine-tuning of gene expression patterns. 
Gene expression can be modulated both in quantity and in quality (spatio-temporal 
expression and tissue specificity) by multiple enhancers and silencers that cooperate 
through various possible mechanisms conferring robustness during gene expression 
in vivo.  
 
4.2. Gremlin1 (Grem1), a critical protagonist for limb bud 
development  
4.2.1. Basic concepts: Limb bud development 
 
The limb is an easily accessible organ whose intricate outgrowth and patterning 
mechanisms depend on the gene regulatory networks (GRNs) that control vertebrate 
organogenesis. Wide variability in morphology is observed in the vertebrate clade, 
emphasizing the importance of gene regulation during limb morphogenesis. Limb 
development is one of the foremost genetic and molecular models for developmental 
biologists. Limbs originate from the lateral plate mesoderm, through a localized 
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epithelial-to-mesenchymal transition (EMT), and growth along the three main 
developmental axes (Gros and Tabin, 2014; Petit et al., 2017; Zuniga, 2015, Figure 
7). As a result, the limb ridge, surrounded by ectoderm arises at embryonic day 9.5 
(E9.5). The limb ridge is already polarized along the antero-posterior (AP), the dorso-
ventral (DV) and proximo-distal (PD) axis. The emerging limb grows in a burgeon-like 
shape, hence its “limb bud” appellation from E10 to E11.5 (Figure 7a), before digits 
condensations aggregate giving the limb a paddle-like shape at E12.0 (Drossopoulou 
et al., 2000; Harfe et al., 2004; Wanek et al., 1989, Figure 7b). It is during this 
developmental window, from the ridge- to the paddle-shaped limb, that the 
mesenchymal progenitors give rise to limb skeletal primordia through proliferation and 
differentiation, making this a critical stage for limb morphology. 
 
 
 
Figure 7. Schematic of limb bud development through embryogenesis. (A) 
Scanning electron microscopy image of a whole mouse embryo at E11.0. (B) 
Schematic of limb morphological evolution through embryonic development from 
embryonic day 9.5 to 16.5 (E9.5 to E16.5). From Zuniga et al. (2015). 
 
 
At E9.75-E10.0, at the DV interface, the apical ectodermal ridge (AER) protrudes 
distally (Saunders, 1948, Figure 8). The AER represents one of the two main limb bud 
signaling centers. It notably produces several fibroblast growth factor (FGF) ligands 
(Fallon et al., 1994; Mariani et al., 2008; Niswander et al., 1993) and maintains the 
underlying mesenchymal progenitors in an undifferentiated state, allowing limb bud 
proliferative expansion and patterning (Fallon et al., 1994; Lewandoski et al., 2000; 
Mariani et al., 2008; Petit et al., 2017; ten Berge et al., 2008; Towers et al., 2008; Zhu 
et al., 2008). AER-FGFs are essential cell survival factors during early limb 
development (Sun et al., 2002). The morphogen Shh is expressed by the second main 
limb bud signaling center, the posterior zone of polarizing activity (ZPA, Benazet and 
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Zeller, 2009; Gasseling and Saunders, 1961; Zhu et al., 2008, Figure 8). In the nascent 
limb bud (E9.5-E9.75), the ZPA is initiated and spatially restricted as a result of pre-
patterning mechanisms between the transcriptional regulators HAND2, which 
promotes Shh expression, and the GLI3R-mediated repression of Hand2 expression 
(Galli et al., 2010; Osterwalder et al., 2014; Vokes et al., 2008). A Shh morphogen AP 
gradient participates in the PD axis organization through the establishment of the limb 
bud distal identities. Indeed, the SHH pathway has a positive effect on AER-Fgfs 
expression, leading to the clearance of retinoic acid from the distal limb bud by the 
AER-FGF signaling target Cyp26b1 (Probst et al., 2011). Primarily, the SHH gradient 
is essential for the organization of the limb bud AP axis. The SHH pathway regulates 
cell survival and proliferation, ensuring an adequate number of cellular progenitors for 
digit formation (Zhu et al., 2008). In mice and humans, the AP axis is reflected by the 
digit identities (Ahn and Joyner, 2004; Drossopoulou et al., 2000; Harfe et al., 2004; 
Zhu et al., 2008). The most anterior digit, digit 1 (the thumb), is SHH-independent while 
the intermediate digits (2 to 4), and the most posterior digit, digit 5 (little finger), are 
dependent on the SHH gradient (Zhu et al., 2008). The digits are part of the most distal 
fragment of the limb, the autopod. The medial part of the limb is the zeugopod 
(forelimb: radius-ulna; hindlimb: tibia-fibula, Figure 7b) and the most proximal the 
stylopod (forelimb: humerus; hindlimb: femur, Figure 7b). AER and ZPA depend and 
interact with each other to coordinate limb bud outgrowth and patterning (Chiang et 
al., 2001; Laufer et al., 1994; Niswander et al., 1994; Tickle, 1981; Todt and Fallon, 
1987). This coordination relies on key developmental genes. 
 
 
Figure 8. Schematic of the limb epithelial-mesenchymal (e-m) feedback loops. A 
self-regulatory feedback loop is established between the zone of polarizing activity 
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(ZPA, green) and the apical ectodermal ridge (AER, blue) superimposed on a mouse 
limb bud scanning electron micrograph. Arrows represent a simplified summary of the 
regulatory interactions between AER and ZPA. From Zeller and Zuniga (2007). 
 
 
4.2.2. Grem1 and the limb bud regulatory networks  
 
The bone morphogenetic protein (BMP) antagonist GREM1 is a secreted protein, 
which directly binds to BMP ligands, blocking the activation of the BMP pathway 
(Figure 9a). Initially, the BMP pathway activity is required for the establishment of a 
functional AER, and to restrict its length (Ahn et al., 2001; Benazet and Zeller, 2013; 
Nissim et al., 2006; Niswander et al., 1994; Scherz et al., 2004; Zeller et al., 2009; 
Zuniga and Zeller, 1999, Figure 9b). High BMPs activity correlates with the 
transcriptional activation of Grem1 in the limb posterior distal domain (Benazet et al., 
2009; Zeller et al., 2009, Figure 9b,c).  
Secreted by the Grem1-expressing cells in the distal posterior limb bud, GREM1 
proteins prevent BMPs from binding to their cognate receptors, prompting a significant 
reduction of overall BMP activities (Benazet et al., 2009; Khokha et al., 2003; Michos 
et al., 2004; Zuniga and Zeller, 1999). In turn, low BMP activity stimulates the AER to 
increase FGFs production and sustains the Shh expression emanating from the ZPA. 
The BMP/GREM1 regulatory loop is called the initiator module of the limb 
SHH/GREM1/AER-FGF self-regulatory feedback loop (Benazet and Zeller, 2009; 
Zeller et al., 2009, Figure 9b). The ZPA and the AER coordinated activities support 
mesenchymal cell proliferation and specification (Khokha et al., 2003; Laufer et al., 
1994; Niswander et al., 1994; Scherz et al., 2004; Todt and Fallon, 1987). When BMPs 
activity is low, Grem1 expression is upheld by the SHH signaling pathway (Benazet et 
al., 2009; Khokha et al., 2003; Michos et al., 2004; Zuniga and Zeller, 1999, Figure 
9b). To date, GREM1 is the only known essential active BMP antagonist at these 
stages. Grem1 expression is the cornerstone of the establishment of the 
SHH/GREM1/AER-FGF self-regulatory feedback loop and thereby of the distal 
progression of limb bud development (Benazet et al., 2009, Figure 9b).  
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A combination of several events leads to the self-termination of this feedback loop. 
First, Shh descendant cells are refractory to Grem1 activation, increasing the gap 
between the domains of Shh and of Grem1 expression (Nissim et al., 2006; Scherz et 
al., 2004). In addition, GLI3R, from the anterior SHH-free mesenchyme, and high AER-
FGF activity, inhibit Grem1 expression (Lopez-Rios et al., 2012; Scherz et al., 2004; 
Verheyden and Sun, 2008; Zeller et al., 2009). As a consequence, Grem1 expression 
is terminated around E12.0 and the SHH/GREM1/AER-FGF loop collapses (Figure 
9b).  
The tight control of the Grem1 expression throughout limb development is reflected in 
its very dynamic spatio-temporal expression pattern (Figure 9c). Grem1 is transcribed 
in a posterior distal domain during limb bud initiation. Its domain expends distally and 
anteriorly during the propagation phase before progressively fading and disappearing 
in the autopod after E12.0 (Figure 9c). 
In the post-patterning phase, BMP activities increase, which stimulates BMP-
dependent chondrogenic differentiation and inter-digital apoptosis (Barna and 
Niswander, 2007; Benazet et al., 2012; Ganan et al., 1996; Lopez-Rios et al., 2012; 
Pizette and Niswander, 2000, 2001; Yoon et al., 2005).  
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Figure 9. Grem1 is a key factor during limb bud development. (a) A BMP ligand 
dimer binds its cognate receptor (BMPR) and triggers a phosphorylation cascade 
leading to Smad 1/5/8 pathway activation. Gremlin1 (Grem1) directly binds to BMP 
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ligands and blocks the activation of the BMP pathway. From left to right (b) Initiation 
phase: High mesenchymal BMP activity (blue) results in the establishment of a 
functional AER (green) and activates Grem1 transcription (pink). Propagation phase: 
GREM1 blocks BMP activity which permits AER-FGFs to increase ZPA Shh 
expression (red). Shh is then responsible for maintaining high Grem1 expression 
precondition to the set-up of the SHH/GREM1/AER-FGF epithelial-mesenchymal (e-
m) self-regulatory feedback loop. Termination phase: Reduction of Grem1 
transcription through an increase of AER-FGFs activity and Grem1 refractoriness of 
Shh-expressing cells descendants prompting the regulatory feedback loop to end. (c) 
Dynamic Grem1 expression throughout limb development from E9.5 to E12.0 
uncovered by whole-mount in situ hybridization (WISH). Adapted from (for the upper 
panel) Marquez-Exposito et al. (2020), (for the middle panel) Zeller et al. (2009) and 
(for the lower panel) Zuniga et al. (2012a). 
 
 
4.2.3.  The Grem1 cis-regulatory landscape  
 
4.2.3.1. Grem1 and mouse limb development  
 
Until the breakthrough of Zuniga and colleagues (Zuniga et al., 2004), limb deformity 
(ld) phenotypes had been attributed to the LOF of the Formin1 (Fmn1) gene (Figure 
10a). The 24 exons of Fmn1 span a 345 kb region in length, which is located 35 kb 
downstream of the Grem1 gene 2 exons that span a much smaller 10 kb genomic 
region. The Grem1 and the Fmn1 genes are transcribed in opposite directions. 
Random insertional mutagenesis experiments had allowed the identification of the ld 
locus (Messing et al., 1990; Woychik et al., 1990a; Woychik et al., 1985). At the time, 
the ld locus was called the ld gene (Mass et al., 1990; Vogt et al., 1992; Woychik et 
al., 1990a; Woychik et al., 1985; Zeller et al., 1989). Fmn1 was associated with the ld 
gene as all ld mutant alleles had been mapped within its sequence (Jackson-Grusby 
et al., 1992; Vogt et al., 1993; Vogt et al., 1992; Woychik et al., 1990b; Wynshaw-Boris 
et al., 1997). The ld mutations can result in high-frequency uni- and bilateral renal 
aplasia (Kleinebrecht et al., 1982; Mass et al., 1990) associated with limb long bones 
synostosis with autopod syndactyly and oligosyndactyly (Green et al., 1968; 
Kleinebrecht et al., 1982; Woychik et al., 1985; Zeller et al., 1989, Figure 10a). FMNs 
family proteins are involved in the regulation of actin filament and microtubule 
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cytoskeleton dynamics (Evangelista et al., 2002; Ishizaki et al., 2001; Manseau et al., 
1996; Pring et al., 2003; Sagot et al., 2002; Wallar and Alberts, 2003). FMN1 can 
associate with microtubules (Zhou et al., 2006) or stimulate actin polymerization 
(Kobielak et al., 2004; O'Rourke et al., 2000). Nevertheless, inactivation of specific 
Formin1 isoforms in the mouse was associated with partial renal agenesis phenotypes 
while displaying normal limb morphogenesis (Wynshaw-Boris et al., 1997). Also, not 
all ld alleles were within Fmn1: two spontaneous ld mutations, the ldOR and the ldJ 
alleles affect Grem1 open reading frame (ORF, Mass et al., 1990; Woychik et al., 
1985; Wynshaw-Boris et al., 1997, Figure 10b).   
In an elegant genetic study, Zuniga and colleagues excluded that Fmn1 was involved 
in ld phenotypes. In an attempt to generate their own ld allele with a lacZ reporter, they 
engineered 1) the loss of Fmn1 exon 10 (Fmn1∆10), resulting in a frameshift in the 
FMN1 protein C-terminal domain resulting in the degradation of FMN1 proteins, 2) 
mice lacking the Fmn1 exon 10 to exon 24 (Fmn1∆10.24) region (Zuniga et al., 2004, 
Figure 10c). Fmn1 was truncated in both Fmn1∆10 and Fmn1∆10.24 alleles at the level 
of the exon 9/10 boundary, without any aberrant splicing. The Fmn1∆10 homozygous 
embryos were phenotypically wild-type, despite the degradation of FMN1 isoforms, 
unlike the Fmn1∆10.24 ones which displayed ld phenotypes (Zuniga et al., 2004, Figure 
10d). Grem1 expression was maintained in Fmn1∆10/∆10 but lost, exclusively in the limb 
bud, in the Fmn∆10.24/∆10.24 embryos (Zuniga et al., 2004, Figure 10d). These mutants 
survived to adulthood with normal lung and kidney organogenesis.   
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Figure 10. Mapping of limb deformity (ld) mutations within the Grem1-Fmn1 
landscape. (a) Skeletal stainings of wild-type (WT) compared to ld/ld mutant distal 
forelimbs >E17.0 where autopod oligosyndactyly and zeugopod synostosis is 
observed. (b) Schematic of the Grem1-Fmn1 chromosomal landscape with all known 
mutations indicated above (ldJ point mutation, ldIn2 inversions and ldTgHd, ldTgBri 
transgene insertions) or below (deletions indicated with brackets) the genomic map. 
Fmn1 ∆4, ∆5, ∆6, ∆10, ∆10–24 are targeted mutations affecting Fmn1 respective 
exons. Grem1∆ is the Grem1 null allele generated by gene targeting. Some mutations 
result in ld recessive phenotypes (blue) while others (black) do not hinder limb 
development. (c) Schematic of the genetically engineered Fmn1∆10 and Fmn1∆10.24 
alleles. (Neo) PGK-NeoR gene used during gene targeting; (Hygro) PGK-HygroR 
gene used during gene targeting; (lacZ) IRES-LacZ gene used to tag Fmn1 transcripts. 
(d) left panels: skeletal phenotypes of WT and homozygous ∆10 and ∆10–24 mutants; 
right panels: Grem1 limb bud expression in WT and ∆10, ∆10–24 homozygous mice. 
Adapted from (a,b) Zeller and Zuniga (2007) and (c,d) Zuniga et al. (2004). 
 
 
Finally, using homologous recombination, they inactivated the second exon of the 
Grem1 gene which encodes its complete ORF. Thus, they generated the Grem1∆ or 
Grem1∆ORF allele which 1) did not complement the Fmn1∆10.24 allele, 2) phenocopied 
the Fmn1∆10.24|∆10.24 mutants ld phenotype when homozygous (Zuniga et al., 2004). As 
a conclusion, they demonstrated that Fmn1 was not implicated in ld phenotypes. The 
ld defects were the consequences of the loss or the alteration of the Grem1 
expression, either by the disruption of the Grem1 ORF (e.g. ldOR and ldJ, Figure 10a) 
or by the disruption of the Grem1 cis-regulatory landscape (e.g. ldIn2, ldTgHd, ldTgBri, 
Figure 10a), located between the exon 10 and the exon 24 of Fmn1. With the Grem1∆ 
mice, Zuniga and colleagues phenocopied ld limb and kidney phenotypes that, 
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together with defects in lung late organogenesis, led to embryonic lethality (Zuniga et 
al., 2004). 
 
4.2.3.2. Grem1 cis-regulatory landscape: what we know so 
far 
 
After showing that the Fmn1 exons 10 to 24 locus acts as a cis-regulatory region on 
Grem1 transcription, Zuniga and colleagues focused on the previously described 
ldTgBri mutation to study Grem1 transcriptional regulation (Messing et al., 1990; Vogt 
et al., 1992). This allele was defined as a deletion of at least 36 kb including exons 21-
22 of Fmn1 but the boundaries of the deletion were uncertain (Vogt et al., 1992). In 
addition, it was not clear if further rearrangements had occurred (Vogt et al., 1992). 
Using a bacterial artificial chromosome (BAC, ref. Rp23:113h17, mm10 
chr2:113,611,498-113,847,298) where a lacZ reporter gene was inserted into the 
Grem1 ORF and was transcribed like Grem1, they revealed an essential role of a ± 70 
kb Fmn1 region located between exons 19 and 23 in the activation of the transgene 
(Zuniga et al., 2004, Figure 11). The BAC construct could drive reporter expression in 
the posterior distal part of the limb mesenchyme (Figure 11a). The deletion of the 
targeted region Fmn1 exons 19 to 23 abolished the transgene reporter activity (Figure 
11b). As a result, this region was renamed as the Grem1 GCR because of its similarity 
with the HoxD GCR (Montavon et al., 2011; Spitz et al., 2003). 
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Figure 11. Grem1 global control region (GCR) in a bacterial artificial 
chromosome (BAC) is essential for transgene activation. (a) The 236 kb BAC 
(mm10 chr2:113,611,498-113,847,298, from 25 kb upstream of Fmn1 exon 19 to 150 
kb upstream of Grem1) including Grem1 GCR located between Fmn1 exons 19 and 
23 drive lacZ transgene inserted in-frame into Grem1 ORF expression in the posterior 
distal part of the limb bud mesenchyme (black arrowhead). (b) The deletion of the 
GCR inactivates the BAC enhancer activity. From Zuniga et al. (2004). 
  
 
Looking into the newly identified GCR, Zuniga and colleagues isolated the SHH 
pathway target GLI binding regions (GBRs, Marigo et al., 1996; Ruiz i Altaba, 1998; 
Vokes et al., 2008), highly conserved between human, mouse, chicken and opossum 
(HMCO1, HMCO2, Zuniga et al., 2012a). HMCO1 belonged to the 9.6kb Grem1 
regulatory sequence 1 (GRS1) which possessed two additional GBRs outside of 
HMCO1, as identified by ChIP-qPCR experiments (Zuniga et al., 2012a). Those GBRs 
were not as conserved as those in HMCO1. Following up with the same BAC 
experimental set up (Figure 12a), they showed that both GRS1 and HMCO2 were 
associated with Grem1 transcriptional regulation (Figure 12b and 12c). In this BAC, 
GRS1 was necessary for lacZ transgene expression (Figure 12b), while HMCO2 
removal reduced the strength of transgene expression (Figure 12c).  
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Figure 12. BAC-based strategy reveals human, mouse, chicken and opossum 
(HMCO1) as critical for GCR enhancer function and HMCO2 as important for the 
transcriptional strength of the lacZ transgene. (a) BAC construct with a lacZ 
cassette inserted in-frame into Grem1 ORF drives endogenous enhancer activity in 
the posterior and distal limb bud mesenchyme. (b) The removal of HMCO1 from the 
BAC prevents lacZ expression. (c) The removal of HMCO2 from the BAC reduces lacZ 
expression. From Zuniga et al. (2012a). 
 
 
One element they did not focus on during their study is the GBR4 (fourth GLI binding 
site after GRS1 and HMCO2) because it is not conserved like the HMCOs. The GBR4 
was eventually analyzed by the group of Dr. S. Vokes as a Grem1 enhancer in the 
limb posterior domain and as a Grem1 repressor in the limb anterior domain (Li et al., 
2014, Figure 13). Its enhancer or silencer activities depended on its interaction with 
the activator (present in the posterior limb bud mesenchyme) or repressor (present in 
the anterior limb bud mesenchyme) isoform of GLI3 (Ahn and Joyner, 2004; Wang et 
al., 2000; Wen et al., 2010). Thus, this regulatory element was renamed as GLI 
responsive element 1 (GRE1, Li et al., 2014; Vokes et al., 2008).  
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Figure 13. GRE1 interaction with GLI3 represses Grem1 anterior expression. (A-
B) Comparison of Grem1 WISH in forelimbs of E10.5 (35-36 somites) mouse wild-type 
(WT) and GRE1 homozygous deleted embryos (GRE1∆/∆). Grem1-free domains are 
indicated with white brackets. (B) Dotted white arrow shows ectopic distal-anterior 
Grem1 expression in GRE1∆/∆ backgrounds. Lower panel: schematic of GLI3 
repression of Grem1 might occur in WT and GRE1∆/∆ backgrounds through GRE1 
and/or other putative silencers. Adapted from Li et al. (2014). 
 
 
4.2.4. Grem1 and human limb congenital diseases 
 
In humans, congenital limb malformations (CLMs) affect ± 1 in 500 live births (Giele et 
al., 2001). Cenani-Lenz (C-L) syndrome is a limb congenital malformation 
characterized by syndactyly of the hands and feet with complete fusion of bones and 
soft tissue. Individuals suffering from C-L syndrome also display shortening and fusion 
of zeugopod skeleton in forelimbs and hindlimbs and require reconstructive surgery 
(Cenani and Lenz, 1967; De Smet et al., 1992; Furniss et al., 2009; Malik, 2012). The 
C-L syndrome phenotypes can be associated with various systemic features such as 
renal defects (Bacchelli et al., 2001; Dimitrov et al., 2010). The murine ld model 
displays the most similar phenotypes to human C-L syndrome. Grem1 transcriptional 
disruption in mice is responsible for the pleiotropic ld phenotypes. Dimitrov and 
colleagues in 2010 studied the case of C-L-like individuals in which the Grem1 cis-
regulatory landscape was affected but not the Grem1 gene itself (Dimitrov et al., 2010). 
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One patient showed ld-like phenotypes with radioulnar synostosis, syndactyly in both 
hands and feet plus an agenesis of the left kidney (Dimitrov et al., 2010, Figure 14a). 
Those phenotypes are identical to the mouse ld phenotypes. This patient carried a 
deletion of at least 246 kb, including the first 12 exons of Fmn1. This deletion did not 
encompass the Grem1 annotated GCR (Zuniga et al., 2004) suggesting a loss of 
essential Grem1 CRMS outside of the GCR and/or a structural disruption of Grem1 
cis-regulatory landscapes that, in humans, could cause C-L syndrome (Figure 14b). 
 
 
Figure 14. Cenani-Lenz-like phenotype observed in patient correlates with 
Grem1 cis-regulatory landscape mutation. (a) young patient hands with 
oligosyndactyly because of (b) a 246 kb deletion (minimal size) including at least the 
first 12 exons of Fmn1. From Dimitrov et al. (2010). 
 
We have discussed so far the Grem1 LOF phenotypes. It is noteworthy that the Grem1 
gain of function (GOF) has deleterious effects. High expression of Grem1 has been 
reported in different tumor types, such as in breast and colorectal cancer (Jaeger et 
al., 2012; Ren et al., 2019). Hereditary mixed polyposis syndrome (HMPS) 
characterized by autosomal dominant inheritance of various forms of colorectal polyp 
resulting in colorectal carcinoma (CRC) at high frequency is the consequence of a 40 
kb duplication upstream of Grem1. Once again, this mutation does not affect the GCR.  
 
Despite the amazing progress that have been made, much remains to be done in the 
understanding of Grem1 transcriptional regulation. 
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5. Aims of the thesis 
 
 
My Ph.D. project revolved around the understanding of the mechanisms by which the 
Grem1 gene, a key developmental player of limb patterning and outgrowth, is 
transcriptionally regulated during mouse organogenesis.  
Aim 1 – To identify all Grem1-associated CRMs, using chromatin profiling and 
transgenic reporter assays to locate possible Grem1 CRMs.  
Aim 2 – To characterize the functional role(s) of the identified CRMs in the regulation 
of Grem1 expression, using a loss of enhancer function strategy based on the 
CRISPR/Cas9 technology.  
Aim 3 – To elucidate the chromatin organization of the Grem1 landscape in wild-type 
and genetic mutant backgrounds using 4C-seq experiments.  
Aim 4 – To get a more comprehensive understanding of the cellular mechanisms by 
which Grem1 transcriptional defects lead to a spectrum of ld phenotypes; using Lyso 
Tracker experiments to look for abnormal apoptotic cell clusters and using 
fluorescence-activated cell sorting (FACS) to control the proliferation rate in mutant 
limb buds.  
In addition to my own project, I was given the opportunity to participate in the study of 
the BMP signaling transducer SMAD4 functions during early limb bud development 
(Gamart et al., manuscript in preparation). As BMPs are direct transcriptional 
regulators of Grem1, this project complemented and enriched my own research. In 
addition, I was given the chance to support my colleagues working on getting insights 
into the underlying transcriptional mechanisms supporting vertebrate limb 
diversification by performing ATAC-seq experiments in pig embryonic limb bud at 
different stages. 
 
  38 
6. Results 
 
6.1. Identification of Grem1 putative cis-regulatory elements 
 
6.1.1. Characterization of the 310 kb Grem1 TAD 
 
Grem1 defines a functionally essential node in the SHH/GREM1/AER-FGF self-
regulatory feedback loop governing limb bud outgrowth and patterning (Benazet et al., 
2009). Previous studies have shown alterations of the Grem1 chromatin landscape, 
leading to severe limb deformity phenotypes, reflecting major transcriptional alteration 
both in mouse and in human (Dimitrov et al., 2010; Jaeger et al., 2012; Khokha et al., 
2003; Zuniga et al., 2004; Zuniga et al., 2012b). I thus investigated Grem1 flanking 
genomic region to look for Grem1-associated chromatin, containing the CRMs in 
charge of tightly controlling Grem1 dynamic expression in space and time during limb 
bud development. Hi-C maps offer the possibility to observe three-dimensional 
chromatin organization in order to identify regulatory blocks within which CRMs and 
their associated gene(s) interacted at high-frequency (Dixon et al., 2012; Nora et al., 
2012; Sexton et al., 2012). Those regulatory units or TADs are organized in loop 
domains demarcated by divergent CTCF sites hindering inter-TAD interactions 
(Fudenberg et al., 2016; Rao et al., 2014). TADs are described as well-conserved 
throughout different cell types and species, once established they stay unchanged 
during embryonic development (Dixon et al., 2012).  
Analysis of Hi-C experiments performed on mouse embryonic fibroblast with a 10 kb 
resolution by Barutcu and colleagues suggested the Grem1 gene belonged to a 530 
kb TAD at chromosomal coordinates mm10 chr2:113,298,340-113,830,145 (Barutcu 
et al., 2018), in which convergent CTCF sites would organize intra-TAD looping 
(Andrey et al., 2017, Figure 15). Grem1 segregated together with Scg5 and Fmn1 
genes and I observed divergent CTCF motifs 5’ of Fmn1, separating Grem1, Scg5 and 
the 3’ portion of Fmn1 from the Fmn1 5’ region and thus generating two relatively 
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independent TADs (dashed lines Figure 15). This hinge, where the sub-TADs collide, 
was located between exon 8 and 9 of Fmn1 (chromosomal coordinates mm10 
chr2:113469703-113494902), potentially isolating the Fmn1 regulatory landscape 
from the Grem1/Scg5 specific regulatory elements. By looking at the CTCF sites and 
according to their orientations, I presumed the regulatory region of Grem1 was 
contained within a 310 kb TAD at chromosomal coordinates mm10 chr2:113,493,843-
113,807,346 (Figure 15, blue dashed lines). I could not exclude that the region 
structurally associated with the Fmn1 gene (chromosomal coordinates mm10 
chr2:113,298,340-113,493,843, Figure 15, grey dashed lines) would be associated 
with Grem1 transcriptional control as the frequency of interaction between these two 
loops was quite high (Figure 15, red dashed lines). These observations did not strictly 
exclude a role of potential CRMs located within the Fmn1 TAD in Grem1 transcriptional 
regulation.   
Transcriptome profiles from mouse forelimb buds at E11.5 (and E10.5, Appendixes 
Figure 1) showed a high Grem1 transcriptional level while Fmn1 and Scg5 were very 
lowly transcribed (Andrey et al., 2017, Figure 15). These observations were supported 
by WISH experiments performed by Victorio Palacio showing a low signal for Fmn1 
transcripts and the absence of signal for Scg5 transcripts. In contrast, the Grem1 
signal was strong and characterized by a crescent-shape pattern at developmental 
stages E10.5-E11.0 (Figure 15). Fmn1 seemed to be weakly transcribed in the 
mesenchymal part of the limb bud and accumulated in the AER, while Scg5 was 
inactive in the limb (Iguchi et al., 1984; Pavel et al., 2007; Westphal et al., 1999, Figure 
15). Zuniga and colleagues have previously demonstrated that Fmn1 was not involved 
in limb development (Zuniga et al., 2004). All these observations suggested that the 
regulatory regions within the 530 kb TAD could be 1) active CRMs associated with 
Grem1, 2) CRMs associated with Fmn1 or Scg5 and weakly active or inactive in our 
model (Figure 15).  
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Figure 15. Identification of the Grem1 topologically associated domain (TAD). 
Upper panel: Hi-C map (Barutcu et al., 2018) obtained from mouse embryonic 
fibroblasts with a 10kb resolution shows the distribution of TADs on either side of the 
Grem1 gene in black, other genes are represented in dark grey lines, dashed lines 
indicate TADs. Lower panel: UCSC browser windows displaying E11.5 mouse 
forelimb bud CTCF ChIP-seq (Andrey et al., 2017) identify CTCF binding sites, their 
orientation is represented with orange and green arrowheads. Blue and grey dashed 
lines unveil a potential Grem1 TAD and a potential Fmn1 TAD respectively. E11.5 
mouse forelimb bud RNA-seq (Andrey et al., 2017) showing the transcriptional activity 
of Grem1 and its neighboring genes. Lower panel: WISH, performed by Victorio 
Palacio for Fmn1 and Scg5, showing the limb expression pattern of Grem1 TAD 
genes, Fmn1 in the mesenchyme (mes) and in the AER, Grem1 and Scg5 that was 
not detected (n=3). Scale bar: 250μm  
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I identified a 530 kb TAD, that could be divided into a Grem1-associated TAD 
and a Fmn1-associated TAD. I predicted that the Grem1- and Fmn1-related TADs 
would contain CRM-like regions. Each sub-TADs being relatively independent 
of each other, I estimated that Grem1 CRMs would be located within the 310 kb 
loop domain uncovered by Hi-C-seq experiments. 
 
6.1.2. Identification of 14 potential CRMs in the Grem1-Fmn1 
TAD  
 
Our CRM discovery strategy relied on well-established criteria of epigenomic profiling. 
CRMs are located at chromatin accessible regions. ATAC-seq experiments, 
performed by Dr. Rushikesh Sheth and Jens Stolte, expose open chromatin regions 
including CRMs but not exclusively (Buenrostro et al., 2013). In order to reveal 
potential Grem1 CRMs, I aligned mouse forelimb ATAC-seq profiles at embryonic 
stages 10.5 and 11.5 – when Grem1 transcription is strongest and highly dynamic – 
with ChIP-seq profiles of different histones marks (Andrey et al., 2017). The H3K27ac 
and H3K4me1 modifications are associated with active and distal enhancers while the 
combination of H3K27ac and H3K4me3 decoration highlights promoter sequences. 
As CRMs can be highly conserved through evolution, I compared the previous data 
sets with available mammalian conservation profiles (Figure 16). I thus identified 10 
CRM-like loci (Figure 16, light blue vertical bars) within the Grem1 loop domain (Figure 
16, black bar) and could define 4 CRM-like loci (Figure 16, light blue vertical bars) in 
the Fmn1 loop domain (Figure 2, grey bar). The histone “code” and CTCF ChIP-seq 
profiles (Andrey et al., 2017) allowed us to pinpoint promoter and boundary elements 
among the CRM-like regions identified by our chromatin profiling (Figure 15, Figure 
16). I classified these elements from CRM1 to CRM14, the closest (in linear distances) 
to Grem1 being the number 1 and the most distant the number 14. The CRM12 was 
decorated by the promoter mark H2K4me3 in accordance with previous studies 
describing the CRM12 region as an alternative Fmn1 promoter (Jackson-Grusby et 
al., 1992). 
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Figure 16. Identification of putative Grem1 CRMs. Upper panel: UCSC browser 
windows displaying E10.5 forelimb bud ATAC-seq profile, assays by Dr. Rushikesh 
Sheth and Jens Stolte, ChIP-seq profiles obtained from E10.5 mouse forelimb bud 
tissue targeting the enhancer marks H3K27ac and H3K4me1 and the promoter 
signature H3K4me3 (Andrey et al., 2017). Lower panel: E11.5 forelimb bud ATAC-seq 
profile, ChIP-seq profiles for enhancer marks H3K27ac and H3K4me1 and the 
promoter signature H3K4me3 (Andrey et al., 2017). The last track shows mammalian 
conservation. The grey and black lines represent the Fmn1 and the Grem1 loop 
domains respectively. 
 
 
Another criterion for CRM discovery is their ability to bind TFs to regulate the 
expression of their associated genes according to environmental cues. The signaling 
pathways regulating the highly dynamic transcription of Grem1 have been extensively 
studied for the past 20 years. The BMP4 pathway, the SHH pathway, the WNT/ß-
catenin pathway and the developmental regulators HoxA;D genes are all involved in 
the initiation or propagation of Grem1 expression during limb bud development 
(Benazet et al., 2009; Sheth et al., 2013; Dr. Unal Ph.D. thesis; Sheth et al., manuscript 
in preparation). I intended to uncover possible physical interactions between the 
putative CRMs and the TFs relaying those signaling pathways regulatory information. 
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To this end, ChIP-seq experiments, in E11.5 mouse embryo forelimbs, targeting the 
nuclear mediators of the Shh pathway – GLI3 ChIP-seq (in collaboration with Dr. Kevin 
Peterson) – of the Wnt pathway – ß-catenin ChIP-seq (Sheth et al., manuscript in 
preparation) – of HOXA13 and HOXD13 (Sheth et al., 2016) – were analyzed (Figure 
17a). BMP pathway being involved in the initiation of Grem1 transcription (Benazet et 
al., 2009), I analyzed ChIP-seq data from a FLAG-tagged SMAD4 mouse line 
(SMAD43xF) at early developmental stages E9.5 and E10.5 (Figure 17b, Gamart et al., 
manuscript in preparation). I observed that all the CRM-like regions I identified were 
able to bind at least one transcription factor. Most CRM candidates were interacting 
with several TFs. I noted only one CRM-like locus (CRM2) bound by SMAD4 at E9.5. 
This interaction was lost at E10.5. This element was hypothesized to be the only CRM 
involved in integrating BMP pathway activity at early limb developmental stages.  
 
 
 
Figure 17. Identification of interactions between Grem1 putative CRMs and 
Grem1 trans-acting factors. (a) UCSC browser windows displaying ChIP-seq 
profiles in E11.5 mouse forelimb buds for the transcription factors β-catenin (Sheth et 
al., manuscript in preparation), GLI3 (in collaboration with Dr. Kevin Peterson), 
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HOXA13 and HOXD13 (Sheth et al., 2016). (b) UCSC browser windows displaying 
ChIP-seq profiles in E9.5 and E10.5 mouse forelimb bud targeting BMP pathway 
readout SMAD43xF (Gamart et al., manuscript in preparation). The grey and black lines 
represent the Grem1 and the Fmn1 loop domains respectively. 
 
 
Fourteen CRM-like regions had been identified at this stage of analyses. I 
grouped them according to their localization within the Grem1 TAD (CRM1 to 
CRM10) or the Fmn1 (CRM11 to CRM14).  
 
6.1.3. Analysis of Grem1 putative CRMs enhancer activity 
 
At this stage of the analyses, 14 putative CRM elements were identified. I intended to 
pinpoint which of these regions were active to drive a reporter expression in 
overlapping fashion with Grem1 endogenous expression. In order to test those regions 
for enhancer activity, I used a lacZ reporter assay in transgenic mice, in collaboration 
with the Center for Transgenic Model (CTM, Appendixes table 1). I cloned the CRMs 
from mouse genomic DNA into an hsp68-lacZ expression vector using the Gibson 
Assembly® Method. 
 
 
6.1.3.1. The Grem1 TAD presents 8 limb CRMs 
 
I screened CRM1 to CRM10 for enhancer activity. I discovered that CRM8 and CRM9, 
despite presenting all epigenetic characteristics of enhancers, were not able to drive 
a reproducible lacZ pattern of expression in our assay (Figure 18, Appendixes table 
1). CRM8 and CRM9 were not limb bud enhancers.  
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Figure 18. CRM8 and CRM9 enhancer activities in transgenic mouse embryos. 
(a) Schematic of the Grem1-Fmn1 locus (b-c) CRM8 and CRM9 transgenic embryos 
collected at E11.5. Scale bar: 250µm  
 
 
The remaining CRMs were all able to drive reporter expression in the limb bud 
(Appendixes table 1). I compared the LACZ protein spread to the pattern observed in 
the Tg-GLE(tg/+) reporter mouse line established in the laboratory (Skarnes et al., 
2011, Figure 19). This mouse strain is a knock-in where the ß-galactosidase reporter 
gene, under the control of the Grem1 cis-regulatory region, is expressed exclusively 
in the limb bud. 
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Figure 19. LacZ expression in the Tg-GLE(tg/+) transgenic mouse line forelimb 
and hindlimb at E11.5. The lacZ reporter staining overlaps with the endogenous 
Grem1 expression domain in the limb buds. Scale bar: 250µm 
 
 
These CRMs could be distinguished into two categories. The first category contained 
CRM1, CRM3, CRM4, CRM6, CRM7 and CRM10. This group of regulatory elements 
contained limb enhancers, some able to drive a reproducible reporter expression that 
partially overlaps with Grem1-expressing cells (Figure 19, Figure 20). A total of 62.5% 
CRM1 transgenic limb that expressed lacZ (n=5/8, Figure 20b) showed a reproducible 
signal covering the autopod entirely, including the Grem1 expression domain as 
observed by WISH (Figure 15) and in the Tg-GLE(tg/+) embryonic limb (Figure 19). 
CRM3 provided a reproducible lacZ expression in the anterior and distal parts of the 
autopods in 87.5% of the transgenic limb expressers (n=7/8, Figure 20c), partially 
overlapping with the anterior distal Grem1 activity. CRM4 limb expressers displayed 
lacZ expression in the posterior distal part of the limb bud for all of them (8/8, Figure 
20d) and this time partially overlapping with the posterior distal Grem1 activity. CRM6 
was a limb enhancer but did not drive a reproducible lacZ expression as two-third of 
the transgenic limbs showed different activity patterns, partially overlapping with the 
Grem1 expression domain, while the last embryo was stained in the AER (Figure 20e). 
CRM7 showed for 66% of the lacZ-expressing limbs a distal and anterior enhancer 
activity (n=4/6, Figure 20f), outside of the Grem1 expression domain, while in forelimbs 
CRM10-induced expression appeared mosaic and not reproducible. CRM10-driven 
hindlimb expression was highly reproducible and overlapped with the Grem1 hindlimb 
posterior distal domain of expression (n=3/4, Figure 20g). While forelimb expression 
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of the reporter gene for CRM10 constructs was quite weak, the hindlimb reporter signal 
suggested the CRM10 enhancer as a Grem1 hindlimb-specific enhancer. 
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Figure 20. CRM1, CRM3, CRM4, CRM6, CRM7, CRM10 enhancer activities in 
transgenic mouse embryos. (a) Schematic representation of the Grem1-Fmn1 locus 
(b-g) CRM1, CRM3, CRM4, CRM6, CRM7, CRM10 transgenic embryonic limb buds 
collected at E11.5 showing the lacZ reporter activity under the control of each different 
CRMs. Scale bar: 250µm  
 
 
Among these active limb enhancers, CRM3 and CRM4 had already been identified as 
HMCO2 in our laboratory (Zuniga et al., 2012a), and by Li and colleagues as GRE1 
(Li et al., 2014). While HMCO2 had been described as a region unable to drive a 
reproducible lacZ expression (Zuniga et al., 2012a), successful collaboration with the 
CTM revealed CRM3 as a strong limb enhancer: 87.5% of the transgenic CRM3-
hsp68-lacZ were limb expressers (see Material and Methods section, Table 9.5.1). 
Together, our data suggested that all the CRMs in this category were potential 
modulators of Grem1 transcription in the limb with distinct spatial activities.  
According to their spatial enhancer activities, CRM2 and CRM5 did not belong to any 
of the heretofore described categories. Grem1-associated enhancers were expected 
to display a posterior distal enhancer activity with an anterior expansion around E11.0. 
These two promising loci distinguished themselves from all the previously described 
elements as they were able to drive reporter expression in the transgenic forelimbs 
similar to what was observed in the Tg-GLE(tg/+) mouse transgenic line (Figure 19), 
in accordance with our expectations. CRM2 – previously known as GRS1 (Zuniga et 
al., 2012a) – and CRM5 could induce a reporter expression in the limb bud 
mesenchyme posteriorly and distally with an anterior expansion characteristic of 
endogenous Grem1-expressing cells localization (Zuniga et al., 2012a, Figure 15, 
Figure 21b,c). CRM2 drove a Grem1-like forelimb reporter expression pattern in all 
limb expressers embryos, while CRM5 forelimb activity was weaker than the activity 
of CRM2 and detected in a Grem1-like domain in 50% of the forelimb expresser 
embryos. A total of 50% of CRM5 embryos displayed a wide hindlimb signal spread, 
engulfing the full hindlimb Tg-GLE(tg/+) pattern (Figure 19, Figure 21c). My results 
confirmed CRM2 as a strong limb enhancer which drove the closest endogenous 
Grem1-like expression pattern and identified CRM5 as a second enhancer with similar 
activity, albeit less robust. I had yet to validate their association with Grem1 
transcriptional regulation and to further validate their individual role(s). 
  49 
 
 
Figure 21. CRM2 and CRM5 enhancer activities in transgenic mouse embryos. 
(a) schematic of the Grem1-Fmn1 locus highlighting CRM2 and CRM5 with blue ovals 
(b-c) CRM2 and CRM5 transgenic embryos limb bud forelimbs collected at E11.5 
showing the lacZ reporter activity under the control of each different CRMs. Scale bar: 
250µm 
 
 
Interestingly, Zuniga and colleagues had demonstrated that a 170 kb deletion between 
exon 10 and exon 24 of Fmn1 (chromosomal coordinates mm10 chr2: 113,528,475-
113,709,592) was sufficient to inactivate Grem1 expression during mouse limb bud 
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development, leading to severe limb deformity phenotype with a 100% penetrance 
(Zuniga et al., 2004). Their study suggested that outside of this region, relabeled as 
the Cis region in our study (Figure 22a, dashed lines), no enhancer was able to drive 
Grem1 transcription. I was indeed able to reproduce their observations (Figure 22b). 
RT-qPCR and WISH analysis of Cis∆/∆ embryos confirmed the loss of Grem1 
expression and 100% of the forelimb skeletal of E14.5 forelimb had severe ld 
phenotypes (Appendixes table 1).  
 
 
 
Figure 22. Effect of the Cis∆/∆ mutation on Grem1 transcription and limb 
development. (a) schematic representation of the Cis deletion, dashed lines highlight 
the Cis region (b) qPCR quantification of Grem1 expression level at E11.0 (40ss to 
42ss, n=7) ***P=0.0006 (n=7 littermates, two-tailed Mann-Whitney test), WISH of 
forelimbs (n>3) from E9.75 (26ss to 28ss), E10.5 (34ss to 36ss), E11.0 (40ss to 42ss) 
to E12.0 (50ss to 53ss), Skeletal stainings of E14.5 embryos. Scale bars: 500μm 
(skeletal stainings), 250μm (WISH) 
 
 
The deletion of the Cis region did not include the Fmn1 TAD either CRM1 or CRM10 
enhancers. I had tested Grem1 promoter activity in lacZ assays: it was unable to drive 
reporter expression in the limb on its own (Appendixes Figure 2). Grem1 transcription 
needed enhancers to be activated. Nevertheless, there was no residual Grem1 
expression in this mutant (Figure 22). These observations led us to consider the 
remaining enhancers as non-Grem1 associated and to remove CRM1 and CRM10 to 
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CRM14 from our analysis. All the CRMs able to drive reporter expression in a pattern 
similar to Grem1 in the forelimb bud during mouse embryonic development were 
comprised within the Cis region.  
 
CRM2 to CRM7 were the active limb enhancers that fulfilled all our criteria to be 
associated with Grem1 expression. Based on their pattern of activity, CRM2 and 
CRM5 were the enhancers recapitulating the Grem1 expression pattern the 
closest. 
 
6.1.3.2. CRMs present in the Fmn1 TAD do not seem 
associated to Grem1 expression 
 
All the CRM-like regions identified by chromatin profiling in the Fmn1 TAD exhibited 
limb enhancer activity (Figure 23). The putative CRMs regions in the Fmn1 loop 
domain segregated into two categories of limb enhancers. The first category grouped 
CRM11 and CRM13 with weak limb enhancer activity (<50% limb expression rate) and 
no reproducible pattern (Figure 23b-d). The second category included CRM12 and 
CRM14 and had a high activity rate (>50% limb expression rate, Figure 23c-e, 
Appendixes table 1). The LACZ protein accumulated in the AER in a reproducible 
fashion, 67% (n=4/6) and 91.7% (n=11/12) for CRM12 and CRM14 transgenic limb 
buds respectively. This pattern mimicked Fmn1 endogenous expression in the AER 
(Zuniga et al., 2004, Figure 15, Appendixes table 1). Since Grem1 is not expressed in 
the AER, these results suggest that 1) CRM12 and CRM14 were associated with 
Fmn1 AER expression and not Grem1 or Fmn1 mesenchymal expression, 2) CRM11 
and CRM13 were weak limb enhancers, not associated with Grem1 in a wild-type 
genetic background. CRM12 was an alternative Fmn1 promoter (Jackson-Grusby et 
al., 1992) with a distinctive enhancer potential. 
 
The lack of limb mesenchymal lacZ activity together with the presence of activity 
in the AER suggest that CRM11-14 do not regulate Grem1 expression during 
limb bud development. 
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Figure 23. CRM11-14 enhancer activity in transgenic mouse embryos. (a) 
Schematic map of the Grem1-Fmn1 locus (b-e) CRM11-14 transgenic embryos 
collected at E11.5. Transgenic embryos labeled with blue roman numerals show limb 
enhancer activity. Scale bar: 500µm  
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By combining TF footprints, epigenetic chromatin modifications and reporter 
assays, I identified and tested the enhancer properties of the CRMs of interest. 
Further analysis was needed to assess each CRM role(s) in vivo. Besides, 
reporter assay did not discriminate for any other cis-regulatory activity. CRM8 
and CRM9 could potentially have regulatory properties undisclosed by this 
analysis.  
 
6.2. Genetic dissection of the Grem1 regulatory landscape 
 
To identify the in vivo function of the CRMs of interest, I used CRISPR/Cas9 
technology to delete CRMs and addressed their functional relevance for the 
endogenous Grem1 transcriptional regulation.  
 
6.2.1. Disclosing Enhancer Cluster 1 (EC1) as a major 
regulator of Grem1 transcriptional regulation.  
 
Previous publication by the laboratory postulated that CRM2-4 belonged to a 70 kb 
GCR, necessary for the activation of Grem1 expression in the posterior limb bud 
mesenchyme (Zuniga et al., 2004). I dissected this region (mm10 chr2:113,636,776-
113,707,974) relabeled as enhancer cluster 1 (EC1). CRM4 was proposed to be a 
Grem1 repressor in the anterior part of the limb at E10.5 (Li et al., 2014). I proceeded 
to analyze the deletions of CRM2 and CRM3 individually in mice, in order to clarify 
their respective properties within the previously described GCR (Material and Methods 
Table 9.5.3). RT-qPCR at E11.0 showed that the deletion of CRM2 reduced Grem1 
transcript count to ± 50% of its wild-type counterpart when Grem1 expression was at 
its peak and formed a crescent shape. I performed WISH experiments to assess 
whether endogenous Grem1 expression was altered by enhancer deletions. The onset 
of Grem1 expression occurs at around E9.5 and is quite variable at this stage. It was 
therefore difficult to assess whether expression was changed in mutants (Appendixes 
Figure 3). At E10.5 (35-37ss), Grem1 expression domain in CRM2∆/∆ mutant limb buds 
were confined to the most distal posterior part of the limb mesenchyme (Figure 24b,c). 
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Previous analyses by the laboratory had quantified an approximative 50% of the 
Grem1 expression levels reduction at this stage (data not shown). This observation 
suggested an essential role for CRM2 during the expansion phase of Grem1-
expressing domain in the anterior distal part of the bud at E10.5. Grem1 territory then 
expanded in CRM2∆/∆ forelimbs and caught up with the wild-type embryos signal in a 
thinner crescent shape (Appendixes Figure 4, Figure 24c). At E11.0 (40-42ss), the 
Grem1 crescent was narrower than what was observed in the wild-type limb buds; the 
proximal and anterior areas of Grem1 domains appeared slightly truncated (Figure 
24b,c). Surprisingly, E12.0 forelimb buds showed a premature termination of Grem1 
transcription. Homozygous CRM2∆/∆ embryos developed normal limb skeleton despite 
having a strongly restricted Grem1 domain at E10.5, a thinner domain of expression 
at E11.0 and an early termination at E12.0 (Figure 24b,c). Thus, Grem1 expression at 
E12.0 did not seem essential for limb bud development. CRM2 enhancer appeared to 
be essential for proper Grem1 transcription in terms of levels, spatial and temporal 
regulations. CRM3 loss did not significantly impact Grem1 transcription levels and 
WISH did not reveal noticeable changes of spatial or temporal localization of Grem1 
transcript except at E11.0 where a wider distance between the Grem1 signal and the 
AER region was noticed (Figure 24b-d). Limb skeletons were normal at E14.5 (Figure 
24d). This suggested that CRM3 could be involved in the activation of Grem1 in the 
limb bud distal domain at E11.0 but this role was not essential for forelimb 
development, in absence of other perturbation(s).  
Individually, our single deletions did not affect the essential aspects of Grem1 
transcriptional regulation. There were neither sufficient to fully inactivate Grem1 
activity nor to hinder limb development on their own.  
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Figure 24. Genetic dissection of EC1. (a) Scheme of the Cis locus, active EC1 
enhancers CRM2, CRM3 and CRM4 are represented in blue ovals. Dashed lines 
highlight deleted regions. (b-d) Comparison of Grem1 expression levels of (b) WT, (c) 
CRM2∆/∆ and (d) CRM3∆/∆ at E11.0 ***P=0.0006 (n=7 littermates, two-tailed Mann-
Whitney test). WISH of forelimbs (n>3) from E9.75 (26ss to 28ss), E10.5 (34ss to 
36ss), E11.0 (40ss to 42ss) to E12.0 (50ss to 53ss), brackets in (d) indicates the in 
anterior limb buds Grem1-free domain and of E14.5 embryos skeletal stainings. Scale 
bars: 500μm (skeletal stainings), 250μm (WISH) 
 
 
To further understand the functional relevance of EC1, I next analyzed the double 
mutants for CRM2CRM3 and for CRM2CRM4 deletions (Figure 25a, Material and 
Methods section 9.1.2 and Table 9.5.3). I expected to see changes in Grem1 
expression that would at least recapitulate the CRM2∆/∆ phenotype (Figure 25b,c). I 
quantified Grem1 expression levels by RT-qPCR at E11.0 and measured a 65% 
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decrease for CRM2CRM3∆/∆ (Figure 25c) and a 50% decrease for CRM2CRM4∆/∆ 
(Figure 25d) of Grem1 transcriptional levels. The Grem1 expression domain for these 
two mutants was similarly restricted distally and posteriorly (Figure 25c,d). 
CRM2CRM3∆/∆ and CRM2CRM4∆/∆ presented a much more restricted version of the 
crescent shape pattern of the wild-type or the CRM2∆/∆ mutants (Figure 25b-d, Figure 
24c). Both mutants displayed a distal and anterior loss of Grem1 expression, 
suggesting the involvement of these two elements in Grem1 expression in those 
domains at E11.0. Thus, combined enhancer activities of CRM3 and CRM4 at E11.0 
seemed essential for Grem1 anterior expansion at E11.0. Individually, CRM3 and 
CRM4 did not display a direct enhancer activity toward Grem1 transcriptional levels. 
Nevertheless, they seemed to have major roles in refining the Grem1 territory in its 
anterior and distal expression domains. Grem1 transcripts from CRM2CRM4∆/∆ 
mutants seemed, in the anterior part, to occupy a wider area than in the 
CRM2CRM3∆/∆ homozygous mutants (white arrows Figure 25d). These results could 
corroborate the reported role of CRM4 as a Grem1 limb anterior repressor at E11.0 
(Li et al., 2014). The combined loss of CRM2 and CRM4 did not trigger an obvious 
anteriorization of its expression domain such as described by Li and colleagues at 
E10.5 in CRM4∆/∆ mutants (Appendixes Figure 5) but reproduced the reduction of 
expression domain obtained by deleting CRM2 alone (Appendixes Figure 5, Figure 
24c). This observation suggested 1) a critical and unique role of CRM2 for boosting 
the expression of Grem1 at E10.5, 2) that CRM2 and CRM4, at least, cooperated to 
shape the anterior domain of Grem1 expression at this stage but, 3) that at E11.0, 
different mechanisms involving CRM2, CRM3 and CRM4, at least, were set up to 
regulate Grem1 expression.  
Ectopic or restricted Grem1 transcription at E10.5 did not appear to be critical for limb 
skeletal development, as long as Grem1 was indeed expressed in the posterior distal 
part of the bud. Skeletal staining gave mild phenotypes as CRM2CRM3∆/∆ and 
CRM2CRM4∆/∆ showed variable severity of soft tissue fusion between digit 2 and 3 
(Figure 25c,d, Appendixes Table 1) Our observations suggest that the E11.0 
developmental stage represented a crucial time window for limb development. Those 
deletions were not sufficient to severely challenge limb bud development (no 
syndactyly was observed in forelimb skeletons) and so I considered the possibility that 
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the whole EC1 was required for Grem1 transcriptional regulation. Therefore, EC1∆/∆ 
mice were generated and analyzed.  
 
 
 
Figure 25. Grem1 WISH at E11.0 for CRM2CRM3∆/∆ and CRM2CRM4∆/∆ double 
mutants. (a) schematic of the Cis locus, active EC1 enhancers CRM2, CRM3 and 
CRM4 are represented in blue ovals. Dashed lines highlight deleted regions. (b-d) 
Comparison of Grem1 expression levels of (b) WT, (c) CRM2CRM3∆/∆ and (d) 
CRM2CRM4∆/∆ at E11.0 **P<0.01 (n=7 littermates, two-tailed Mann-Whitney test), 
brackets in (c-d) indicate the in anterior limb buds Grem1-free domain, white arrows 
indicate distal-anterior Grem1 expression, WISH of forelimbs at E11.0 (40ss to 42ss) 
and of E14.5 embryos skeletal stainings. Scale bars: 500μm (skeletal stainings), 
250μm (WISH) 
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The deletion of the EC1 locus (Figure 26a) consisted of the first 70 kb of the Cis region, 
3’ of Grem1 (Material and Methods Table 9.5.3). CRM2, CRM3, and CRM4 were 
deleted simultaneously in the EC1∆/∆ mutants (Figure 26a). The homozygous deletion 
of EC1 led to a ± 50% decrease in Grem1 expression levels (Figure 26b,c), analogous 
to the previously measured reductions of Grem1 expression in CRM2∆/∆, 
CRM2CRM3∆/∆ and CRM2CRM4∆/∆ mutant handplates. The EC1∆/∆ homozygous 
mutants WISH showed a comparable distribution of Grem1 transcript to CRM2∆/∆ 
mutants at E9.75, E10.5 and E12.0 where I saw an early termination of Grem1 
expression (Figure 24c, Figure 26c). Once again, the E11.0 stage stood out as the 
most critical stage for Grem1 regulation of limb development as WISH patterns greatly 
diverge only at this stage between CRM2∆/∆ and EC1∆/∆ (Figure 26b). EC1∆/∆ combined 
phenotypes of both CRM2CRM3∆/∆ and CRM2CRM4∆/∆ in an additive manner with a 
narrow Grem1 crescent shape and the slight anterior expansion described earlier at 
E11.0 for CRM2CRM4∆/∆ (Figure 25d). Interestingly, I observed that the limbs adopted 
a trapezoidal shape at E12.0, a precursor sign of limb deformity phenotypes: the 
reduction of Grem1 domain at E10.5 and the early termination of Grem1 only 
combined with significant changes of Grem1 domain at E11.0 were associated with 
limb developmental defects. During skeletal staining process at E14.5, I observed 
100% penetrance of soft tissue fusions (digits 2 to 3, also observed in the 
CRM2CRM3∆/∆ and CRM2CRM4∆/∆ mutants, Figure 25c,d and Figure 26c) and even 
more compelling for our study, 20% of them had a C-L type syndactyly (Appendixes 
Table 1, Figure 26c). EC1 loss caused a more severe skeletal phenotype at E14.5 
than the previously described double mutants CRM2CRM3∆/∆ or CRM2CRM4∆/∆. By 
narrowing down the Cis region and deleting EC1, Grem1 transcription was significantly 
affected and this challenged Grem1 regulatory mechanisms beyond their 
compensatory capacities, resulting in mild ld phenotypes.  
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Figure 26. Analysis of EC1 homozygous mutant. (a) Schematic of the Cis locus, 
active EC1 enhancers CRM2, CRM3 and CRM4 are represented in blue ovals. 
Dashed lines highlight deleted regions. (b-c) Comparison of Grem1 expression levels 
of (b) WT and (c) EC1∆/∆ at E11.0 ***P=0.0006 (n=7 littermate, two-tailed Mann-
Whitney test), WISH (n>3) from E9.75 (26ss to 28ss), E10.5 (34ss to 36ss), E11.0 
(40ss to 42ss) to E12.0 (50ss to 53ss), brackets in (d) indicates the in anterior limb 
buds Grem1-free domain and of E14.5 embryos skeletal stainings. Scale bars: 500μm 
(skeletal stainings), 250μm (WISH) 
 
These results uncover CRM2 as a preeminent Grem1 enhancer. CRM2 is part of 
a system that regulated the levels and the termination of Grem1 transcription. I 
observed that CRM2 worked in combination with CRM3 and CRM4 to adjust the 
spatial Grem1 expression within the EC1 unit. EC1 combined the transcriptional 
spatial, temporal and levels enhancer properties of CRM2, CRM3 and CRM4 and 
was necessary for Grem1 transcriptional regulation. Deletion of EC1 affected 
limb development but was not sufficient to reproduce Grem1 LOF phenotype, 
suggesting that other elements were responsible for controlling Grem1 
expression outside of EC1.  
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6.2.2. EC2 contains all the remaining Grem1 CRMs necessary 
for its expression in the limb bud 
 
Having previously identified CRM5, CRM6 and CRM7 as active limb enhancers, I 
tested their requirement for Grem1 expression. From our reporter assays, I identified 
CRM5 as the second most promising enhancer after CRM2. To test this hypothesis, I 
generated the single deletion of CRM5 and removed CRM5, CRM6 and CRM7 
together as the 35 kb EC2 (Figure 27a, Material and Methods table 9.5.3). Although 
CRM8 was not an active limb enhancer, it was also included in EC2 as it was located 
only 4 kb away from CRM7.  
The loss of the CRM5 enhancer led to a 30% decline in Grem1 expression levels 
(Figure 27b,c). At E11.0 I detected a slight reduction in the distal region of the Grem1 
domain (Figure 27c, black brackets). However, overall the crescent shape was 
maintained in the CRM5∆/∆ limb buds. The other stages did not differ from the wild-
type profile by WISH (Figure 27c). In comparison, the deletion of EC2 resulted in a 
50% reduction of Grem1 transcriptional levels at E11.0 (Figure 27d). Nevertheless, 
Grem1 spatial spread only seemed affected at E11.0 when the distal domain of its 
expression appeared slightly truncated in comparison to the previously described 
enhancer mutants with distal reduction of the Grem1 domain (Figure 27d, black 
brackets). The Grem1 spatio-temporal expression was not affected at other stages. In 
summary, a 50% decrease of Grem1 and a distal and possibly anterior truncation of 
its domain at E11.0 upon the loss of EC2 did not affect limb bud development as no 
limb phenotype was observed (Figure 27d). Either those regulatory elements were not 
essential for Grem1 transcription during limb development or a compensatory 
mechanism occurring at the level of the limb self-regulatory feedback loops in these 
mutants balanced the engineered deletion. EC2 on its own was an active regulatory 
locus with enhancer activity associated with Grem1 transcriptional regulation. Despite 
a 50% drop in Grem1 expression, no phenotype was observed. EC2 was less critical 
than EC1 for Grem1 transcriptional regulation during limb bud development.  
To test if other enhancers might play a compensatory role, I decided to retarget the 
EC1∆/∆ mouse line and remove either CRM5 or EC2 in cis. In parallel, the CRM2∆/∆ 
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line was retargeted to generate CRM2 and CRM5  double mutants, as these two 
elements on their own seemed to be responsible for the most important fraction of 
Grem1 transcriptional levels. At the transcriptional level, CRM2CRM5∆/∆ showed 
additive behavior as I measured an 80% decrease in Grem1 transcripts at E11.0 
(CRM2∆/∆ 50% added to CRM5 30% loss in Grem1 transcription levels, Figure 27e). 
The spatial and temporal distribution of the Grem1 signal reproduced the pattern 
observed in the CRM2 single deletion and these genetic alterations did not cause any 
limb skeleton deformity (Figure 27e). While CRM2 and CRM5 were the only enhancers 
able to drive a reporter expression recapitulating endogenous Grem1 transcript 
localization, this double mutant still displayed a posterior Grem1 domain at E10.5 that 
expanded distally and anteriorly at E11.0. In contrast, the EC1CRM5∆/∆ double 
mutants showed novel changes in Grem1 expression (Figure 27f). Expression levels 
at E11.0 were reduced by 80%, just like in the CRM2CRM5∆/∆ mouse line (Figure 
27e,f). Unexpectedly, at E10.5, I observed a slight ectopic expansion of the Grem1 
domain in the limb bud that was not seen in the previously described mutant limb buds 
(Figure 27f, black and white arrows). This early expansion preceded a significant 
reduction of Grem1 territory in width at E11.0, while the signal was also detected in 
ectopic anterior domains (Figure 27f, black and white arrows). The Grem1 expression 
levels in EC1CRM5∆/∆ mutants at E11.0 were identical to the ones measured in the 
CRM2CRM5∆/∆ forelimbs (Figure 27e,f). CRM5 had an enhancer role to amplify Grem1 
transcription at E11.0 but the anteriorization of the WISH signal in EC1CRM5∆/∆ 
mutants suggested that CRM5 might participate to repress Grem1 transcriptional 
activity in the anterior limb bud. Additionally, the normal anterior distal Grem1 domain 
in EC1CRM5∆/∆ limbs was completely erased. As expected from any generated 
deletions coupled to the removal of CRM2, I recorded an early termination of Grem1 
expression at E12.0, associated with a trapezoidal limb shape (Figure 27f). The 
penetrance of mice displaying syndactyly (4 digits) in EC1CRM5∆/∆ background was 
100% (Appendixes table 1). Those digits were organized so that the handplates 
followed a bilateral symmetry around the AP axis. This limb deformity phenotype was 
stabilized by the combined deletions of EC1 and CRM5 and tipped the scale in favor 
of tetradactyly. I assumed, in light of our previous skeletal analysis, that digits 2 and 3 
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in this mutant had fused to generate a single digit however, in absence of lineage 
tracing, it is difficult to prove.  
At this phase of the project, the EC1CRM5∆/∆ mutants had reached the threshold under 
which the limb bud could not recover and compensate for the introduced genetic 
alterations of the Grem1 expression. Nonetheless, in the EC1CRM5∆/∆ double 
mutants, 20% of Grem1 expression was maintained, most likely supported by the 
remaining CRMs in the landscape (e.g. CRM6 and CRM7). Since these remaining 
20% may be supported by multiple CRMs together, such decreases, as a result of 
additional enhancer deletions, might not be detectable with RT-qPCR assays. Thus, I 
proceeded with the analyses of EC1EC2∆/∆ mutants (Figure 27g). At E10.5, I observed 
a barely discernible signal in the posterior distal part of bud (Figure 27g). qPCR 
analysis measured at E11.0 a total loss of Grem1 transcripts (3% left versus 5% for 
the Cis∆/∆, Figure 22b and Figure 27g). WISH could detect residual Grem1 signal at 
E11.0 but in those mutants, later at E12.0, the absence of transcripts was observed in 
a fin-shaped limb bud, characteristic of the severe limb deformity phenotypes of 
Grem1∆/∆ and Cis∆/∆ mutant embryos. Indeed, 100% of the EC1EC2∆/∆ mice had a 
major limb deformity phenotype with an oligosyndactyly of 3 digits. The residual Grem1 
expression in EC1EC2∆/∆ at E11.0 was not sufficient to maintain normal forelimb 
development, not even to maintain tetradactyly, which most likely led to the breakdown 
of the limb self-regulatory feedback loop that controlled limb bud outgrowth and 
patterning. This E11.0 residual Grem1 signal could stem from the Grem1 proximal 
promoter under the control of the only CRMs left outside of EC1 and EC2: CRM1 and 
CRM10. This Grem1 expression activated by the remaining CRMs in the EC1EC2 
double mutant limb buds, the intensity and/or spatial spread were not sufficient to 
prevent the ld phenotype. 
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Figure 27. Genetic dissection of the Cis region. (a) Scheme of the Cis locus, active 
EC1 enhancers are represented in blue ovals, CRMs of EC2 are represented in 
maroon ovals. Dashed lines highlight deleted regions. (b-g) Comparison of Grem1 
expression levels of (b) WT, (c) CRM5∆/∆, (d) EC2∆/∆, (e) CRM2CRM5∆/∆, (f) 
EC1CRM5∆/∆ and (g) EC1EC2∆/∆ at E11.0 ***P=0.0006, *P<0.0175 (n=7 littermates, 
two-tailed Mann-Whitney test). WISH of forelimbs (n>3) from E9.75 (26ss to 28ss), 
E10.5 (34ss to 36ss), E11.0 (40ss to 42ss) to E12.0 (50ss to 53ss), brackets indicate 
the in anterior limb buds abnormal Grem1-free domain and arrows highlight the 
expansion of Grem1 expression domains and E14.5 embryos skeletal stainings. Scale 
bars: 500μm (skeletal stainings), 250μm (WISH) 
 
EC1 and EC2 contain all the structural and transcriptional modules necessary 
for Grem1 expression and normal limb bud development. With these results I 
established that there was a hierarchy between those clusters. EC1 alone was 
sufficient to maintain Grem1 expression in terms of time, space and intensity 
that are required for normal limb development in mice. The most important 
elements for Grem1 spatial and temporal transcription were located within EC1. 
However, EC1 and EC2, in a cooperative and additive manner, controlled Grem1 
expression levels. Upon the removal of EC1, EC2 on its own was not sufficient 
to maintain proper limb development. The combined loss of EC1 and CRM5 
preferentially resulted in tetradactyly. It appeared that the most crucial stage for 
the activity of Grem1 enhancers was E11.0. 
 
6.3. The 3D chromatin structure brings new insight into the 
transcriptional regulation of Grem1 by its enhancer clusters 
 
I next decided to address the roles of 3D chromatin architecture on the Grem1 
transcriptional regulation. Chromatin interactions are essential for many aspects of 
transcriptional regulation and long linear distances do not reflect close physical 
proximity. Using 4C-seq (Simonis et al., 2006), I was able to visualize the Grem1 
regulatory landscape interactions with its promoter as the viewpoint in wild-type and 
selected mutant backgrounds (Figure 28a, brackets). Following the principle of 
proximity ligation, 4C-seq allowed me to pinpoint the physical contacts of the Grem1 
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promoter at a kilobase resolution. This method uncovered the frequency of 
interactions of the Grem1 promoter with the Grem1 TAD was much higher than with 
the Fmn1 TAD, corroborating the analysis of Hi-C seq profiles, and CTCF location and 
orientation (Figure 28, see section 6.1.1).   
Having established a Grem1 promoter interaction map, I could investigate whether 
deletions of specific CRMs or CRM clusters affected the genomic architecture of the 
landscape. I compared the interactions of the Grem1 promoter in wild-type and Cis∆/∆ 
mice limb buds. The results established the physical interactions with the Grem1 
promoter were drastically decreased in the full cis-regulatory landscape (Figure 28b). 
The relatively infrequent interaction between the Grem1 promoter and the Fmn1 TAD 
remained with low frequency, despite a 170 kb shorter linear distance after the Cis 
deletion. There was no recruitment of CRM outside of the Cis region while Grem1 
interaction with its TAD boundaries had greatly decreased. Besides, there were no 
regions able to contact Grem1 promoter de novo (Figure 28b). Our results suggested 
no regulatory element outside of this region was able to enhance Grem1 expression: 
all relevant interactions occurred within the Grem1 TAD (Figure 28b). 
In contrast, analysis of 4C-seq profiles for CRM2∆/∆ mutant limb buds revealed only 
mild interaction changes along the TADs (Figure 28c). In particular, I identified 
interesting short-range changes. I observed de novo contacts with CRM3 and CRM4, 
nonexistent in the wild-type samples, in combination with the higher frequency of 
interactions with CRM5 (Figure 28c). Contacts with CRM6 were unchanged and 
contacts with CRM7 seemed to be lower but still happened at high frequency (Figure 
28c). In CRM2∆/∆ mutants the Grem1 expression domain could be maintained by 
CRM3 to CRM7. No CRM was able to compensate for the spatial and temporal 
changes in Grem1 expression observed with the loss of CRM2 (Figure 24c).  
EC1∆/∆ 4C-seq profiles revealed contact changes mainly within Grem1 TAD (Figure 
28d and black bar at the bottom of the figure). I could clearly distinguish a local 
increase in interactions frequency within the Grem1 TAD. The EC2 cluster established 
more frequent contacts with the Grem1 promoter. Those enhanced interactions could 
be enhancing the transcriptional levels of the targeted gene Grem1 to compensate for 
the loss of EC1. However, none of the identified CRMs were able to mimic a wild-type-
like Grem1 spatial and temporal distribution in the absence of EC1. This suggested 
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that in the wild-type environment, EC2 could actually be responsible for less than 50% 
of Grem1 transcriptional levels. Its enhancer functions could be increased through the 
increased frequency of contacts established in EC1∆/∆ mutants. Those profiles did not 
show de novo interactions in or outside of the Grem1 TAD in EC1∆/∆ forelimbs at E11.0 
(Figure 28d). 
The most surprising results was the 4C-seq for EC2∆/∆ (Figure 28e). I had expected 
high contact frequency with EC1 and in particular with CRM2, as Grem1 spatial and 
temporal expression was not affected in those mutants. So far, I had attributed the 
decrease of the Grem1 transcriptional levels to the loss of EC2 enhancer functions 
only. However, with EC2 loss, a local decrease of contacts within the Grem1 TAD was 
detected; this reduction of contact frequency also affected EC1 (Figure 28e). Thus, 
the loss of enhancer activity measured with EC2 homozygous deletion could also 
reflect deficient EC1/Grem1 promoter interactions. As I assumed CRM5 to be in 
charge of approximately 30% of Grem1 transcriptional expression, I suggested the 
rest of EC2 enhancers activity (50-30= 20%) could rely not only on CRM6 or CRM7 
but also on promoting EC1 interactions with Grem1 locus (Figure 28e). EC2 seemed 
to be essential to ensure high contact frequency between Grem1 and EC1, suggesting 
a structural role of this region. CRM2 and CRM3 did not interact with the promoter in 
those mutants. 
The Cis region spans 170 kb from exon 10 to exon 24 of Fmn1 and EC1 encompasses 
the 70 kb between exon 19 and 24 of Fmn1. The 30 kb EC2 is located within the 
remaining 100 kb region between exon 10 and exon 19 of Fmn1. Therefore, I asked 
the question if EC2 deletion and the loss of the region between exon 10 and exon 19 
of Fmn1, called the F1∆1019 region from now on, would have redundant or 
overlapping effects or if I would be seeing any noticeable differences. I engineered the 
F1∆1019 deletion mutants and some striking differences with EC2∆/∆ profile were 
observed in the 4C-seq analysis (Figure 28e-f). The frequency of contacts with EC1 
did not decrease in those mutants, on the opposite, F1∆1019 homozygous mutants 
displayed an increase in contact frequencies with EC1’s CRMs (Figure 28f). The 
Grem1 promoter interactions with CRM2 appeared to increase and once again, just 
as in the CRM2∆/∆ mutants, I could distinguish that, while absent in the wild-type 
profiles, de novo contacts were initiated with CRM3 and CRM4 enhancers (Figure 
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28f). These mutants did not show any significant change in Grem1 transcriptional 
levels and the spatial distribution of Grem1 transcripts was similar to the wild-type limb 
buds at E11.0 (Figure 29b). The skeletal stainings of the F1∆1019 embryos forelimbs 
were normal (Figure 29b).   
The physical proximity between the Grem1 promoter and the Grem1 TAD external 
CTCF boundaries remained strong, in all engineered mutants, despite being located 
from 50 kb to 275 kb away from them. Only in the Cis∆/∆ mutants, those contacts 
appeared weaker than the wild-types (Figure 28b). 
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Figure 28. 4C-seq identifies various changes in chromatin configuration in wild-
type and selected mutant alleles. (a) Schematic of the Grem1-Fmn1 locus, active 
EC1 enhancers are represented in blue ovals, EC2 CRMs are represented in maroon 
ovals. Dashed lines highlight deleted regions and orange and green arrows represent 
CTCF binding sited and their orientation. (b-f) 4C-seq profiles of (b) Cis∆/∆, (c) 
CRM2∆/∆, (d) EC1∆/∆, (e) EC2∆/∆  and (f) F1∆1019∆/∆ mouse forelimb buds at E11.0 
(40ss-42ss) in comparison to wild-type profiles. Vertical lines indicate the position of 
each CRM-like region and CRMs in the locus. Horizontal lines represent the Fmn1 
and the Grem1 TAD. The viewpoint (VP) is highlighted with brackets. 
 
 
Figure 29. Genetic analysis of the F1∆1019 mutants shows no difference with 
wild-type. (a) schematic of the Cis locus highlighting the F∆1019 deletion (b) 
quantification of Grem1 transcription levels at E11.0 in F1∆1019∆/∆ forelimb buds, 
comparison of Grem1 expression domain at E11.0 between F1∆1019∆/∆ and wild-type 
forelimbs, skeletal staining of F1∆1019∆/∆ E14.5 forelimb. Scale bars: 500μm (skeletal 
stainings), 250μm (WISH).
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I have identified changes in chromatin interactions with the Grem1 promoter in 
selected mutants. The deletions not only caused modifications at the level of 
CRM-promoter contacts but also generated differences within the Grem1 TAD, 
without affecting its boundaries. I observed that the promoter preferentially 
interacted within Grem1 TAD CTCF boundaries in all genetic backgrounds. It 
appeared that transcriptional levels of Grem1 could be associated with the 
presence or the absence of contacts and with subtle variations of the frequency 
of physical interactions between promoters and CRMs. In some cases, the 
increase of interactions and recruitment of CRMs to the promoter (EC1, CRM2 
and F1∆1019 mutants) were potentially parts of compensatory mechanisms. In 
other cases, the deletions seemed to affect the expression of the Grem1 gene 
not only through the loss of CRM functions but also because of structural 
alteration such as a TAD-wide decrease of contacts with the promoter (EC2 
mutants) or the opposite (EC1 mutants). Some CRMs regulated the expression 
of the target gene without interacting with its promoter directly (CRM3 and 
CRM4) but also appeared to be able to physically interact with the promoter in 
certain mutant contexts (F1∆1019∆/∆ and CRM2∆/∆ mutants), most likely to 
modulate transcription. EC2 seemed to have an intrinsic structural role to 
maintain or enhance contacts between EC1 and the promoter.  
 
6.4. Mechanisms underlying the phenotypic consequences of 
altering Grem1 cis-regulation   
 
6.4.1.  A glimpse into the dynamics of the limb self-regulatory 
feedback loop   
 
6.4.1.1. Bmp and Shh pathways activities  
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Previous publications have highlighted the critical role of Grem1 in the establishment 
and maintenance of the self-regulatory feedback loops controlling limb bud outgrowth 
and patterning (Khokha et al., 2003; Michos et al., 2004; Zuniga et al., 2004; Zuniga 
and Zeller, 1999). This present study described Grem1 transcriptional regulation as 
critical for normal limb development. I had strong evidence that pentadactyly was in 
parts preserved due to 1) the spatial distribution of Grem1 transcript and to 2) the 
transcriptional levels of Grem1. At E11.0, the Grem1-mediated antagonism of the BMP 
pathway activity in the limb mesenchyme is essential for handplate patterning and 
specification of digits 2 to 5 by the Shh pathway activity (Benazet et al., 2009). In this 
part of the study, I was curious about the consequences of Grem1 transcriptional 
misregulation on the BMP pathway activity and how it could be correlated to the 
presence or absence of phenotypes. Grem1 downregulation was supposed to result 
in an upregulation of the BMP pathways activity and indirectly in the repression of the 
SHH pathways. I proceeded to measure the possible changes in the BMP and the 
SHH pathway activities by measuring Bmp4 and Shh transcription levels by RT-qPCR. 
I also quantified the expression of activity sensors Id1 for the BMP pathway (Hollnagel 
et al., 1999; Korchynskyi and ten Dijke, 2002) and Gli1 for the SHH pathway (Marigo 
et al., 1996; Ruiz i Altaba, 1998). 
 
• Mutants with little changes in Grem1 in expression levels. 
 
The first tier I looked at consisted of mutants where at least 70% of Grem1 expression 
remained. This category only concerned the CRM5 enhancer deletion. In these 
mutants I observed a slight difference with the wild-type samples on Grem1 WISH with 
a truncated distal domain at E11.0 (Figure 27c). This mouse line developed a wild-
type limb. The loss of CRM5 barely affected the Grem1 expression domain. 
Unsurprisingly, no significant effect was observed on the BMP or the SHH pathways 
(Figure 30).  
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Figure 30. Rt-qPCR analysis of BMP and SHH pathway activity in CRM5∆/∆ 
homozygous mutants at E11.0. WT and homozygous mutant handplates at E11.0 
(40ss to 42ss) were dissected from littermate embryos, (n=7; mean ± SEM, two-tailed 
Mann-Whitney test), p-values are indicated on top. 
 
 
• Mutants with a 50% decrease in Grem1 expression levels and no severe 
phenotype. 
 
The second tier gathered the genotypes in which approximately 50% of Grem1 
transcription was maintained. CRM2 homozygous deletion had a significant and 
negative effect on Shh transcription (only 40% of transcripts remained in comparison 
with wild-type littermates) but this change did not affect the Shh pathway activity as its 
downstream target Gli1 transcription was unaffected. There was no detectible change 
in the BMP pathway (Figure 31a). The CRM2CRM3∆/∆ forelimb buds did not showcase 
any significant alteration of BMP or Shh pathways, despite displaying soft-tissue fusion 
at later developmental stages (Figure 25c,d, Figure 31b). The CRM2CRM4∆/∆ 
embryonic forelimbs did not present any change in the Bmp pathway while the Shh 
and Gli1 levels were reduced to 30% and 80% respectively compared to wild-type. 
During the process of skeletal staining, these homozygous mutants revealed soft-
tissue fusions comparable to the CRM2CRM3∆/∆ observed handplate phenotypes 
(Figure 31c, data not shown). Interestingly, in EC2∆/∆ forelimb buds, Bmp4 and Shh 
expression were respectively 50% and 40% significantly lower than in their wild-type 
littermates, while their known targets and readouts Id1 and Gli1 were unchanged 
(Figure 31d). EC1-deficient forelimb buds displayed a two-fold increase in Id1 
transcription and no significant effects on BMP4, Shh or Gli1 transcription levels 
(Figure 31e). In EC1∆/∆ mutants, I observed the disruption of the self-regulatory initiator 
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module between GREM1 and BMPs (Benazet et al., 2009) which disturbed limb bud 
outgrowth and patterning to the extent of generating a spectrum of mild limb deformity 
phenotypes such as inter-digit soft tissue fusion and C-L type syndactyly (20% 
penetrance at E14.5, Appendixes table 1). SHH pathway was unaffected, which was 
surprising as the downregulation of BMP activity by GREM1 had been described as 
essential for the set-up of the SHH/GREM1/AER-FGF limb propagation loop (Benazet 
et al., 2009). I suggested this observed phenotype could be due to a high BMP activity-
induced apoptosis (Kaltcheva et al., 2016; Zou and Niswander, 1996) independently 
of the SHH pathway, and will come back to this hypothesis later in section 6.4.2.1. 
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Figure 31. RT-qPCR analysis of BMP and SHH pathway activity in mutants where 
Grem1 expression was quantified to approximately 50% of the wild-type levels 
of expression. Homozygous mutant handplates were dissected from E11.0 embryos 
  74 
(40ss to 42ss) and analyzed in comparison to WT littermates at E11.0 (40ss to 42ss) 
for (a) CRM2∆/∆, (b) CRM2CRM3∆/∆, (c) CRM2CRM4∆/∆, (d) EC2∆/∆, (e) EC1∆/∆. Dashed 
red boxes highlight significant changes in gene expression. (n=7; mean ± SEM, two-
tailed Mann-Whitney test), p-values are indicated on top. Significant changes are 
highlighted with red dashed boxes. 
 
 
• Mutants with >50% decrease in Grem1 expression levels.  
 
Another category consisted of CRM2CRM5∆/∆ (Figure 32a) and EC1CRM5∆/∆ (Figure 
32b) mutants that displayed approximately an 80% reduction of Grem1 transcription. 
Both mutants exhibited a significant reduction of Bmp4 transcriptional levels (60% and 
30% reductions respectively) and Shh (60% and 70% reductions respectively). 
However, in both mutants, the SHH pathway seemed to be unaffected as Gli1 levels 
were normal (Figure 32). The BMP activity readout Id1 was unaffected in 
CRM2CRM5∆/∆ individuals (Figure 32a) while it was significantly reduced to 80% of its 
wild-type expression levels in EC1CRM5∆/∆ handplates (Figure 32b). Besides, I had 
quantified a decrease of BMP pathway activity, while Grem1 expression levels were 
also decreased (Figure 27f and Figure 32b) and in opposition with the two-fold 
increase of Id1 transcript levels characterizing the EC1∆/∆ limbs at this stage (Figure 
31e). In those mutants, the significant decrease of Grem1 expression levels and strong 
change in its expression pattern combined with a counterintuitive decrease of BMP 
activities and a normal SHH pathway activity stabilized tetradactyly (Figure 27f, Figure 
32b). 
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Figure 32. qPCR analysis of BMP and SHH pathway activity in mutants where 
Grem1 expression was quantified to approximately 20% of the wild-type levels 
of expression. Homozygous mutant handplates were dissected from E11.0 embryos 
and analyzed in comparison with WT littermates at E11.0 (40ss to 42ss) for (a) 
CRM2CRM5∆/∆, (b) EC1CRM5∆/∆. Dashed red boxes highlight significant changes in 
gene expression. (n=7; mean ± SEM, two-tailed Mann-Whitney test), p-values are 
indicated on top. 
 
 
• Mutants with >95% decrease in Grem1 expression levels and skeletal 
phenotype. 
 
The last tier I analyzed consisted of the mutants expressing very low Grem1 levels 
(below 5%) at E11.0: EC1EC2∆/∆ and Cis∆/∆ mutants. Surprisingly, the two mutants 
that both suffered from a near-total loss of Grem1 expression and similar 
morphological phenotypes did show differences in the expression of other limb genes. 
EC1EC2∆/∆ handplates, despite the loss of Grem1, showed unchanged BMP pathway 
activity (Figure 33a), unlike Cis∆/∆ homozygous mutants that doubled the activity of 
BMPs (Figure 33b), as measured with Id1 RT-PCR. I noticed that BMP activity, for the 
Cis∆/∆ mutants, increased in the same range as in the EC1∆/∆ mutants, suggesting that 
at this stage the measured BMPs activity was the maximum activity one could obtain 
after losing GREM1 antagonism toward BMPs. Regarding the SHH pathway, both 
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mutants followed the same pattern with a significantly reduced activity (-50% of Gli1 
transcriptional levels for EC1EC2∆/∆ and -80% for Cis∆/∆). 
 
 
 
Figure 33. qPCR analysis of BMP and SHH pathway activity in mutants where 
Grem1 expression was lost E11.0. Homozygous mutant handplates were dissected 
from E11.0 embryos and analyzed in comparison with WT littermates at E11.0 (40ss 
to 42ss) for (a) EC1EC2∆/∆, (b) Cis∆/∆. Dashed red boxes highlight significant changes 
in gene expression. (n=7; mean ± SEM, two-tailed Mann-Whitney test), p-values are 
indicated on top. 
 
 
Based on the data presented here, it appeared likely that there were additional aspects 
to the self-regulatory feedback loop model than the ones previously established 
(Bastida et al., 2004; Benazet et al., 2009; Khokha et al., 2003). The Cis∆/∆ forelimb 
buds analyses were in agreement with the published limb self-regulatory feedback 
loop (Benazet et al., 2009). I showed that significant fluctuations of transcription levels 
of Bmp4 or Shh could occur without consequences on the activity of their respective 
downstream mediators in our Grem1 mutants. According to the established model, 
Grem1 is important for the upregulation of Shh during limb bud patterning (Benazet et 
al., 2009). The effects I observed on SHH pathway activity are coherent with the 
feedback loop model: lower Grem1 expression could result in lowered SHH pathway 
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activity (Figure 31c, Figure 33). However, the changes with the BMP pathway were 
intriguing. According to the feedback loop model, Grem1 is important for the 
downregulation of the BMP pathway activity during limb bud patterning (Benazet et 
al., 2009). When Grem1 expression was significantly diminished, I expected an 
increase in BMP pathway activity. However, in the EC1CRM5∆/∆ mutant embryos with 
only transcribe 20% of normal Grem1 expression levels, I measured a significant 
handplate reduction of Id1 expression (Figure 32b). This revealed a reduction of the 
entire BMP pathway activity in the limb. Especially, in the EC1EC2∆/∆ mutants which 
suffer from a Grem1 LOF and display a ld phenotype, no change was detectable in 
the BMP pathway activity (Figure 33a). These observations suggest that measuring 
transcriptional activity may be an insufficient criterion to understand changes in gene 
activity per se. Having shown that Grem1 spatial expression varied in our mutants 
without differences in the overall transcriptional levels (Figures 24 to 27), I decided to 
investigate the Id1 expression domain in different mutants.  
 
Our qPCR analysis revealed that limb deformity phenotypes, induced by Grem1 
transcriptional defects, did not always result from changes in the activities of 
the BMP and the SHH pathways. Furthermore, fluctuations in the BMP or the 
SHH pathway activities did not always correlate with each other. Severe limb 
deformity phenotypes could arise with or without changes in BMP and/or SHH 
pathways. Nevertheless, all our tridactyl mutants had a significant reduction of 
the SHH pathway activity (independently of the BMP pathway changes). I 
hypothesized that change of expression domain, without any significant change 
in global transcription levels, could happen for the BMP pathway as well. 
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6.4.1.2. Changes in the Id1 expression domain in the Grem1 
enhancer mutants 
 
 
Following up on the RT-qPCR analysis, I used WISH to study possible spatial changes 
in BMP pathway activity. I could divide our mutants into three groups.  
 
The first one consisted of mutants in which the Id1 expression was unchanged (Figure 
34b). Their Grem1 expression domain followed a crescent-shaped pattern, identical 
or close to the normal expression pattern. Their overall Grem1 levels were either 
unaffected (CRM3∆/∆, F1∆1019∆/∆, Figure 24d and Figure 29b) or reduced to +50% 
(CRM2∆/∆, EC2∆/∆, Figure 24c and Figure 27d). The mutants in this first group, 
CRM2∆/∆, CRM3∆/∆, F1∆1019∆/∆ and EC2∆/∆ did not display limb deformity phenotype.  
 
The second group exhibited ectopic expression of Id1 in the posterior and distal part 
of the limb bud without any change of Id1 transcriptional levels (Figure 34c, dashed 
lines). They did not present any limb skeletal deformity phenotype despite this 
expansion of the Id1 expression domain. While the Id1 expression domains in 
CRM2CRM3∆/∆ and CRM2CRM4∆/∆ mutants were overlapping, the Id1 expression 
domain in CRM2CRM5∆/∆ was restricted to the distal periphery of the limb bud, with a 
thinner mesenchymal domain of expression (Figure 34c, dashed lines).   
 
The last group contained the mutants in which Id1 activity was altered and its 
expression covered large ectopic domains along the periphery of the limb bud. EC1∆/∆ 
and EC1CRM5∆/∆ domains were nearly identical (both in localization and signal 
strength, Figure 34d, dashed lines), despite the fact that EC1∆/∆ had a two-fold 
increase and EC1CRM5∆/∆ a 20% decrease in Id1 transcripts levels. The EC1EC2∆/∆ 
and Cis∆/∆ limb buds, despite their reduced size, had an Id1 domain that was broad 
and ectopically covering large areas at the limb periphery (Figure 34d, dashed lines). 
In EC1EC2∆/∆ and Cis∆/∆, Id1-expressing domains were very similar despite their two-
fold difference in Id1 expression levels. 
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In summary, mutants expressing at least 50% of Grem1 normal level in a crescent 
shape pattern did not show alteration in BMP pathway activity measured by Id1 RT-
qPCR as a readout (CRM2∆/∆, F1∆1019∆/∆, CRM3∆/∆, Figure 34b). The mutants that 
either lost the Grem1 crescent-shaped pattern (CRM2CRM3∆/∆, CRM2CRM4∆/∆, 
EC1∆/∆, EC1CRM5∆/∆) or had considerably downregulated Grem1 expression (at least 
an 80% downregulation for CRM2CRM5∆/∆ and EC1CRM5∆/∆ mutants) showed ectopic 
BMP pathway activity (dashed lines Figure 34b,c), similarly to what I observed in the 
Grem1 LOF mutants (Cis∆/∆ and EC1EC2∆/∆ mutants). The mutants with simultaneous 
reduction of both Grem1 levels and domains of expression at E11.0, that resulted into 
a change in BMP pathway activity (e.g. two-fold increase for EC1∆/∆ or a 30% decrease 
for EC1CRM5∆/∆ in Id1 expression levels), were the ones with skeletal deformity 
phenotypes (syndactyly). The phenotypes caused by the downregulation of Grem1 
expression could not be interpreted through our analysis of the BMP pathway activity 
strength or domain.  
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Figure 34. Id1 was expressed in ectopic domains in the mutants that showed at 
least a 50% decrease of Grem1 transcripts and reduction of the Grem1 
expression domain. (a) Schematic of the Cis locus, active EC1 enhancers are 
represented in blue ovals, EC2 CRMs are represented in maroon ovals. (b-d) WISH 
comparison of Id1 expression domains of (b) WT, CRM2∆/∆, CRM3∆/∆, F1∆1019∆/∆, 
EC2∆/∆ (c) CRM2CRM3∆/∆, CRM2CRM4∆/∆, CRM2CRM5∆/∆ (d) EC1∆/∆, EC1CRM5∆/∆, 
EC1EC2∆/∆, Cis∆/∆ in forelimbs (n>3) from E11.0 (40ss to 42ss). Dashed lines highlight 
a distal expansion of the Id1 expression domain. Scale bars: 250μm 
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A common feature in the Grem1 enhancer mutants was the expansion of the Id1 
domain when the Grem1 expression was reduced and restricted spatially in the 
limb bud mesenchyme. With RT-qPCR assays alone, I could not measure or 
predict those events in whole limb buds. Using WISH, I observed critical 
changes in the Id1 expression domain in the distal and the posterior limb bud 
cell populations. This suggested that locally restricted changes in Bmp activity 
were not reflected in the global changes measured from the whole organ. These 
results illustrate the importance of using different methods for measuring gene 
activity. 
 
6.4.2. Apoptosis or a deficit in cellular proliferation? What is the 
cellular defect underlying the loss of digits? 
 
6.4.2.1. Abnormal apoptotic cell clusters correlate with loss 
of Grem1 activity  
 
 
The GREM1-mediated BMP antagonism in the limb bud mesenchyme has been 
shown to be essential for cellular survival and proliferation (Benazet et al., 2009; 
Michos et al., 2004; Zhu et al., 2008). The SHH signaling pathway, known to contribute 
to the survival and proliferation of limb mesenchymal cells, is necessary for the 
establishment of the future digit identities (1 to 5 along the AP axis, Zhu et al., 2008). 
I had identified a significant reduction of SHH pathway activity through the 
measurement of its target Gli1 at this stage. I, therefore, assessed cell death in the 
limb buds of selected mutants with at least a 50% decrease in Grem1 transcripts to 
determine if 1) I would find a correlation between Grem1 expression levels and cell 
death, 2) I would uncover a connection between SHH and/or BMP pathways activities 
and potential cell death, 3) cell death at this stage could be an explanation for digit 
loss in our C-L type syndactyly phenotypes. 
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Using the Lyso Tracker assay (Haller et al., 1996; Zucker et al., 1999; Zucker et al., 
1998) on E11.0 WT forelimb buds, I observed, in wild-types, apoptotic cells located in 
the proximal central part of the mesenchyme and diffused anteriorly and distally up to 
variable distances to the median anterior part of the limb mesenchyme. The CRM2∆/∆ 
forelimbs were indistinguishable from the wild-type limbs (Figure 35a). The EC2∆/∆ 
forelimb buds with an ectopic Id1 expression displayed some variability. I detected a 
wild-type like apoptotic cell distribution and a pattern with slight enrichment of 
apoptotic cells in an anterior median locus (Figure 35a). The EC1∆/∆ forelimbs behaved 
like wild-type forelimbs (Figure 35b). These mutants revealed that C-L type syndactyly 
could occur without de novo apoptosis during the limb bud patterning stage, even 
under high BMP activity conditions. The EC1CRM5∆/∆ individuals, with 4 digits at E14.5 
(Figure 27f), presented apoptotic patterns either identical to the EC1∆/∆ or the EC2∆/∆ 
mutants (Figure 35c). At this developmental stage, the apoptotic pattern could not be 
correlated to the digit loss.  
In mutants displaying a near-total loss of Grem1 expression (Cis∆/∆; EC1EC2∆/∆) and 
a decrease of SHH pathway activity, an abnormal cluster of apoptotic cells was located 
in the anterior distal portion of the limb (wider and more distal than the previously 
described in the anterior medial limb portion; Figure 35d). Those abnormal apoptotic 
cell clusters did not correlate with the activity of BMPs. Apoptosis in this cluster of 
cells, of those cell populations, at E11.0, could be a determining factor for C-L type 
syndactyly.  
 
  83 
 
 
Figure 35. De novo apoptosis segregated tridactyl from tetradactyly and wild-
type pentadactyly. Lyso Tracker assay targeting apoptotic cells in (a) pentadactyly 
mutants with normal BMP pathway phenotypes, (b) embryos with variable skeletal 
phenotypes with low penetrance of tetradactyly and high BMP activity, (c) mutants with 
lower BMP pathway activity and 100% of tetradactyly phenotype, (d) mutants with loss 
(near-loss) of Grem1 expression and tridactyl phenotype. Scale bars: 250μm  
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The Grem1 loss of function mutants have smaller limbs at E11.0 (Figure 9b, Figure 
27g). However, at E10.5, Grem1∆/∆ limb buds are indistinguishable from wild-type limb 
buds by shape or by apoptosis tracking (Figure 36).  
 
 
 
Figure 36. Lyso Tracker assay detecting programmed cell death by apoptosis in 
WT and Grem1∆/∆ in E10.5 embryos (37ss). Dashed boxes delimitate limb buds and 
white arrows point toward the anterior distal apoptotic cell cluster. Scale bar: 500µm 
 
The complete loss of Grem1 expression was associated with abnormal clusters 
of apoptotic cells in the anterior distal limb bud mesenchymal field at E11.0, in 
conjunction with previous studies (Bastida et al., 2004; Michos et al., 2004; 
Reinhardt et al., 2019). Our observations were 1) those apoptotic clusters could 
arise in contexts where BMP pathway activity was unchanged in the limb 
(EC1EC2∆/∆) and 2) high BMP activity did not always correlate with abnormal 
apoptosis at E11.0 (EC1∆/∆). As apoptosis was normal in EC1∆/∆ and EC1CRM5∆/∆, 
their phenotypes are likely caused by other mechanisms. In particular, as these 
two mutants had trapezoidal limb shape at E12.0, I hypothesized that limb 
progenitors were either already absent at E11.0 or depleted between E11.0 and 
E12.0. It is highly possible that our method of detecting apoptosis was only 
sensitive enough to detect bigger apoptotic cell clusters. Therefore, other 
smaller and undetected clusters of cell death might be involved in Grem1 mutant 
phenotypes. 
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6.4.2.2. Cell proliferation decrease: a prognosis of C-L type 
syndactyly at E11.0  
 
The limb bud mesenchyme contains molecularly distinct cell populations that 
contribute to the osteochondrogenic lineages of the appendicular skeleton, the 
tendons and the connective tissue (Osterwalder et al., 2014; Reinhardt et al., 2019; 
Zhu et al., 2008; Zuniga, 2015). Surprisingly, little is known about the cellular 
heterogeneity of the limb mesenchymal progenitors (LMPs) or how they are controlled 
by the limb regulatory networks. During limb bud outgrowth and patterning, distal 
LMPs are kept in an undifferentiated and proliferative state (Karamboulas et al., 2010; 
Pearse et al., 2007; ten Berge et al., 2008) while the core mesenchyme undergoes a 
transition to chondrocyte identity under the influence of high BMP pathway activity 
(Akiyama et al., 2005; Barna and Niswander, 2007; Wright et al., 1995). Early 
termination of Grem1 expression had been associated with premature mesenchymal 
condensation and chondrogenic differentiation (Bandyopadhyay 2006; Pizette and 
Niswander 2000; Lopez-Rios 2012). In addition, GREM1 has been directly linked to 
the maintenance of immature LMPs in the distal limb bud (Reinhardt et al., 2019). 
Together with Dr. Robert Reinhardt, we undertook cell proliferation assays using 
fluorescence-activated cell sorting (FACS) on mouse forelimb bud tissue at E11.0 to 
estimate LMPs proliferative activity by quantifying differences in the cell cycle (Figure 
37). Therefore, we investigated if changes in cell proliferation could correlate with the 
phenotypes we observed in the Grem1 loss of enhancer function mutants. We 
compared proliferation rates between wild-type and mutants with > 50% decrease in 
Grem1 expression levels at E11.0 and 1) a crescent-shaped Grem1 domain at E11.0, 
no change in Id1 expression domain and normal apoptosis (CRM2∆/∆), 2) a crescent-
shaped Grem1 domain with ectopic Id1 expression and variable apoptotic profiles 
(EC2∆/∆), 3) reduced Grem1 domain at E11.0, ectopic and increased Id1 expression 
and no abnormal apoptosis at E11.0 (EC1∆/∆) and 4) our loss of Grem1 function 
mutants with abnormal apoptotic cell clusters the Cis∆/∆ with high and the EC1EC2∆/∆ 
with normal BMP pathway activity (Figure 37). After the removal of the lineage-positive 
cells, we established a clear correlation between the mice mutant alleles resulting in 
C-L type syndactyly phenotypes (EC1∆/∆, EC1EC2∆/∆ and Cis∆/∆) and the significant 
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reduction in cell proliferation/cell division (mitotic or synthesis phases of the cell cycle 
– M phase or S phase, Figure 37a,b). The Cis∆/∆ and EC1∆/∆ homozygous mutant lost 
40% and 30% respectively of cells in mitosis over the WT individuals (Figure 37a,b). 
EC1EC2∆/∆ lost 25% of cells in the replication phase (Figure 37a).  
The measured high BMP activity changes in our RT-qPCR assay for EC1∆/∆ (Figure 
31e) and Cis∆/∆ (Figure 33a) homozygous mutants correlated with a reduction of the 
fraction of progenitors occupying the M-phase while the near-total loss of Grem1 in 
EC1EC2∆/∆ mutant with a normal BMP activity (Figure 33b) correlated with a decrease 
of progenitors in S-phase.   
 
 
Figure 37. Forelimb bud cell cycle analysis in selected Grem1 loss of enhancer 
function mutants. (a) Analysis of all cell cycle phases and (b) mitotic cells in lineage 
negative (Lin-) cells from mouse forelimb buds at E11.0 (39-43ss), n>7 paired 
forelimbs, data are mean + SD, two-tailed Mann-Whitney test), 
*P≤0.1,**P≤0.01,***P≤0.001.  
 
 
Cellular proliferation was gradually reduced in the enhancer mutant alleles in 
correlation to the phenotypic severity. Significant decreases of cellular 
proliferation in E11.0 forelimb buds seemed to be an immediate consequence of 
significant Grem1 transcriptional alterations. Together with the elevated 
apoptosis levels, premature exit from the cell cycle and significantly reduced 
proliferation appeared to strongly correlate with limb skeletal deformity 
phenotypes. 
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7. Discussion 
 
 
The findings of my Ph.D. thesis project provide insights of general importance into the 
cis-regulatory control of the Grem1 expression dynamics during mouse limb bud 
development. I show that the 310 kb Grem1 TAD (or Grem1-Fmn1 intra-TAD) 
contains all the essential CRMs, with enhancer activity, that control Grem1 expression 
levels and its spatio-temporal expression kinetics in limb buds. In particular, my 
analysis shows Grem1 CRMs activities are dependent on their genomic arrangement 
within the TAD but also on trans-acting signaling pathways (space) and developmental 
stage (time). The CRM interactions are more complex than first expected, which goes 
beyond being simple ON/OFF switches, with respect to the Grem1 expression. Here, 
I will discuss and interpret my results in the general context of the field and consider 
some of the major scientific questions raised. 
 
7.1. False enhancers discovery   
 
7.1.1. The Enhancer Chain Model 
  
TADs have been described as conserved and discreet insulating structural chromatin 
interaction domains, that restrict enhancer activity toward their associated genes, and 
prevent inappropriate enhancer-promoter interactions (Dixon et al., 2012; Nora et al., 
2012; Rao et al., 2014; Sexton et al., 2012). Together, my analysis shows that the 
Grem1 TAD contains all the cis-regulatory enhancers participating in the Grem1 gene 
transcriptional regulation during limb bud outgrowth and patterning. No elements, 
outside the Grem1 TAD boundaries, are interacting with the Grem1 promoter when 
the TAD boundaries are maintained (Figure 28). To identify the relevant Grem1 CRMs, 
I used genomic profiling to identify the likely candidate CRMs (Figure 16, Figure 17). 
Interestingly, some of these regions are not enhancers, despite having the expected 
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chromatin state and histone modifications, TFs binding profile (Figure 17) and physical 
interactions with the Grem1 promoter (Figure 15, Figure 28). These include CRM8 
and CRM9, as no enhancer activity is detected in reporter assay (Figure 18), despite 
them displaying molecular features of enhancers. CRM8 and CRM9 are cohesin 
binding domains (Figure 38, Appendixes Figure 6, DeMare et al., 2013) and CRM9 is 
located within 1.8 kb of a CTCF binding region (Appendixes Figure 7). To date, the full 
spectrum of cohesin functions in gene regulation remains unclear (Dorsett, 2019; 
Kentepozidou et al., 2020; Merkenschlager and Nora, 2016; Rao et al., 2017). 
CTCF/Cohesin complexes have been described as TADs anchors, maintaining them 
through embryonic development (Handoko et al., 2011; Phillips and Corces, 2009; 
Sanyal et al., 2012) and reinforcing TAD sub-domains (100 kb to 1 Mb) around genes 
expressed during embryonic development (Phillips-Cremins and Corces, 2013). 
Cohesins were predicted to regulate gene expression through their structural role in 
intra-TAD interactions (<100 kb). Cohesins interact with other proteins, such as 
Mediator proteins, at promoter and enhancer sites to bring them in close physical 
proximity (Kagey et al., 2010; Phillips-Cremins and Corces, 2013). Thus, these higher 
chromatin structures render linear distances, on the DNA, rather irrelevant for the 
understanding of transcriptional regulation. Unfortunately, there is no available ChIP-
seq data for Mediator in mouse limb buds before E12.5, but only data for cohesion 
binding to CRM8, CRM9, and CRM2 to CRM4 (Appendices Figure 6, Kagey et al., 
2010). Studies by others have provided evidence that promoter/enhancer interactions 
are optimized when these elements are located at CTCF boundaries loci and brought 
in close proximity by direct and persistent contacts (Hou and Corces, 2012; Kagey et 
al., 2010; Tang et al., 2015). When elements are not in close proximity to CTCF 
binding sites, contacts are in general transient and weak as part of loop extrusion 
mechanisms (Fudenberg et al., 2016; Hou and Corces, 2012; Kagey et al., 2010; Tang 
et al., 2015). The Grem1 promoter does not overlap with CTCF and/or cohesin binding 
regions but is still constitutively and robustly contacting the Grem1 TAD CTCF 
boundaries. Thus, the Grem1 promoter region is continuously associated with 
CTCF/cohesin binding regions, which also interact with other cohesin binding regions 
such as CRM8 or CRM9. Hi-C-seq analysis of human cell lines showed that the most 
distal enhancer at the linear genomic level coordinately controls the effects of the other 
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“chain enhancers”, in the 3D chromatin space, that regulate the transcription of their 
target gene (Song et al., 2019, Figure 38). This most distal enhancer has been 
proposed to be the only enhancer directly interacting with the promoter. Such “first” 
enhancers should be enriched in CTCF and cohesin binding sites while the other 
enhancers in the “Enhancer Chain” (ECh) stabilize the contacts and fine-tune gene 
expression by physically interacting with each other and promoters through the most 
distal enhancer (Song et al., 2019, Figure 38a). The linear distance between 
enhancers in an ECh and promoter did not define their rank in the chains but rather 
the lowest number of intermediate contacts with other enhancers (Figure 38b). In wild-
type limb buds, CRM3 and CRM4 do not directly interact with the Grem1 promoter 
(Figure 28, Figure 39a). Therefore, they could regulate Grem1 expression (Figure 
25c,d) via their interactions with other Grem1 enhancers as part on an ECh. 
 
 
 
 
Figure 38. Examples of enhancer chains (ECh). (a) One example of regulatory 
element networks, (b) schematic of possible EChs, defined according to the rank of 
connected enhancers relative to their closest target promoter. Adapted from Song et 
al. (2019). 
 
 
Song et al. (2019) also proposed that in the absence of the first enhancer, the others 
would contact the promoter through a neutral genomic region. As a consequence, the 
transcription levels of the gene of interest would be reduced. The binding of cohesins 
at the CRM8 and the CRM9 loci suggests that these elements, interacting with the 
Grem1 promoter at high frequency, could have intrinsic structural roles such as 
promoting long-range contacts with the Grem1 promoter (Figure 28). In our model, 4C 
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experiments had revealed the loss of the entire EC2 region (encoding CRM5 to CRM8) 
results in an about 50% reduction of Grem1 expression and widespread reduction in 
promoter/CRM interactions. As, within EC2, only CRM8, which wasn’t a limb enhancer 
according to my reporter assays, was binding cohesin, this may point to a similar 
mechanism as proposed by Song and coworkers: CRM8 could be the first element of 
a Grem1 ECh. In fact, Song et al. (2019) did not functionally assess their candidate 
enhancers, in contrast to my study, as they defined enhancers simply by chromatin 
profiling and marks as we did initially (Figure 16, Figure 17). Therefore, my analysis 
indicates that EC2, and by extension CRM8, could be essential for the establishment 
and/or maintenance of robust interactions of CRMs with the Grem1 promoter (Figure 
39a-d). In addition, 4C-seq analysis using the Grem1 promoter as viewpoint provided 
deep insights into the chromatin architecture of the Grem1 TAD in both wild-type and 
mutant limb buds. De novo and/or enhanced contacts (with CRM3 and CRM4) are 
observed in the F1∆1019 deletion, which only leaves EC1 intact, but this is not 
accompanied by a significant reduction in Grem1 expression (Figure 28, Figure 29, 
Figure 39e). In F1∆1019∆/∆ limb buds, CRM4, which also binds cohesin, would be the 
most distal enhancer (Appendixes Figure 6). Therefore, CRM4 could organize a new 
ECh with CRM3 and CRM2 in F1∆1019∆/∆ limb buds, which could explain the 
maintenance of Grem1 expression. This suggests that in the context of the F1∆1019 
deletion, additional functions of CRM3 and CRM4 could be uncovered to compensate 
for the Grem1 cis-regulatory landscape alterations. Besides, my analysis shows that 
in mutant contexts, no CRM outside the critical region is recruited to the Grem1 
promoter (Figure 39f).  
 
My study indicates that the chromatin architecture of the Grem1 TAD functions 
in providing Grem1 expression with cis-regulatory robustness. 
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Figure 39. Schematic illustration of the Grem1 TAD conformations in different 
enhancer loss-of function Grem1 mutations. (a) WT, (b) CRM2∆/∆, (c) EC1∆/∆, (d) 
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EC2∆/∆, (e) F∆1019∆/∆, (f) Cis∆/∆ hypothesized Grem1 intra-TAD structural 
organizations.  
 
7.1.2. The Replication Domain Model 
 
In 2014, Pope and colleagues showed that TAD boundaries overlap with a nearly one-
to-one correlation with replication domain boundaries. TADs were described as “stable 
regulatory units of replication timing” (Pope et al., 2014, Figure 40).  
 
 
 
Figure 40. The replication domain model. Upper panel: Upon differentiation, TADs 
with uniform replication timing can switch it. Lower panel: After switching, the TAD 
structural boundaries, enriched in CTCF and transcription permissive marks, overlap 
with the boundaries of replication domains. From Pope et al. (2014). 
 
 
Recently, loci with enhancer signatures have been associated with Early Replication 
Control Elements (ERCEs, Sima et al., 2019). ERCEs are open chromatin regions, 
enriched in enhancer histone decorations, that maintain physical contacts despite 
CTCF depletion (Sima et al., 2019). Their sizes vary from 3 kb to 46 kb, but the authors 
did not test the ECRC regions for enhancer activity. ERCEs that function in a CTCF-
independent manner were described as essential for chromatin compartmentalization 
into A (open and transcriptionally active) and B domains (closed and transcriptionally 
inactive, Dixon et al., 2012; Lieberman-Aiden et al., 2009, Figure 41). It was shown 
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that inverting ERCEs regions creates new TAD boundaries, which demonstrated that 
chromatin looping is regulated independently by both CTCF and ERCEs.  
 
 
 
Figure 41. Model for the function of early replication control elements (ERCEs). 
Scheme of a co-regulation model illustrating ERCE roles in replication timing, A/B 
compartmentalization, transcription and chromatin looping. From Sima et al. (2019). 
 
 
These studies showed that CRMs with enhancer-like features could also function in 
regulating replication during tissue development and/or homeostasis in addition to 
transcriptional regulation of their target gene(s).  
 
 
Therefore, it is theoretically possible that some of the CRMs such as CRM9 (and 
possibly others), which lacks enhancer activity, could also function in 
structural-dependent nuclear mechanisms other than Grem1 cis-regulation.  
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7.2. The respective functions of the Grem1 enhancers 
 
For my research, we have generated several mouse lines harboring various CRM 
and/or enhancer cluster deletions in the Grem1 critical cis-regulatory region. The 
analyses show that such of these enhancers have specific essential functions while 
others function in a cooperative manner.  
 
For example, CRM2 is essential for the up-regulation of Grem1 expression in the distal 
and anterior limb bud mesenchyme and for the maintenance of its expression in 
handplates during digit formation (Figure 24c). Benazet et al. (2009) showed that the 
onset and the up-regulation of Grem1 expression depend initially on a high BMP 
pathway activity. Interestingly, SMAD4 ChIP-seq reveals that CRM2 is the only 
enhancer, in the Grem1 landscape, enriched in SMAD4 chromatin complexes (Gamart 
et al., manuscript in preparation, Figure 17b), which indicates that CRM2 relays BMP 
signal transduction in early limb buds. In agreement, the activity of CRM2 (GRS1) 
remains posteriorly restricted in Smad4-deficient mouse limb buds (Zuniga et al., 
2012a), which is corroborated by the fact that the Smad4 deficiency reduces Grem1 
expression to a similar extent as the deletion of CRM2 in early limb buds (Figure 24c, 
Appendixes Figure 8).  
 
CRM4 has been proposed to have a silencer activity, as it appears to function in the 
anterior restriction of the Grem1 expression (Li et al., 2014). However, the inactivation 
of CRM4 in the context of the CRM2 deficiency (Appendixes Figure 5) and part of 
EC1∆/∆ (Figure 26c) and EC1CRM5∆/∆ (Figure 27f) did not result in ectopic Grem1 
expression. These results suggest 1) CRM2 is necessary for the anterior expansion 
of Grem1 expression and that 2) the silencer function of CRM4 might prevent 
precocious anterior Grem1 expression. In addition, EC1CRM5∆/∆ limb buds, but not 
the CRM5∆/∆ or CRM2CRM5∆/∆ ones, display an ectopic proximal-anterior Grem1 
expression domain (Figure 27c,e). This observation implied that other CRMs than 
CRM2 can drive Grem1 in ectopic domains, in the absence of EC1, when CRM5 is 
lost in cis. Thus, it appeared that in such a sensitized background (EC1∆/∆), CRM5 is 
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functioning in the repression of Grem1 expression in the anterior-proximal limb bud 
mesenchyme. These changes could be explained by a “CRM chain model” similar to 
the ECh model (Song et al., 2019), in which the CRM4 silencing activity depended on 
its interactions, not with the Grem1 promoter, but with the other CRMs. This “CRM 
chain” could rewire to include other silencers, such as CRM5, in the absence of EC1, 
but this hypothesis would need to be tested by comparative HiC-seq analysis using 
the appropriate wild-type and mutant backgrounds. Besides, while the repressor 
activity of CRM4 had been associated with the GLI3 transcriptional repressor in the 
anterior limb bud (Li 2014), CRM5 appears not to be enriched in GLI3 chromatin 
complexes (Figure 17, Appendixes Figure 9). However, comparative analysis of 
enhancer-transcription factor interactions, in wildtype and mutant limb buds, is lacking 
as deletion of one CRM could potentially identify de novo binding sites. This genetic 
analysis reveals the robustness underlying the spatial regulation of the Grem1 
expression, due to the redundant activity of all the enhancers in the landscape (Figure 
42). It appears that two of the CRMs (CRM4 and potentially CRM5) are not only 
enhancers but also spatial repressors which refine the Grem1 expression domain.  
 
During limb bud outgrowth, the deletion of individual CRMs had no detrimental 
consequences for limb skeletal development (Figure 42). This may be due to the fact 
that four of the enhancers in the Grem1 TAD (CRM2 to CRM4 and CRM5) display, at 
least, partially overlapping spatial enhancer activities. Indeed, a recent publication 
showed that enhancers work in pairs of redundant elements during limb patterning, 
but in an additive manner to regulate the transcriptional levels (Osterwalder et al., 
2018). Furthermore, Ihh expression, in a variety of embryonic tissues including limb 
buds, is maintained by interactions among nine redundant enhancers, functioning in 
an exclusively additive manner (Will et al., 2017). In CRM2-deficient limb buds, it 
appears that the interactions between CRM3 and CRM4 with the Grem1 promoter 
could be increased (Figure 28c). Both CRM3 and CRM4 have enhancers activities in 
limb buds, which partially overlap in the distal limb bud mesenchyme (Figure 20c,d) 
and are regulated by the same TFs (Figure 17a). Their individual deletion failed to 
reveal major functions in the regulation of Grem1 expression (Li et al., 2014, Figure 
24d). This, together with the analysis of compound mutants lacking two or all CRMs 
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in EC1, reveals synergism between the CRM3/CRM4 and CRM2 enhancers (Figure 
25c,d). In fact, it is likely that both primarily function as so-called shadow enhancers 
as their functions become apparent as CRM2 is inactivated. Shadow enhancers had 
been defined in invertebrates as loci providing “spatial refinement, temporal synchrony 
and robustness” to gene expression binding to the same TFs complexes (Hong et al., 
2008). Nevertheless, CRM3/CRM4 recruitment to the Grem1 promoter, in F1∆1019-
deficient limb buds, suggests their support toward CRM2 enhancer activity can 
operate to reinforce CRM2 action in genetically challenged backgrounds. Finally, the 
deletion of all enhancers encoded by EC1 results in slightly aggravated spatial 
changes in comparison to deleting CRM2 alone. This weakens the robustness of digit 
patterning system as partial fusions of anterior digits are observed in EC1- deficient 
limb buds.  
 
My genetic analysis shows that CRM2 and CRM5 both have essential functions in 
regulating Grem1 transcript levels albeit their spatial activity being rather similar 
(Figure 21b,c). This is due to them interacting largely with the same TF complexes, 
namely HOXA13, HOXD13 and ß-catenin while CRM2 also interacts with SMAD4 
complexes (Figure 17). They are likely the primary enhancers of their respective ECs 
that have both specific and cooperative functions. Indeed, the inactivation of both 
enhancers reduces Grem1 expression by 80%, but the spatio-temporal changes are 
similar to the single CRM2∆/∆ deletion (Figure 24c). The observed reduction in Grem1 
transcript levels is strictly additive as it has been shown for the transcriptional 
regulation of other genes such as Ihh (Will et al., 2017), Gli3, Shox2 (Osterwalder et 
al., 2018) or Twist (Hirsch et al., 2018) during mouse limb bud development. However, 
in spite of this drastic reduction in the absence of CRM2 and CRM5 in cis, the Grem1 
cis-regulatory landscape was able to sustain an almost normal spatial Grem1 
expression and normal digit development. Therefore, it is not unlikely that their deletion 
is compensated by the activity of shadow enhancers such as CRM3/CRM4 (Figure 
28c).  
 
The deletion of EC2 exposes the function of EC1 in preserving the wild-type-like 
spatial expression Grem1 domain and, albeit a 50% reduction in transcript levels, limb 
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bud development is not significantly altered and pentadactyly is maintained. The distal 
margin between the AER and the Grem1 crescent seemed broader but this is 
apparently not sufficient to disturb limb patterning. In addition, the deletion of EC2 
shows that this enhancer cluster is not essential for the spatio-temporal regulation of 
the Grem1 expression (Figure 27d; Figure 28d,e). In summary, the genetic analysis 
shows that EC1 and EC2 contribute in an additive manner to Grem1 transcription level 
while the enhancers belonging to EC1 regulate the spatio-temporal kinetics of the 
Grem1 expression (see before). In addition, EC2 has a general function in maintaining 
the chromatin architecture within the Grem1 TAD, while in EC1-deficient limb buds, 
the intra-TAD contacts with the Grem1 promoter are not reduced but elevated (Figure 
28d). Furthermore, the inactivation of CRM5 in the context of the EC1 deficiency 
causes tetradactyly, which is paralleled by more severe spatial changes and reveals 
the loss of robustness of the limb bud patterning system upon deletion of both CRM5 
and EC1 (Figure 27f). Previous studies showed that anteriorization of Grem1 
expression can cause preaxial polydactyly phenotypes (Capdevila et al., 1999; Lopez-
Rios et al., 2012; Merino et al., 1999), however no such phenotypes were detected. 
The observed anterior expansion of the Grem1 domain is, apparently, not sufficient to 
prevent the BMP activity from limiting digit numbers (Norrie et al., 2014).  
 
This genetic analysis reveals both additive and cooperative interactions between 
individual CRMs and the two ECs. Therefore, it might be too simplistic to categorize 
individual enhancers/repressors and the enhancer cluster as essential primary or 
shadow enhancers (Cannavo et al., 2016; Degenhardt et al., 2010; Frankel et al., 
2010; Montavon et al., 2011). All CRMs have specific activities and inherent 
properties, but their functions are likely context-dependent and the underlying 
compensatory mechanisms become apparent only when the genomic context is 
altered. During limb bud outgrowth, Grem1 expression levels are maintained by the 
additive CRM activities and intra-TAD enhancer interactions (Figure 28). My analyses 
also provide evidence that some CRMs can adapt their functions depending on genetic 
background (e.g. CRM3 and CRM4) and that intra-TAD interactions and adjustments 
are likely part of the compensatory mechanisms that provide spatial Grem1 expression 
with robustness. However, the anterior-distal and distal Grem1 expression could be 
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altered by some of the single CRM deletions without leading to digit phenotypes. In 
contrast, Grem1 expression in the posterior limb mesenchyme is more robust (Figure 
42). 
 
In EC1EC2∆/∆ double mutant limb buds, low level residual Grem1 expression is 
observed by WISH, but this results in a Grem1 null digit phenotype. This residual 
expression could be driven by low level cryptic enhancer activity but none of the 
potential CRM located outside the EC1 and EC2 clusters displays significant enhancer 
activities. It might also be a possibility that in EC1EC2∆/∆ double mutant limb buds, the 
proximal Grem1 promoter still shows basal activity. If this was the case, this could be 
further quantified in cell-based luciferase assays.  
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Figure 42: Schematic of CRM enhancer contributions to the spatio-temporal 
kinetics of Grem1 expression. (a) schematic of Grem1 TAD, EC1 CRMs (blue ovals) 
and EC2 CRMs (maroon ovals) are represented together with the other TADs CRMs 
(grey ovals). Dotted lines represent EC1, EC2 and F1∆1019 deletions. (b) Schematic 
of the enhancer contribution to Grem1 expression domain in different compound 
mutant limb buds.  
 
 
Our data show how the CRM enhancers function, in an additive manner to regulate 
Grem1 transcription levels and in a cooperative manner in spatial regulation of the 
Grem1 expression domain in the posterior limb bud mesenchyme. Analysis of 
individual and compound mutants has allowed me to define the minimal requirements 
for apparently normal digit development, which shows that maintenance of spatial 
expression is most relevant (Figure 43). Disturbing the cooperativity between CRM2 
to CRM4 (EC1) and CRM5 caused a significant spatial changes that disrupted the 
robustness of the digit patterning system, resulting in such variable fusions of anterior 
digits (EC1∆/∆) and tetradactyly phenotypes (EC1CRM5∆/∆).  
 
 
 
Figure 43: Schematic of the normal Grem1 expression domains in wild-type limb 
buds in comparison to the minimal Grem1 expression required for normal digit 
development. Upper panel: Grem1 expression (purple) in wild-type limb buds. Lower 
panel: Grem1 expression (orange) that ensures proper limb bud outgrowth and digit 
patterning (levels can be reduced to with 20% of wild-type Grem1 transcripts).  
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The activities of individual Grem1 CRMs are integrated in different ways. The 
Grem1 transcript levels are regulated in an additive manner, while the spatial 
dynamics are regulated in a synergistic manner by the functionally relevant 
CRMs. The robustness of the limb patterning system relies more on the spatial 
dynamics than the overall transcript levels and on the different and partially 
overlapping functions between CRM2 to CRM5. These CRMs do not operate as 
shadow enhancers, but each of them has distinct and essential functions on 
their own or in interaction with the others. 
 
7.3. Novel insights into the self-regulatory SHH/GREM1/AER-FGF 
feedback signaling system regulating limb bud development 
 
In addition to analyzing the impact of the different CRM deficiencies on Grem1 
expression, I also studied the impact of these alterations on the feedback signaling 
system (Benazet et al., 2009; Khokha et al., 2003; Verheyden and Sun, 2008). The 
compound Grem1 null mutants with digit phenotypes (EC1EC2∆/∆ and Cis∆/∆) show a 
significant reduction in SHH pathway activity (Figure 33a,b) as predicted by the 
feedback loop operating between SHH and GREM1 (Benazet et al., 2009). In 
particular, EC1EC2∆/∆ limb buds showed a significant decrease in Gli1 transcripts, 
reflecting the reduced SHH pathway activity, while BMP activity was not affected 
(Figure 33). Analysis of the allelic series of CRM mutants shows that the downstream 
consequences are rather complex. In some alleles, SHH pathway activity is 
significantly impaired without effects on the BMP pathway activity while in others, high 
BMP activity did not concur with reduced SHH pathway activity. These observations 
suggest that there are additional or alternative interactions, that regulate the 
interactions between the SHH and BMP pathways, in the self-regulatory limb bud 
signaling system (Benazet et al., 2009). It is important to remember that GREM1 is a 
secreted antagonist that impacts BMP ligands and not an intracellular antagonist. In 
certain cancer types, GREM1 has been shown to act in a TGF-β dependent manner 
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(Grillo et al., 2016; Lavoz et al., 2015; Marquez-Exposito et al., 2020; Mitola et al., 
2010; Yin et al., 2017). At E11.0, the TGF-β signaling, together with the BMP pathway, 
promotes chondrogenesis (Karamboulas et al., 2010). As a consequence, this 
pathway, known for its cross-regulatory interactions with the Wnt, Bmp and Shh 
pathways, could play a role in the response to alteration in Grem1 expression 
(Castellone and Laukkanen, 2017; Zhang et al., 2016).  
In addition, my results suggest that Id1 is not a good transcriptional readout of BMP 
pathway activity during limb bud outgrowth. In fact, I failed to observe strong 
correlations between Id1 transcript levels, spatial changes and digit phenotypes. 
Furthermore, low Grem1 expression levels did not consistently result in elevated BMP 
pathway activity during limb bud outgrowth (Figure 32 and Figure 33a). It is important 
to note that Benazet et al. (2009) showed that the GREM1/BMP initiation loop is active 
predominantly during the onset of limb bud development (Benazet et al., 2009). 
Transcriptional profiling of Grem1-null mutants through RNA-seq and searching for 
other BMP target genes among the differentially expressed genes is one way to find 
alternatives to Id1. An alternative approach to gain insight into how the progressive 
reduction of Grem1 expression by CRM deletions affect the limb bud signaling system 
would be to genetically reduce the levels of other components (Shh, Bmp) in the most 
relevant Grem1 enhancer mutants and assess the effects on limb bud development 
and digit patterning. Alternatively, additional genes and regulatory pathways might be 
part of the signaling system. For example, the group has been able to show that the 
Wnt pathway is required for Grem1 normal expression during limb bud development 
(E. Unal Ph.D. thesis, Sheth et al., manuscript in preparation). Furthermore, the 5’HOX 
genes are required for Grem1 expression (Sheth et al., 2013) and Tbx2 is a BMP 
induced transcriptional regulator that inhibits Grem1 expression (Farin et al., 2013; 
Nissim et al., 2006). I have generated preliminary data showing that the Tbx2 
expression domain varies. In mutants with decreased Grem1 expression, but no limb 
phenotypes, Tbx2 remains restricted, while in Grem1 mutants with digit phenotypes, 
its limb bud domain is expanded. Therefore, there could be a balance between the 
TBX2-mediated Grem1 repression and the spatial alterations in CRM mutant limb 
buds that result in digit phenotypes (Appendixes Figure 10).  
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It is clear that further analyses of the GRNs regulating limb bud outgrowth and 
patterning are necessary to understand how spatial alterations in Grem1 expression 
correlate with digit phenotypes. When Grem1 expression is reduced, rather than 
completely disrupted, the feedback loop could rewire, or additional gene could impact 
phenotypic outcomes. ChIP-seq analyses show at least two transcription factor 
complexes interact with the relevant CRMs and one can expect that additional TFs 
participate in Grem1 cis-regulation by interacting with specific CRMs. A deeper 
understanding of Grem1 regulation in limb buds could identify additional players of the 
self-regulatory feedback signaling system. Analyzing total full limb buds may miss 
subtle events at the cellular level. This can be addressed by single-cell transcriptomics 
of LMPs to characterize their gene expression dynamics at cellular resolution in wild-
type and select CRM mutant limb buds (Cao et al., 2019; Feregrino et al., 2019). This 
approach would allow the discovery of auxiliary factors/pathways (e.g. TBX2 or Wnt 
signaling components) impacting the self-regulatory feedback signaling system. In 
addition, ChIP-seq experiments in enhancer loss of function mutants in comparison to 
wild-type limb buds could help to establish alterations in TFs footprints, which would 
provide a better understanding of the trans-regulatory control of Grem1 CRMs (Hung 
et al., 2019; Lee et al., 2018).  
 
Analysis of key genes, in the self-regulatory feedback signaling system, does 
not fully explain the digit phenotypes observed in the allelic Grem1 enhancer 
mutant series. This suggests that additional factors and regulatory interactions 
underlie the molecular alterations and phenotypes observed. 
 
7.4. Grem1 phenotypes: an explanation at the cellular level? 
 
Prior to our research, genetic analyses had associated Grem1 inactivation and 
subsequent precocious rise in BMP activity with apoptosis in the limb bud 
mesenchyme at E11.0 (Michos et al., 2004). In addition, at E10.5-E10.75, a small 
fraction (9 + 21%) of distal-posterior limb bud progenitor cells, the SOX9-negative and 
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JAGGED1 (JAG1)-positive population (S9-JAG1+) of LMPs had been shown to 
undergo apoptosis in the Grem1∆/∆ mutants due to precocious exposure to elevated 
BMP pathway activity (Reinhardt et al., 2019). This study concluded that the protection 
of these cells from BMP activity by the GREM1-mediate BMP antagonism is necessary 
to preserve the JAG1+ LMPs, which in turn could be essential for the specification of 
the skeletal condensation resulting in digit ray formation. Indeed, in all single and 
compound Grem1 enhancer mutants with digit phenotypes, the expression of Grem1 
is more restricted as limb bud outgrowth progresses and terminates precociously, 
which indicates that the survival JAG1+ LMPs and their descendants could be affected, 
which in turn could alter the response to SHH signaling and digit identities, especially 
as a fraction of JAG1+ LMPs arises from Shh-expressing cells (Reinhardt et al., 2019).  
In two mutant alleles, EC1∆/∆ and Cis∆/∆ limb buds, BMP pathway activity is increased 
during limb bud outgrowth (Figure 31e and Figure 33b), but only in the Cis∆/∆ limb buds 
abnormal apoptotic cell clusters are detected (Figure 35d). The same apoptotic profile 
is also observed in EC1EC2∆/∆ limb buds, except the BMP pathway activity is not 
elevated (Figure 33a and Figure 35d). Furthermore, no abnormal BMP activity nor 
increased apoptosis is observed in EC1CRM5∆/∆ limb buds, which are tetradactylous 
(Figure 27f and Figure 32b). As discussed before, a compensatory effect by another 
unidentified BMP antagonist active in limb buds cannot be excluded (Appendixes 
Figure 11). It is not clear how these findings fit the well-established facts that aberrant 
BMP activity, as a consequence of Grem1 LOF, induces limb bud mesenchymal 
apoptosis (see e.g. Bastida et al., 2004; Michos et al., 2004). One additional feature 
of Grem1 null mutants is a significant decrease in SHH pathway activity as measured 
by the Gli1 transcriptional sensor (Figure 33). However, in CRM mutants with reduced 
Grem1, there is no clear correlation between SHH pathway activities and digit 
phenotypes either. 
During handplate formation, the autopod shape of all enhancer mutants with digit 
reductions is apparent as primordia appear smaller. As I could not correlate these 
shape alterations with apoptosis, we assessed if the proliferation rates of CRM 
mutants with digit phenotypes correlated with the different autopod deformities 
(Boehm et al., 2010). Indeed, this analysis indicates that the limb mesenchymal cell 
proliferation/division rates are lowered in all enhancer mutants with digit reductions 
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(Figure 37a). Reduced proliferation accompanied by the apoptotic loss of limb bud 
mesenchymal progenitors is the likely cellular phenotype of enhancer mutants in which 
there is no compensatory mechanism for the reduction and/or loss of Grem1, resulting 
in digit reductions (e.g. EC1EC2∆/∆ and Cis∆/∆). These results show that it will be 
important to understand how the heterogeneity of the limb bud mesenchyme cellular 
population and their individual response to the different limb signaling pathways are 
impacted by the reduction or loss of the Grem1 expression. For limb buds, cellular 
differences in HoxD gene cluster expression have been identified using single-cell 
transcriptomics, which highlights the transcriptional diversity of limb bud progenitors 
(Fabre et al., 2018). Considering a similar mechanism for Grem1 expression, limb bud 
progenitor may regulate Grem1 and other genes in the GRN and limb bud signaling 
system in a cell-type specific manner, which would add another level of complexity to 
transcriptional regulation. 
 
Loss or alteration of Grem1 expression in limb buds seems to affect the 
mesenchymal progenitor populations giving rise to the skeletal elements. In 
addition to apoptosis, I have identified changes in proliferation of LMPs. This 
could provide a possible explanation of the observed digit phenotypes. It is 
important to consider, that different limb bud progenitor populations may be 
affected differently depending on their transcriptional signature. Also, it cannot 
be excluded that the progenitors for missing digits never emerged.  
 
 
7.5. Alteration of the Grem1 cis-regulatory landscape 
underlying congenital malformations and disease 
 
In humans, TADs encoding less than three genes, such as is the case for the Grem1- 
Fmn1 genomic landscape, appear more prone to mutations resulting in congenital 
malformations and disease (Muro et al., 2019). Deletions in the Grem1 cis-regulatory 
landscape have been associated with some rare and recessive congenital limb 
malformations, in both humans and mice (Dimitrov et al., 2010; Jackson-Grusby et al., 
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1992; Maas et al., 1991; Zuniga et al., 2004). The Grem1-Fmn1 locus in humans is 
located on chromosome 15q 13.3 (Jaeger et al., 2012) and mutations have been linked 
to the Cenani-Lenz (C-L) syndrome (Al-Qattan and Alkuraya, 2019). This recessive 
syndrome is characterized by oligosyndactyly, metacarpal synostosis, phalangeal 
disorganization and other variable clinical features similar to Grem1-deficient mice (Al-
Qattan and Alkuraya, 2019; Grzeschik, 2002; Michos et al., 2004; Shi et al., 2001; 
Zhou et al., 2009). In particular, a 263 kb homozygous deletion in the human Fmn1 
gene and duplications upstream of Grem1, have also been linked to the C-L syndrome 
(Dimitrov et al., 2010). Such duplications can cause aberrant expression of Grem1 in 
patients affected by the hereditary mixed polyposis syndrome, which predisposes 
them to colorectal carcinomas (predisposition to colorectal carcinoma, Jaeger et al., 
2012; Jaeger et al., 2008; Venkatachalam et al., 2011). Our research provides novel 
insight into the mechanisms underlying these human congenital malformations and 
disease phenotypes. The 263 kb deletion in the Fmn1-Grem1 landscape (Dimitrov et 
al., 2010) corresponds to the deletion of the region orthologous to the mouse EC2 
enhancer cluster but leaves the EC1 cluster intact. In addition, this deletion also 
encompasses the Fmn1 TAD and the downstream Grem1 TAD boundary with its 
CTCF sites. Our 4C experiments had clearly highlighted that 1) only CRMs within 
Grem1 TAD interact with its promoter at high frequency and 2) Grem1 promoter makes 
the strongest contacts within its TAD boundaries (Figure 28). The boundary loss in the 
human loci might redirect contacts of Grem1 CRMs to neighboring genes, which may, 
in turn, disrupt the Grem1 expression and/or cause unspecific enhancers to alter 
Grem1 expression during embryonic and limb bud development. It is likely that this 
deletion would disrupt the human Grem1 ECh and thereby chromatin architecture. The 
predisposing duplications upstream of Grem1 affected the upstream Grem1 TAD 
boundary and CTCF sites (Jaeger et al., 2012). This 40 kb duplication results in a 
Grem1 overexpression in colonic crypts and predisposes to colorectal cancer. This 
overexpression of Grem1 points to 1) de novo enhancer activity upstream of the 
Grem1 gene and 2) ectopic Grem1 expression and GREM1 secretion in cells, 
promoting an abnormal survival/proliferation. Grem1 TAD boundaries prevent such an 
excessive Grem1 transcription by limiting Grem1 promoter upstream contacts to the 
CRMs within its TAD. Therefore, this type of genetic alteration results in TADopathies 
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(Matharu and Ahituv, 2015). Dimitrov et al. (2010) have also identified a 1.7 Mb 
duplication, including the entire Fmn1-Grem1 landscape that results in a C-L-like 
syndrome, but without a predisposition to colon carcinomas.  
 
 
The analyses of our data bring new perspectives in the understanding of human 
congenital limb malformations and Grem1-related cancer.
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8. Conclusions and Outlook 
 
 
In the past ten years, tremendous advances have uncovered the large scope of the 
mechanisms associated with transcriptional regulation. When starting my Ph.D. 
project, I aimed to gain a molecular understanding of the transcriptional regulation of 
the Grem1 gene during mouse limb bud development. I used a variety of genome-
wide molecular and genetic approaches to identify and study the functions of the 
Grem1-associated CRMs during limb bud development.  
My research established that all functionally relevant CRMs for Grem1 regulation 
during limb bud development are located within a critical region in the Grem1 TAD. 
The functionally relevant CRMs with enhancer activity are organized in two enhancer 
clusters, EC1 and EC2. These CRMs interact with the Grem1 promoter to control 
Grem1 transcript levels in an additive fashion and the spatial expression dynamic in a 
cooperative manner. For one of the CRMs, an essential function in regulating the 
temporal kinetics during handplate development was identified. By analyzing 
individual and compound mutant mice, it becomes apparent that CRMs have both 
specific and context-dependent functions that depend on 1) genetic alterations and 2) 
the activity of the other CRMs in the landscape. Furthermore, intra-TAD interactions 
are altered by genomic modifications and likely contribute to compensatory efforts by 
increasing or decreasing existing contacts and also by the de novo recruitment of 
regulatory regions. As a consequence, individual CRMs may appear dispensable 
when removed individually, but essential and cooperative functions are uncovered in 
compound mutants that result in larger alterations of the Grem1 TAD structures. These 
interactions confer robustness to the cis-regulation of the Grem1 expression. This 
robustness does not entirely rely on redundancy among CRMs but synergies from 
coordinated CRM interactions, that provide in particular the spatio-temporal Grem1 
expression with robustness. The progressive loss of spatial robustness in Grem1 
expression eventually results in increasingly more severe digit reductions and loss 
(ranging from mild soft-tissue fusion to tridactyly). In addition to mesenchymal 
apoptosis during limb bud outgrowth, alterations of cell proliferation correlating with 
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the severity of digit defects were identified. Through this study, I gave evidence that 
the existing limb self-regulatory system might be incomplete and does not apply to all 
Grem1 mutants. My Ph.D. thesis research has provided deep molecular insights into 
the cis-regulatory robustness underling the spatial dynamics of the Grem1 expression. 
Furthermore, I shed light on the functional redundancy, synergy and hierarchy of ECs 
in the regulation of a single gene during embryonic tissue development. Another novel 
finding of my studies is how CRMs cooperate in different ways to maintain expression 
levels and the spatial domain of Grem1. The functional analysis of the Grem1 CRMs 
is directly relevant to a better understanding of human C-L syndromes and Grem1-
related tumors. Another fascinating field that will profit from my studies is the evolution 
and diversification of the deeply conserved CRMs that regulate Grem1 expression in 
tetrapods. For example, I have designed a compound mutant mouse strain lacking 
several CRMs (EC1CRM5∆/∆) which results in spatial changes in Grem1 expression, 
a trapezoidal limb bud shape and tetradactyly that is highly reminiscent to what is 
observed for limb buds of artiodactyl species such as pig embryos (Jonas Malkmus, 
personal communication). We have initiated studies to test the possible association 
between the limb diversity from different vertebrates and the evolution of the Grem1 
cis-regulatory landscape.  
 
In summary, my Ph.D. project has uncovered the complex cis-regulatory 
mechanisms that confers robustness to the dynamic regulation of Grem1 
expression, which is key to normal mouse limb bud development.
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9. Materials and Methods 
 
9.1. Mouse husbandry and embryo analysis 
 
9.1.1. Ethics statements 
 
All experiments with mice were performed with strict respect Swiss laws, the 3R 
principles and the Basel Declaration. They were classified as grade 0, which implies 
no or only minimal animal suffering. The researchers were licensed for animal 
experimentation by successfully completing the LTK-1 course and following the 
required continuing education courses. 
 
9.1.2. Mouse strains 
 
For this study, the following mouse strains were used:  
 
Experimental Models: 
Organisms/Strains Reference 
Scientist designer of the 
deletion 
Mouse : Tg-GLE(tg/+) EUCOMM project ID: 23892 
European Conditional 
Mouse  
Mutagenesis program 
Mouse: ∆CRM2* this study N. Riesen/ A. Zuniga  
Mouse: ∆CRM2CRM3* this study N. Riesen  
Mouse: ∆CRM2CRM4* this study N. Riesen  
Mouse: ∆CRM2CRM5* this study L. Ramos Martins/ N. Riesen 
Mouse: ∆CRM5* this study L. Ramos Martins 
Mouse: ∆EC1* this study N. Riesen 
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Mouse: ∆EC1CRM5* this study L. Ramos Martins/ N. Riesen 
Mouse: ∆EC1EC2* this study L. Ramos Martins/ N. Riesen 
Mouse: ∆EC2* this study L. Ramos Martins 
Mouse: F1∆1019* this study L. Ramos Martins 
Mouse: F1∆1024 Zuniga et al., 2004 A. Zuniga 
Mouse: Grem1 null Michos et al., 2004 A. Zuniga 
Mouse: Smad43xF Gamart et al., unpublished F. Laurent/ A. Zuniga 
*: strains generated in the laboratory (see Table 9.5.3). 
 
All mouse alleles produced during this study were generated either in the laboratory 
by aggregation chimera (Aline Baur, Dr. Julie Gamart, Laurène Ramos Martins, 
Nathalie Riesen, Dr. Robert Reinhardt, PD.Dr. Aimée Zuniga) or at the Center for 
Transgenic Model (CTM) of the University of Basel by pronuclear injection of the 
CRISPR/Cas9 protein and guides. Double mutant mouse lines were generated by re-
targeting ESCs carrying one of the two deleted alleles (namely EC1 and CRM2) for 
the other allele (namely EC2, CRM3, CRM4 and CRM5). All mice lines were 
maintained in a Swiss Albino background. All embryos and mice were genotyped by 
PCR for relevant alleles using primers listed in the table (Table 4). 
 
9.1.3. Embryo collection and staging 
 
All embryos, regardless of their species, were isolated in ice-cold PBS (140mM NaCl, 
2.7mM KCl, 25mM Tris-HCl pH 7.5) except stated otherwise. The staging was 
performed by counting somite number. During this study, collection of forelimb buds 
was restricted to the handplate for ChIP and 4C assays. 
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9.1.4. Digoxigenin-labelled RNA probe preparation 
To generate riboprobes for RNA in situ hybridization, the corresponding cDNA clone, 
obtained from the laboratory stock and previously described, were linearized using the 
required restriction enzyme and transcribed using the either T3, T7 or SP6 RNA 
polymerases (Roche or Fermentas) and Digoxigenin labeling mix (Roche 
11277073910). Plasmid DNA was removed by digesting the reaction with 8 units of 
TURBO DNase (Invitrogen AM2238) for 45 minutes at 37°C. DIG-labelled RNA probes 
were purified in 0.015% linear polyacrylamide (LPA, Gaillard and Strauss, 1990) and 
0.5M LiCl and precipitated with ethanol (EtOH) twice before dissolving in TE buffer (10 
mM TrisHCl, pH 8.0,100 µM EDTA). For the WISH screen performed for Gamart et al. 
(unpublished), all cDNAs of interest were generated by PCR amplification using 
primers that include a SP6 binding site before DNase treatment as mentioned before 
(Gamart et al., unpublished). The DIG-UTP riboprobes were purified using the mini 
Quick Spin RNA columns (Quiagen).   
The riboprobes were pre-heated at 85°C for 5 min and equilibrated in prehybridization 
buffer (50% deionized formamide, 5xSSC (0.75M NaCl, 0.075M sodium citrate 
dihydrate, pH adjusted to 4.5 with 1N HCl), 2% Blocking Reagent (Roche), 0.1% 
Tween-20; 0.5% CHAPS (Sigma C3023), 50 mg.ml-1 yeast RNA (Sigma R8759), 5mM 
EDTA, 50 mg.ml-1 heparin (Sigma H5515)) at 70°C. Probes in prehybridization buffer 
were stored at -20°C and re-used several times. 
 
9.1.5. Whole-mount in situ hybridization (WISH) 
 
Embryos were fixed in 4% paraformaldehyde (PFA) in PBS at 4°C overnight. The next 
day, they were rinsed twice in PBS-0.1% Tween-20 (PBT) and dehydrated in a 
gradient series of 25%, 50%, 75% and PBT:methanol (MeOH:PBT) before storage in 
100% methanol at -20°C. Except if stated otherwise, all washes were performed at 
room temperature (RT) for 5 minutes. On the first day, embryos were rehydrated in 
reverse gradient series of 75%, 50%, 25% MeOH:PBT and washed twice in PBT 
before splitting them in half along the AP axis. Embryos were bleached in 6% hydrogen 
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peroxide (H2O2):PBT for 15 min and washed 3 times in PBT. Then, the embryos were 
treated for 15 min with 10µg.ml-1 proteinase K in PBT for mesenchymal expressed 
genes, 4 min 5µg.ml-1 proteinase K in PBT for AER expressed genes . To inactivate 
the proteinase K, embryos were washed with fresh 2mg.ml-1 Glycine in PBT. After 2 
washes in PBT, embryos were post-fixed in fresh 0.2% glutaraldehyde, 0.1% Tween-
20 in 4% PFA for 20 min, and rinsed in PBT twice. Then, they were equilibrated in 2ml 
of prewarmed prehybridization buffer at 70°C for at least 1hr. The prehybridization 
buffer was then replaced by 1ml of fresh prewarmed prehybridization buffer containing 
10µl.ml-1 of digoxigenin-labelled RNA riboprobe (see above) and incubated overnight 
at 70°C. 
On the second day, the riboprobe-containing prehybridization buffer was recovered, 
stored at -20°C and substituted by pre-warmed prehybridization buffer, followed by 
serial washes in 75%, 50% and 25% prehybridization buffer: 2xSSC (0.3M NaCl, 
0.03M sodium citrate pH 4.5) at 70°C. Embryos were then washed twice in 2xSSC, 
0.1% CHAPS for 30 min at 70°C on a rotating wheel. The excess of RNA probe was 
eliminated with a 20µg.ml-1 RNase A (Roche 10109169001) in 2xSSC,0.1% CHAPS 
treatment for 45 min at 37°C. This step was followed by 2 times for 10 min washes at 
RT in maleic acid solution (100mM maleic acid disodium, 150mM NaCl pH 7.5) before 
incubations in maleic acid for 30 min 2 times at 70°C. Next, embryos were washed 3 
times in fresh PBST (140mM NaCl, 2.7mM KCl, 25mM Tris-HCl pH 7.5, 1% Tween-
20). The samples were blocked in 10% lamb serum in PBST for at least 1hr after which 
the solution was replaced with a solution containing anti-digoxigenin- Alkaline 
Phosphatase Fab Fragments (Roche 11093274910) diluted 1:2000 in 1% lamb serum 
in PBST. Embryos were incubated overnight (O/N) at 4°C with gentle rocking. 
The next day, embryos were washed 5 times in 0.1% BSA:PBST for 45 min and 2 
times for 30 min in PBST. Embryos were then incubated 3 times for 10 min in NTMT 
(100mM NaCl, 100mM Tris-HCl pH 9.5, 50mM MgCl2, 1% Tween-20), and transferred 
into 1ml of prewarmed BM purple Alkaline Phosphatase substrate (Roche) at RT. The 
in situs were developed in the dark and checked roughly every 30 min. The 
development was stopped at an appropriate timepoint (before the background was too 
strong) by washing the stained embryos 3 times in PBT (10 min) and twice in PBS. 
Pictures were taken using a Leica MZ FLII stereomicroscope and a Leica Application 
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Suite V3 software or a Nikon SMZ25 stereomicroscope and a Nikon application NIS 
Elements Basic Research. Embryos were stored in 30% azide (in PBS) at (4°C). 
 
9.1.6. Generation of lacZ reporter transgenic embryos 
 
9.1.6.1. Constructs preparation for injection 
 
CRMs analyzed in this study were amplified by PCR from genomic DNA extracted 
from mouse embryonic tissue (for primers see table 2). Amplified CRMs were then 
cloned into a hsp68-lacZ reporter vector (Pennacchio et al., 2006) using the Gibson 
Assembly ® Method (Gibson et al., 2009). The ligated products were dialyzed against 
milliQ water on MF nitrocellulose membrane filters (0.22μm pore size; Millipore Ref. 
VSWP01300). Transformation was performed into competent bacteria (XL1-Blue or 
DH5α) in Gene Pulser 0.2cm cuvettes with a Biorad MicroPulser. The colonies were 
plated on ampicillin supplemented LB-agar plates (prepared by Z. Boudebaba and S. 
Rabéhi). Plasmids were recovered using the NucleoBond Xtra Midi kit (Machery 
Nagel, ref. 740410.10). Positive bacterial colonies were) and digested by appropriate 
restriction enzyme to assess transgene insertion. Reporter constructs were linearized 
using the appropriate restriction enzyme and purified by phenol chloroform extraction 
in phase lock gelTM (VWRTM). 
 
9.1.6.2. Constructs pronuclear injection  
 
Transgenic embryos were generated by pronuclear injection at the CTM. Pawel 
Pelczar and Heide Oller (CTM, Basel) injected the linearized reporter constructs in at 
least 150 C57BL/6 zygotes. The surviving embryo were transferred in pseudo 
pregnant females and then were collected at E11.0. Founder embryos were stained 
for LACZ activity as described below (9.1.6.3). 
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9.1.6.3. Whole-mount LACZ staining of mouse embryos 
 
Embryos were fixed in 1% formaldehyde, 0.2% glutaraldehyde, 0.02% NP40 (Igepal 
CA-630, Cas. No: 9002-93-1 MERK), 0.01% sodium deoxycholate in PBS for precisely 
20 min at 4°C. Then, they were washed 3 times 5 min in PBS at RT. The revelation 
step was done in the dark in 1mg.ml-1 X-Gal in dimethyl formamide, 0.25mM 
K3Fe(CN6), 0.25mM K4Fe(CN6), 0.01% NP40, 0.4mM MgCl2. The reaction was 
regularly monitored and was stopped by washing 3 times in PBS at RT.  
 
9.1.7. Skeletal preparation 
 
Performed together by Aline Baur and Victorio Palacio. E14.5 embryos biopsies were 
taken for genotyping before fixation in EtOH 95% O/N. The following day, embryos 
were transcfered to acetone 100% O/N. The samples were then incubated 5 hrs to 6 
hrs in alcian blue staining solution (15mg alcian blue 8GX (Sigma) in an 80:20 mix of 
EtOH:glacial acetic acid). Embryos were then rinsed for approximately 1hr and 2hr in 
an 80:20 mixture of EtOH:glacial acetic acid before an O/N incubation in EtOH 95%. 
The next day, embryos were cleared in 1% potassium hydroxide (KOH) from 45 min 
to 1 hr before counterstaining them with alizarin red (25mg.L-1 Alizarin red (Sigma) in 
1% KOH) for 4 hrs to 5 hrs. Embryos were then cleared in 20:80 1% KOH: Glycerol 
for 1hr. The samples were washed through progressively higher ratios of 
70%EtOH:Glycerol:water (1:2:7, 2:2:6, 3:3:4, 4:4:2, 5:5:0) O/N. Pictures were taken 
using a Leica MZ FLII stereomicroscope. 
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9.1.8. Cell death detection with Lyso Tracker assay  
 
Uteri of pregnant females were dissected in prewarmed (37°C) HBSS buffer (Gibco, 
ref.55021C). Embryos were transferred into a glass vial with 4ml prewarmed (37°C) 
HBSS buffer and Lyso Tracker Red (5µL.ml-1) dye that accumulates in the lysosome 
under acidic conditions during apoptosis, when lysosomes engulf apoptotic bodies, for 
45 min at 37°C. Embryos were extensively washed 5 times 30 min with (37°C) HBSS 
buffer and fixed overnight in 4% PFA at 4°C. The next day, samples were dehydrated 
in a MeOH:PBT series. The embryos were cleared (to avoid diffraction of the 
fluorescent signal in Benzyl Benzoate/Benzyl Alcohol 2:1, BBBA) 30 min in 50% 
methanol/50% BB/BA and then left to sit in 100% BB/BA. The signal was detected by 
epifluorescence (Leica MZ FLIII fluorescence stereomicroscope). 
 
9.1.9. Generation of transgenic mice using CRISPR/Cas9 
genome editing  
 
9.1.9.1. Mouse embryonic fibroblasts culture 
 
Mouse embryonic fibroblasts (MEF) were cultured at 37°C, 5% CO2 in MEF medium 
(DMEM 4.5g.L-1 Glucose/3.5g.L-1 NaHCA3 (Gibco), 10% Fetal Bovine Serum, 1µg.ml-
1 Penicillin Streptomycin (Sigma), 2mM L-Glutamine (Sigma)). Medium was changed 
every 2 days and the MEF split every 2 to 3 days depending on their growth rate. 
Before splitting, cells were rinsed with 37°C PBS and incubated in Trypsin/EDTA 
(Sigma T-3924), for 5 min at 37°C 5% CO2 as follow: 
- 3ml for 10 cm plates 
- 1ml for 6 well plates 
- 100-150µL for 96 well plates 
Cells were dissociated by gentle pipetting 3 times before stopping the trypsinization 
with MEF medium: 
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- 7ml for 10 cm plates  
- 4ml for 6 well plates 
- 100-150µL for 96 well plates 
Then, the cells were resuspended in MEF medium and transferred to 15ml Falcon 
tubes and centrifuged for 5 min at 1200 rpm. After supernatant removal, cells were 
resuspended in MEF medium and plated at varying dilutions (1:3 to 1:4 depending on 
their density). MEFs were passaged a maximum twice after thawing. 
 
9.1.9.2. MEF mitomycin C treatment 
 
Confluent MEF plates were treated with 10µg.ml-1 of Mitomycin C (Sigma, M 0503) in 
MEF medium 2 hrs at 37°C, 5% CO2. The plates were rinsed 3 times with PBS before 
fresh medium was added. Growth-arrested MEF were maintained maximally 1 week 
after treatment ant their medium changed every two days. 
 
9.1.9.3. Mouse Embryonic Stem Cells (ESCs) culture 
 
ESCs from the G4 line were cultured on growth-arrested MEF at 37°C, 5% CO2 in 
ESC medium (DMEM (Gibco 41966029), 15% filtered FCS (PanBiotech, P30.3302), 
100U Penicillin, 0.1mg.ml-1 Streptomycin (Sigma P-0781), 200mM L-Glutamine 
(Sigma G-7513), 0.1mM βMercapto-Ethanol (Gibco 31350-010), 107U.ml-1 EsGRO 
LIF (Gibco 13275-029), 1XNon-Essential Amino Acids (Gibco 11140-035), 100mM 
Sodium Pyruvate (Gibco 11360-39)). Medium was changed every day and ESCs split 
every 2 days to 3 days during deletion positive clone recovery period. Before splitting, 
cells were rinsed with DPBS and incubated in Trypsin/EDTA,15 min at 37°C 5% CO2: 
- 3ml for 10 cm plates 
- 1ml for 6 well plates 
- 100-150µL for 96 well plates 
Colonies were dissociated by gentle pipetting 3 times. Trypsinization was stopped with 
MEF medium: 
- 7ml for 10 cm plates  
- 4ml for 6 well plates 
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- 100-150µL for 96 well plates 
The cells were transferred to 15ml Falcon tubes and centrifuged for 5 min, 1200rpm. 
After supernatant removal, cells were resuspended and plated onto Mitomycin treated 
MEFs in ES medium with a 1:3 dilution. 
 
9.1.9.4. ES cell targeting 
 
The CRISPR sgRNA (see Table 3) were designed using the CRISPOR program (see 
Table 5) and selected based on predicted specificity and efficiency scores. For 
transfection, G4 ES cells (ESCs) were plated in a 6cm dish coated with a monolayer 
of MEFs in ES medium -DMEM (Gibco 41966029), 15% filtered FCS (PanBiotech 
P30.3302), 100U Penicillin, 0.1mg.ml-1 Streptomycin (Sigma P- 0781), 200mM L-
Glutamine (Sigma G-7513), 0.1mM βMercapto-Ethanol (Gibco 31350-010), 107U.ml-
1 EsGRO LIF (Gibco 13275-029), 1X Non-Essential Amino Acids (Gibco 11140-035), 
100mM Sodium Pyruvate (Gibco 11360-39). The next morning, the medium of each 
plate was replaced by 1.75ml ES medium without antibiotics. In the late evening, the 
cells were transfected using FuGENE kit (Promega TM-328, (Kraft et al., 2015)). 
Puromycin-resistant plasmids (4µg, px459­variants) were diluted in OptiMEM-
Glutamax medium in a final volume of 125µL. This DNA-OptiMEM mixture was 
combined with 125µL of FuGENE master mix (100µL of OptiMEM-Glutamax 
supplemented by 25µL of FuGENE reagent added directly to the liquid to prevent 
adhesion to plastic) and incubated 15 min at RT. This final mix of 250µL was added in 
a dropwise manner to the ESC. Precisely, 12 hrs later, the transformation was stopped 
by changing the medium. 24 hrs later, cells were split into 6cm dishes (2 wells with 1:3 
dilution, 1 well with 1:6 dilution, 2 wells with 1:12 dilution) coated with mitomycin-
treated DR4 puromycin-resistant feeders. Cells positives for the lipofection were 
selected using puromycin (1.25µg.ml-1, Sigma-P8833) for 48 hrs. The selection was 
stopped by replacing the puromycin medium by ESC medium. PCR was used to 
screen for the correct CRISPR deletion. The surviving clones were picked and 
expanded. The selected clones were used to generate transgenic mice by aggregation 
chimera. 
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9.1.9.5. Superovulation of oocyte donors and priming of 
pseudo-pregnant females 
 
Female Swiss Albino mice 13 weeks old (approximately 10-20 females) were injected 
intraperitoneally with 25G needle equipped syringes filled with 5 I.U PMSG (Pregnant 
Mare Serum Gonadotropin – Pregnyl from Organon). Sybsequently, 48 hrs after the 
first injections, all females were injected with 5 IU hCG (human chorionic gonadotropin 
Folligon from Intervet). PMSG and hCG were dissolved in sterile PBS to 50 IU.ml-1 
and aliquots of 1ml were stored at -20°C. Matings with Swiss Albino males were set 
immediately after the second injection. 
The day after the first injection, 2 months old females were primed by adding bedding 
from a fertile Swiss Albino male in their cages. Two days later, these females were 
mated with vasectomized Swiss Albino males Only females presenting a clear plug on 
the day after the mating were selected as recipients of for the aggregated embryos. 
 
9.1.9.6. ESCs preparation for aggregation  
 
Five days later, ESCs from a confluent 6cm dish were trypsinized and dissociated by 
pipetting up and down in ES medium. Cells were pre-plated on gelatin-coated dishes 
for 45 min 37°C, 5% CO2, to remove an excess of MEF. ESCs were collected by 
centrifugation and counted. After centrifugation (1200rpm, 5 min), ESCs were re-
suspended to 5x106cells.ml-1 in filtered (0.20µm) aggregation medium (18ml DMEM 
4.5g.L-1 glucose (Gibco ref.41966029), 66mg Calcium lactate (Sigma, ref.21185) and 
10% FCS). Drops of 50µL ESCs were made on a 10cm Petri dish, then covered by 
mineral oil (Sigma, ref.M5310). Drops were incubated 10 min before aggregation. 
 
9.1.9.7. Embryo collection for aggregation 
 
Performed by Aline Baur, Dr. Julie Gamart, Dr. Robert Reinhardt, Nathalie Riesen and 
PD.Dr. Aimée Zuniga. All the solutions were pre-warmed at 37°C. Embryos were 
manipulated using a mouth pipette. Except if stated otherwise, all embryo 
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manipulation occurred in M2 medium. On day 5, embryos (E2.5, morula stage) were 
flushed out of uteri by injecting M2 medium through the infundibulum. They were 
pooled in a 3cm dish in M2 Medium. At this stage, a selection was performed to keep 
only live embryos with a nicely formed zona pellucida and 8 to 16 blastomeres. These 
embryos were then treated with Tyrode’s acid solution (Sigma T1788) for a few 
seconds to remove the zona pellucida. Then they were rinsed 3 times in M2 medium. 
  
Composition of the M2 Medium:   
6.4mg.ml-1 NaCl (Merck, ref.1064041000), 350µg.ml-1 NaHCO3 (Merck 
ref.1063290500), 36µg.ml-1 Na-Pyruvate (Merck, ref.1066190050), 50µg.ml-1 
Streptomycin. Sulf. (Sigma, ref.56501) 160µg.ml-1 KH2PO4 (Merck 1048731000), 
465µg.ml-1 Ca-Lactate.3H20 (Sigma, ref.44388), 356µg.ml-1 KCl (Merck 
1049361000), 294µg.ml-1 MgSO4.7H20 (Merck, ref.1058860500), 1mg.ml-1 Glucose 
(Sigma, ref.G8270), 621µg.ml-1 HEPES (Sigma 54457), 75µg.ml-1 K-PenG (Sigma, 
ref.P7794) and 4mg.ml-1 BSA (Sigma A3311) in Aqua ad inject (Braun/Aichele Medico, 
ref.530108). 
 
9.1.9.8. ES cell-embryo aggregation and preparation for 
transfer 
 
Performed by Aline Baur, Dr. Julie Gamart, Dr. Robert Reinhardt, Nathalie Riesen and 
PD. Dr. Aimée Zuniga. This section of the material and method was written by Dr. Julie 
Gamart. 10 embryos were gently placed in a drop of ESCs; without touching the 
monolayer of ESCs and incubated for 2 hrs at 37°C 5% CO2. During this time, Petri 
dishes with 50µL drops of KSOM (Millipore MR-106-D) covered with mineral oil were 
prepared and prewarmed at 37°C. Aggregated embryos were then gently removed, 
the excess of cells detached by pipetting up and down. For generating good chimeras, 
an embryo must be aggregated with 5 to 10 ESCs. Ten aggregated embryos were 
placed in a drop of KSOM, well separated from each other and incubated overnight at 
37°C in 5% CO2. Around 20 hrs after aggregation, embryos were mostly blastocysts 
and were ready for transfer. They were washed once in prewarmed M2 medium and 
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kept in M2 at 37°C until the transfer. Embryo transfer was performed by Julie Gamart 
or Aline Baur. 
 
9.1.9.9. Zygote CRISPR/Cas9 targeting 
 
The CTM of the University of Basel performed microinjection of the CRISPR/Cas9 
protein and the single guides RNA (see Table 3) in at least 150 C57BL/6 WT or mutant 
(CRM2∆/+, EC1∆/+ zygotes). The surviving embryos were transferred into pseudo 
pregnant females. Founder littermates were screened using PCR and the mice 
positive for the deletion were sequenced to determine the exact coordinates of the 
deletion. The founders carrying the desired deletion were outbred in Swiss Albino 
background for 2 generations before further analysis. 
 
9.2. Molecular biology  
 
9.2.1. RNA extraction and cDNA synthesis 
 
RNA was extracted from embryonic limb buds (40-42ss) dissected in ice-cold PBS. 
After PBS removal, samples were covered with 100µl of RNAlater® (R0901, Sigma-
Aldricht) and stored at -20°C until extraction. Total RNA was extracted using the 
RNeasy Micro Kit (Qiagen). The PrimeScriptTM 1ST strand cDNA synthesis kit 
(TAKARA Bio Inc.) was used to synthetize cDNA. Total RNA (<5µM) was incubated 
with 50µM Oligo dT Primers and 10mM dNTP mixture to a total volume of 12µl of 
annealing reaction, for 5 min at 65°C and immediately cooled on ice. The 12µL of 
annealed product were retrotranscribed in presence of 200U of PrimeScriptRTase 
(200U.µL-1), 20U of RNase Inhibitor (40U.µL-1), 1X PrimeScript Buffer to a total volume 
of 20µL at 50°C for 1h. The enzyme was inactivated at 75°C for 15 min and 
immediately cooled on ice. cDNAs were stored at -20°C before amplification by RT-
qPCR. 
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9.2.2. Real Time-quantitative PCR (RT-qPCR) 
 
RT-qPCR reactions were performed with the Bio-Rad CFX96 Real-Time PCR system 
using iQ SYBR Green Supermix (Bio-Rad). PCR reactions were set in 20µL containing 
0.3µM each primer (see Table 5), 50% SYBR green and either 0.5µL cDNA or 1µL 
ChIP/Input samples (for ChIP-qPCR). The program for qPCR was: 95°C 3 min 95°C 
10sec 13 cycles 60°C 1 min 95°C 10sec 65°C 5sec 95°C 5sec (Benazet et al., 2009). 
For gene expression analysis, the ribosomal protein L19 (RPL19) transcript was used 
as normalizer. Relative Cq values of the target transcripts were normalized to the Cq 
values of RPL19, and normalized fold expression level (2- ΔΔCq) are shown as mean ± 
SEM. (for primers see Tables 6 and 7) 
 
9.2.3. Chromatin Immunoprecipitation and sequencing (ChIP-
seq) 
 
9.2.3.1. SMAD43xFlag ChIP-seq 
 
The ChIP experiments targeting the Smad43xF/3xF were performed by Dr. Julie Gamart 
(Gamart et al., manuscript in preparation) who taught me this protocol. This protocol 
is adapted from Visel et al., 2009a for tissue collection and crosslinked chromatin 
preparation, on Kim et al., 2007 and Vokes et al., 2008 for subsequent steps, and had 
been modified and optimized by Dr. Marco Osterwalder, Dr. Javier Lopez-Rios and 
Dr. Julie Gamart.  
Embryos were collected in ice-cold PBS, and dissected forelimbs from embryos at 
E9.75 (28-31ss), E10.5 (33-35ss) of the same genotype were pooled into 2ml 
Eppendorf tubes. Dissected tissues were washed twice with ice-cold DPBS 
w/Ca2+Mg2+ (Gibco) and transferred to a glass douncer (Tissue Grind Tube Size 2ml, 
Kimble-Chase) on ice. Tissue disaggregation was achieved by applying 25 strokes 
with pestle A (Tissue Grind Pestle LC 2ml, Kimble-Chase) followed by 25 strokes with 
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pestle B (Tissue Grind Pestle SC 2ml, Kimble-Chase). The nuclei solution was 
transferred back to a 2ml Eppendorf tube, and the douncer was rinsed with 300µL of 
cold DPBS w/Ca2+Mg2+ to recover the maximum amount of each sample. After 
centrifugation (3000rpm, 3 min, 4°C), supernatants were discarded and nuclei 
resuspended in 1.5ml DPBS w/Ca2+Mg2+ containing 150µL 11Xcrosslinking buffer 
(0.1M NaCl, 1mM EDTA, 0.5mM EGTA, 50mM Hepes pH 8.0; supplemented with 11% 
formaldehyde just before use) at RT The solutions were incubated 5 min at RT with 
gentle shaking on a horizontal platform. Crosslinking was interrupted with 75µl of 2.5M 
Glycine followed by a 5 min incubation at RT without shaking. The samples were then 
centrifuged (3000rpm, 3 min, 4°C), supernatants removed, and pellets resuspended 
in 1.5ml ice-cold DPBS w/Ca2+Mg2+. After centrifuging once again (3000rpm, 3 
min,4°C), the supernatants were discarded and the nuclear pellets snap-frozen in 
liquid nitrogen (N2) and stored at -80°C. 3 samples of crosslinked nuclei from similar 
amounts of dissected forelimbs were processed for ChIP in parallel per experiments. 
Before performing the actual ChIP, antibodies coupled to magnetic beads were 
prepared. For one ChIP sample, 20µl of Dynabeads® Protein G (Invitrogen) were used 
and transferred to a 2ml Eppendorf tube containing 1ml freshly prepared ice-cold BSA 
(5mg.ml-1 in DPBS w/Ca2+Mg2+). Beads were washed with 1ml cold BSA/PBS on a 
magnetic rack 6 times. Then they were resuspended in 2.5x the original volume of 
beads (50µl per sample) with BSA:PBS and transferred to a 2ml screw cap microtube 
(Starstedt). 2µg of anti-FLAG M2 antibody were used for each ChIP sample and 
incubated overnight on a rotating wheel (4°C).The following day, the Dynabeads-
antibodies complexes were transferred back to a 2ml Eppendorf tube and washed 6 
times with 1ml cold BSA:PBS before being resuspended in the original volume of 
suspended beads (20µl per sample) and kept on ice. In the meantime, snap-frozen 
crosslinked nuclear pellets were thawed on ice and resuspended in 6ml cold Lysis 
buffer (50mM Hepes pH 7.5, 140mM NaCl, 1mMEDTA pH 8.0, 10% Glycerol, 0.5% 
NP-40, 0.25% Triton X-100 (SIGMA-ALDRICHT), 1X Complete mini protease inhibitor 
cocktail (Roche)). Lysates were incubated for 10 min (4°C) with gentle rocking, 
followed by centrifugation (10 min, 2500rpm, 4°C). After discarding the supernatants, 
the pellets were resuspended in 2ml of Protein Extraction Buffer (0.2M NaCl, 1mM 
EDTA pH 8.0,0.5mM EGTA pH 8.0, 10mM Tris-HCl pH 8.0, 1X Complete mini 
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protease inhibitor cocktail) and supplemented with 3ml of Protein Extraction Buffer at 
RT. The samples were incubated for 10 min at RT on a rocking platform and the nuclei 
pelleted by centrifuging (10 min, 2500rpm, 4°C). After discarding the supernatant, the 
nuclei were resuspended in 1ml ice-cold Chromatin Extraction Buffer (1mM EDTA pH 
8.0,1460.5mM EGTA pH 8.0, 10mM Tris-HCl pH 8.0, 0.1% Na-Deoxycholate, 0.5% 
N-lauroylsarcosine, 3xComplete mini protease inhibitor cocktail). Sonication was 
proceeded in Covaris AFA Tubes Fiber & Cap 12x12mm (part number 520081, 
Covaris) with the S220 Covaris Ultra-sonicator. Each sample was sonicated for 15 min 
using the 5% duty cycle, 140 watts peak Incident power and 200 cycles per Burst. The 
sheared chromatin was then transferred to 1.5ml Eppendorf tubes, insoluble debris 
were pelleted by centrifugation (10 min, 13000rpm, 4°C). The supernatants were 
transferred to new 2ml screw cap microtubes, and the volume was topped up to 
1.060ml with Chromatin Extraction Buffer. At this stage, 2x 30µl aliquots were taken 
and separated to new Eppendorf tubes: one for input control and the other to assess 
the quality of the sonicated chromatin on an agarose gel. Aliquots were kept overnight 
(4°C) and treated in parallel with the ChIP sample. 300µl of ChIP cocktail Mix (130µl 
Triton X-100 10%, 3µl Na-Deoxycholate 10%, 26µl Complete protease inhibitor 
solution (from a 50x tablet dissolved in 1ml mQ H2O),131µl TE buffer (100mM Tris 
HCl pH 7.4, 10mM EDTA pH 8.0) and 10µl mQ H2O were added to each 1ml ChIP 
sample to adjust to RIPA buffer conditions (see below). Twenty microliters of the 
freshly washed Dynabead-antibody complexes were added to each ChIP samples and 
incubated overnight on a rotating wheel (4°C).The following day, the Dynabeads were 
transferred to 1.5ml Eppendorf tubes containing 1ml of freshly prepared ice-cold RIPA 
buffer (50mM Hepes pH 8.0, 1mM EDTA pH 8.0, 1% NP-40, 0.7% Na-Deoxycholate, 
0.5M LiCl, 1XComplete mini protease inhibitor cocktail), and washed 6 times with 1ml 
cold RIPA buffer on a magnetic rack. The beads were rinsed with 1ml TE-plus (100mM 
Tris HCl pH 8.0, 10mMEDTA pH 8.0, 50mM NaCl, 1X Complete mini protease inhibitor 
cocktail) and centrifuged ( 3 min, 1000rpm, 4°C). All residual liquid was removed from 
the beads using the magnetic rack, and the beads were resuspended in 100µl freshly 
prepared Elution Buffer (1mM EDTA, 1% SDS, 10mM Tris-HCl pH 8.0). The 
crosslinked protein-DNA complexes were eluted from the Dynabead-antibody 
complexes at 65°C for 15 min on heat blocks shaking at 1300rpm. Beads were then 
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centrifuged for 1 min at 1300rpm and retained in the tube using a magnetic rack, while 
100µl of supernatant containing the protein-DNA complexes were transferred to a 
PCR microtube. In parallel, the 30µl input aliquot and the 30µl chromatin aliquot were 
transferred to PCR microtubes containing 120µl of Elution Buffer. Reverse crosslinking 
was performed for all three samples by an overnight incubation at 65°C (≥12 hrs).The 
samples were then transferred to 1.5ml Eppendorf tubes and treated with RNase A 
(from bovine pancreas, Sigma) in TE (100mM Tris HCl pH 8.0, 10mMEDTA pH 8.0) 
at a final concentration of 0.2µg.µl-1. After 1hr incubation at 37°C, Proteinase K 
(0.2µg.µl-1) was added and proteins were digested for 2 hrs at 55°C. Finally, DNA was 
purified from using the QIAquick Gel Extraction Kit (Qiagen). Elution was achieved in 
using twice 30µl Buffer EB, and the eluted ChIP and input samples were aliquoted and 
stored at -20°C before use for qPCR. Half of the purified chromatin control samples 
were loaded on an 1.5% agarose gel to estimate the range of DNA fragments sizes 
(between 150 bp to ~1.5 kb with a maximal intensity at ~300bp) and evaluate 
sonication quality. Libraries were made by the sequencing facility and Sequencing was 
done on an Illumina 2000 sequencer in a 50-cycles paired-end configuration (Genomic 
core facility, EMBL, Heidelberg). (for Antibody see Table 11) 
 
9.2.3.2. ChIP-seq general protocol 
For GLI3, ChIP-seq was performed on tissue obtained from homozygous mice 
carrying a 3XFLAG epitope knocked-in to the endogenous Gli3 locus (Lopez-Rios et 
al., 2014; Lorberbaum et al., 2016). Briefly, stage-specific embryonic limb buds were 
collected in ice cold PBS and pooled prior to crosslinking in 1% formaldehyde/PBS for 
20 minutes at room temp. Following tissue cross-linking samples were processed for 
ChIP as previously described (Peterson et al. 2012). DNA was purified using QiaQuick 
columns (Qiagen) and quantitated using a Qubit (ThermoFisher). Sequencing libraries 
were prepared according to manufacturer instructions (Takara). All samples were 
sequenced on NextSeq instrument (Illumina) to generate 1X75 bp reads. The resulting 
reads were mapped to genome assembly GRCm38 (mm10) using bwa (Li and Durbin, 
2009). Peak calls were made relative to input controls using macs2 (Zhang et al. 2008) 
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callpeak function and default parameters with the following options: --Call-summits -B 
--trackline. (Paragraph written by Dr. Kevin Peterson) 
 
All other ChIP-Seq and ChIP-qPCR experiments (see table 9.5.7 for primers) were 
performed by and Dr. Rushikesh Sheth and Jens Stolte. This protocol for embryonic 
tissue is adapted from Sheth et al., 2016 and I participated to the establishment of this 
protocol in the laboratory. In the morning, magnetic beads were coupled with the 
corresponding antibody. For one ChIP sample, 20µl of Dynabeads® Protein A and 
20µl of Dynabeads® Protein G and were transferred to a 1.5ml Eppendorf tube 
containing 1ml freshly prepared ice-cold ChIP DIL buffer (Triton 1.0%, Tris pH8 10mM, 
NaCl 150mM , EDTA pH8 2mM) and nutated for 2 min. The tubes were briefly 
centrifuged before resting for 1 min on magnetic racks and washed as described 
earlier two more times. The appropriate antibodies (1 to 10µg) were resuspended in 
1ml of ChIP DIL buffer and incubated 3 hrs to 6 hrs with the beads on the rotating 
platform (4°C).  
Embryos were collected in ice cold PBS and dissected forelimbs from somites-
matched embryos of the same genotype were pooled into 1.5ml low-bind Eppendorf’s. 
The pellet was disaggregated in 1ml of buffer A (Triton 0.25%, Tris pH8 10mM, EDTA 
pH8 10mM, EGTA pH8 0.5mM) with 13 strokes of pestle A (Tissue Grind Pestle LC 
2ml, Kimble-Chase), transferred to 1.5ml Eppendorf followed by 10 min incubation on 
ice. The samples were transferred to 1.5ml Low-Bind Eppendorf’s and centrifugated 
for 3 min at 4000rpm (4°C). After discarding the supernatant, the pellets were 
resuspended in 1ml of buffer B (NaCl 200mM, Tris pH8 10mM, EDTA pH8 1mM, 
EGTA pH8 0.5M) and incubated for 30 min on ice while inverting the tubes every 10 
min. After a 3 min centrifugation 4000rpm (4°C), pellets were resuspended in 300µL 
of buffer CD (SDS 0.5%, Triton 0.5%, Sodium deoxycholate 0.5%, NaCl 140mM, Tris 
pH8 10mM, EDTA pH8 1M, EGTA pH8 0.5mM). DNA was sonicated with the 
Bioruptor® Plus sonication device (Diagenode) in Covaris vials. Each sample was 
sonicated through 17 cycle of 30s ON and 30s OFF. The sheared chromatin was then 
centrifuged for 15 min at 12500rpm (4°C), 20µL of supernatant was kept as input 
stored at -20°C and the recovered supernatant ≈280µL was transferred in a new tube. 
The complexes antibodies-beads were retrieved, quickly centrifuged, set on the 
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magnetic racks where the supernatant was delicately aspired and replaced by 500µL 
of ChIP DIL buffer. The 280µL of supernatant was added to the beads and incubated 
O/N (4°C) on the rotating platform for crosslinking. 
The next day, the bead-DNA complexes were washed with 1ml of IB buffer (Triton 
1.0%, SDS 0.1%,NaCl 150mM, Tris pH8 20mM, EDTA pH8 2mM) and incubated for 
2 min on the rotating platform, transferred to a new LoBind tube, followed by a 2 min 
successive washes on the rotating platform with IC buffer (Triton 1.0%, SDS 0.1%, 
NaCl 500mM, Tris pH8 20mM, EDTA pH8 2mM), ID buffer (Triton 1.0%, SDS 0.1%, 
NaCl 500mM, Tris pH8 20mM, EDTA pH8 2mM) and ITEN buffer (NaCl 50mM, Tris 
pH8 10mM, EDTA pH8 1mM) before transferring the sample to a new LoBind tube. 
After a 1 min centrifugation 2000rpm RT, 2/3 of the supernatant was discarded. The 
tubes were put on magnetic racks and the rest of the supernatant was discarded. 
Reverse cross-linking was performed using 120µL of buffer E (SDS 1.0%, Tris pH8 
10mM, EDTA pH8 10mM) for the beads-DNA complexes and 200µL of buffer E for the 
inputs with a 6 hrs incubation at 65°C. Input and DNA were treated with 50ng of RNAse 
(SIGMA-ALDRICHT) for 15 min RT followed by a 1hr treatment with 100ng of 
Proteinase K (SIGMA-ALDRICHT) at 55°C. Finally, DNA and 50µL of input were 
purified from all samples using the QIAquick Gel Extraction Kit (Qiagen). Elution was 
achieved in two steps using 50µl Buffer EB, and the eluted ChIP and input samples 
were aliquoted and stored at -20°C before use. To assess the quality of the sonication, 
half of the purified chromatin control samples were loaded on an 1.5% agarose gel to 
estimate the range of DNA fragments sizes (between 150bp to ~1.5 kb with a maximal 
intensity at ~300 bp, data not shown). Libraries were made with the Nextera DNA 
Library Preparation Kit (FC-121-1030 , Illumina). Sequencing was done on an Illumina 
2000 sequencer in a 50-cycles paired-end configuration (Genomic core facility, EMBL, 
Heidelberg). (for Antibody see Table 11) 
 
9.2.4. ATAC-seq  
ATAC-seq was performed by following the protocol of Buenrostro et al., 2013, for 2 
biological replicates performed by Dr. Rushikesh Sheth and Jens Stolte. One replicate 
consisted of 75 000 cells for each transposition. After two washes in ice-cold DPBS 
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w/Ca2+Mg2+, dissected tissues were transferred to a glass douncer (Tissue Grind Tube 
Size 2ml, Kimble- Chase) on ice. Then, 20 stokes with pestle A (Tissue Grind Pestle 
LC 2ml, Kimble-Chase) followed by 20 stokes with the pestle B (Tissue Grind Pestle 
SC 2ml, Kimble-Chase) were applied to disaggregate the cells clusters. The volume 
corresponding to 75000 cells was centrifuged (5 min at 500g 4°C) and supernatants 
gently removed before rinsing with 100µL ice-cold DPBS w/Ca2+Mg2+ followed by a 
centrifugation (5 min at 500g 4°C). DPBS was discarded and the samples were lysed 
in 50µL Lysis buffer (10mM Tris-HCl pH 7.5, 10mM NaCl, 3mM MgCl2 and 0.1% 
NP40) by gently pipetting up-and-down and centrifuging (10 min, 2500rpm 4°C). The 
nuclei pellets, freed of supernatant, were transposed for 30 min at 37°C in a 25µL 
reaction mix (25µL TD 2x reaction buffer), 2.5µL TDE1 (Nextera Tn5 Transposase 
(Illumina 15028212)) and 22.5µL nuclease-free H20. Samples were immediately 
purified using a Qiagen minElute PCR Purification Kit. The transposed DNA was 
eluted in 13µL EB buffer (Tris-HCl pH 8.5, stored at -20°C). The second day, 10µL 
transposed DNA fragments were amplified by PCR using 25µL KAPA HiFi HotStart 
Ready Mix (Roche 07958927001) with 25µM PCR Primer 1 (sequence: 5'-AAT GAT 
ACG GCG ACC ACC GAG ATC TAC ACT CGT CGG CAG CGT CA GAT GTG-3’) 
and 25µM barcoded PCR Primer 2.1 (sequence: 5'-CAA GCA GAA GAC GGC ATA 
CGA GAT TCG CCT TAG TCT CGT GGG CTC GGA GAT GT-3') or 2.2 (sequence: 
5'-CAA GCA GAA GAC GGC ATA CGA GAT CTA GTA CGG TCT CGT GGG CTC 
GGA GAT GT-3') from the kit for each replicates in a total volume of 50µL. 
 
PCR program details:  72°C 5 min  
98°C 30sec  
98°C 10 min  13 cycles 
63°C 30sec  
72°C 1 min  
4°C ∞  
 
The amplified library was purified with QIAquick PCR purification kit (Qiagen) and 
eluted in 30µL EB buffer. Sequencing was done using an Illumina NextSeq 500 system 
(SE75) by the Genomics Facility Basel - ETH Zürich. 
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9.2.5. Circular Chromosome Conformation Capture and 
sequencing, 4C-seq (Matelot and Noordermeer, 2016)  
 
9.2.5.1. Forelimb buds collection 
 
One biological replicate consists in 10 pairs of mouse forelimb buds at 40-42ss (2-
4x106 cells) collected in cold DPBS (PCB with w/Ca2+Mg2+ Gibco Ref.D1283) 
supplemented by 10% Fetal Bovine Serum (FBS, filter sterilized through 0.45µm filter 
membrane) in 2ml Eppendorf tubes. After a 1 min centrifugation 300g at 4°C, the 
medium was replaced with 500µL of fresh 10% FBS/DPBS and the pellet was 
disaggregated using 3µL of collagenase D (ROCHE, 300µg.ml-1) at 37°C 750rpm and 
through mechanical disruption by pipetting up and down 20 times every 3 min. Single 
cell suspensions were obtained by passing the tissue through pluriStrainer mini 
(70µm, Pluriselect) in a Falcon 15ml and rinsing the pluriStrainer with 11.4ml of RT 
10%FBS/DPBS allowing us to maximize the recovered amount of cells. Protein-DNA 
complexes were cross-linked by a 10 min incubation with 650µL of formaldehyde 37% 
(SIGMA-ALDRICHT) tumbling. Immediately after cross-linking, samples were 
transferred on ice and the formaldehyde reactivity was quenched using 0.1M cold 
glycine. After an 8 min centrifugation at 400g (4°C), the supernatants were discarded 
and cells were lysed in 5ml lysis buffer (Tris-HCl pH7.5 50mM, NaCl 150mM, EDTA 
50mM, NP40 0.5%, Trition 1%, complete proteinase inhibitor 1X) for 10 min on ice. 
The lysis buffer was gently discarded after a 5 min 400g (4°C) centrifugation and the 
pellet was resuspended in the left-over medium and transferred in a 1.5ml Eppendorf. 
Lastly, the cells were pelleted by a 1 min centrifugation at 800g (4°C), the supernatant 
was discarded and the samples were frozen in N2 and stored at -80°C. 
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9.2.5.2. 4C-seq 
 
The 4C protocol was adapted from Noordermeer et al., 2011. The nuclei pellets were 
washed with 450µL 1.2x DpnII Buffer (NEB). A 1 min 800g centrifugation at 4°C was 
performed to replace the supernatant by 500µL of 1.2x DpnII Buffer 0.3% SDS. The 
tubes were incubated first at 55°C for 10 min at 600rpm then at 37°C for 50 min at 
600rpm. SDS was quenched by adding 50µL of Triton 20% to the samples before 
incubating at 37°C for 1hr 600 rpm. A 5µL aliquot was treated with 100µg of Proteinase 
K in 10mM Tris-HCl pH 7.5 in a final volume of 100µL for 1hr at 65°C and stored at -
20°C as undigested controls. In parallel, the sample were digested with 400U of DpnII 
for 6 hrs at 37°C 600rpm. The reaction was spiked with 400U of DpnII O/N, 37°C 
600rpm. 
The next day, a 5µL aliquot was treated with 100µg of Proteinase K in 10mM Tris-HCl 
pH 7.5 in a final volume of 100µL for 1hr at 65°C and run on a 1.5% agarose gel with 
the undigested controls to assess the digestion. When the digestion was successful, 
the restriction enzyme was inactivated for 25 min at 65°C with 80µL of SDS 10%. The 
sample were transferred to a 15ml tube and incubated 1hr at 37°C 400rpm with 375µL 
of 20% Triton in 1.15x ligation buffer (ATP 10mM, Dithiothreitol 50mM (DTT, MERK), 
MgCl2 50mM, Tris-Hcl pH7.5 0.7M). The samples were cooled down at RT before the 
addition of 100U of T4 ligase (Promega). After a 4 hrs incubation at 16°C, the reaction 
was pursued for 30 min at RT. De-crosslinking was processed O/N at 65°C in 
presence of 30µg of Proteinase K.  
The next morning, the samples were treated with RNase for 45 min at 37°C. 
Purification of the samples was performed by adding 7ml of 
phenol:chlorophorm:isoamyl alcohol (SIGMA ALDRICHT) pre-warmed at RT and 
shaking the tubes until they became white. The DNA was retrieved after a 15 min 
centrifugation at 2200g (RT) and transferred to a 50ml Falcon tube (SIGMA-
ALDRICHT). In order to facilitate DNA precipitation, 7ml of nuclease free water and 
1.5ml of 2M Sodium acetate pH5.6 was gently added to the samples. 35ml of pure 
ethanol was added to the samples and gently mixed before a 2 hrs incubation at -
20°C. After a 45 min centrifugation at 4500g (4°C), DNA pellets were cleaned with 
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10ml of 70% ethanol followed by a 15 min centrifugation 4500g (4°C). The pellets were 
dried and then resuspended in 150µL of 10mM Tris-HCl pH 7.5. After measuring the 
DNA concentration, 200ng per sample were loaded on a 1.5% agarose gel to control 
the ligation. The DNA was diluted to 100ng/µL in the appropriate 1X digestion buffer 
and 1U/µg of secondary enzyme NlaIII was added to the solution and incubated O/N 
at 37°C 600rpm.  
On the fourth day, the restriction enzyme was inactivated by a 20 min incubation at 
65°C. The digested DNA was mixed 1:1 with RT Phenol:Chlorophorm:Isoamyl alcohol 
and transferred to a phase lock gelTM. After a 5 min centrifugation 13000 (RT) the 
upper phase was transferred to a new 1.5ml Eppendorf tube and gently mixed with 
1:10 (depending on the NlaII digestion final volume) 2M Sodium acetate pH5.6 and 
2:1 100% ethanol. After a 30 min incubation at -80°C, the DNA was pelleted thanks to 
a 20 min centrifugation at 13000 rpm (4°) and cleaned with 1ml of 70% ethanol. The 
supernatant was discarded after a 5 min centrifugation 13000 rpm (4°C) and the pellet 
was dried 1 min (RT) and resuspended in 100µL of clean water. A 5µL aliquot was run 
on a 1.5% agarose gel to control the digestion. After transferring the DNA to a new 
50ml tube in large volume of water (≈12.46ml), the ligation was performed with ligation 
buffer in a 1X final concentration with 200U of T4 DNA ligase HC (Promega) for 4 hrs 
at 16°C and then for 30 min at RT. The ligation products were purified with 14ml of 
Phenol:Chlorophorm:Isoamyl alcohol followed by a 10 min 3000g (RT) centrifugation. 
The supernatant was transferred to a new 50ml tube and mixed with 14ml of water 
and 5µg.µL (≈112µL) of glycogen (ROCHE) and 1:10 (approximately 1.5ml) 2M 
Sodium acetate pH5.6 to facilitate DNA precipitation. The samples were divided into 
two 50ml tubes incubates O/N with 2 volumes of 100% ethanol at -20°C.  
On the fifth day, the DNA was pelleted by centrifuging for 45 min at 4500rpm (4°C), 
cleaned with 10ml of 70% ethanol followed by a 15 min centrifugation 4500rpm (4°C) 
and left to dry for 10 min (RT). The purified DNA pellet was dissolved in 200µL of 
10mM Tris-HCl pH7.5 and left to sit at least for 30 min at 37°C. The samples were 
purified with the QIAquick Nucleotide removal kit (QIAgen). Libraries were constructed 
using the highest concentration of 4C template that was still linear on a 1.5% agarose 
after PCR with the index free view point primers designed by PD Dr. Aimée Zuniga 
(C1: 5’-CTT CCG TAG ATG CTG GCC GAT-3’ and C6: 5’AAG CAC CAG GAC CGA 
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GTT TG-3’) using the Expand Long Template PCR system (Roche) polymerase. (see 
Table 8 for primer sequences) 
 
 PCR program details:  94°C 2 min  
 94°C 15sec  
 55°C 1 min  30 cycles 
 68°C 3 min  
 68°C 7 min  
 4°C ∞  
 
The pooled PCR products were purified using a PCR purification kit (Qiagen) such as 
no more than 10µg was loaded on a column. After purification, 2ng of DNA was loaded 
on a fragment analyzer (ThermoFisher) and the samples with the best profiles (no 
primer contamination) were sequenced using an Illumina Next Seq 500 system or Mi-
seq single end sequencing with 75 cycles by the Genomics Facility Basel - ETH Zürich. 
 
9.3. Bioinformatics Analysis 
 
Bioinformatic analysis for SMAD4 ChIP-seq was performed by Iros Barozzi (Lawrence 
Berkeley National Laboratory, Berkeley, CA, USA). The ß-catenin ChIP-seq and the 
ATAC-seq experiments were analyzed by the DBM Bioinformatics Core Facility 
member Florian Geier. This part of the material and methods section was partly written 
by Iros Barozzi for Gamart et al., manusctipt in preparation. Bioinformatic analysis for 
4C-seq were performed by Dr. Shalu Janhwar and the 4C section of the material and 
methods was written by her. The GLI ChIP-seq were performed and analyzed by Dr. 
Kevin Peterson. 
 
9.3.1. ChIP-seq raw data analyses and annotation 
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Short reads obtained from Illumina HiSeq were aligned to the mm9 genome using 
Bowtie v1.1.0 (Langmead et al., 2009). Only those reads with a unique match to the 
genome with two or fewer mismatches (-m 1 -v 2) were retained. In order to make 
different runs comparable, the 3’ of reads were trimmed to 63 bp before alignment. 
This step was performed using fastx_trimmer (-l 63), a tool part of the FASTX-Toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/) (v0.0.13). Peak calling was performed using 
MACS v1.4 (Zhang et al., 2008) with the following parameters: --gsize=mm --bw=300 
--nomodel --shiftsize=100 -- pvalue=1e-2. Matched input DNA was used as control. 
Wiggle tracks were also generated with MACS; these were then re-scaled linearly 
according to sequencing depth (RPM, Reads Per Million sequenced reads). MACS 
was run with a permissive threshold (p-value 0.01) in order to identify a larger list of 
subsignificant regions across biological replicates. Evidences from these replicates 
were combined using MSPC (Jalili et al., 2015), with the following parameters -r 
biological -s 1E-5 -W 1E-2. The confirmed peaks were assigned the best pvalue (as 
defined by MACS) among the overlapping peaks across replicates. Only the peaks 
showing reproducibility were retained for further analysis (we termed this set as 
golden; one golden set per developmental stage). These lists of peaks were annotated 
to the TSS of the nearest RefSeq genes using the script annotatePeaks.pl available 
in HOMER (Heinz et al., 2010). A region was considered as promoter-proximal if 
annotated within 2.5 kb from a RefSeq promoter. The remaining regions were divided 
into intragenic and intergenic, whether the region overlapped the body of an annotated 
gene or not. 
 
9.3.2. ATAC-seq raw data analysis and annotation 
 
Short reads obtained from Illumina HiSeq were aligned to the mm9 genome using 
Bowtie v1.1.0 (Langmead et al., 2009) (-m 1 -v 2, see “Chip-seq raw data analyses 
and annotation”). Accessible regions were identified using MACS v1.4 (Zhang et al., 
2008) with the following parameters: --gsize=mm --bw=150 -- nomodel --nolambda --
shiftsize=75. Genome-wide profiles were generated using MACS and re-scaled 
linearly according to sequencing depth (RPM). Gene annotation was performed using 
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HOMER (Heinz et al., 2010), as described in “Chip-seq raw data analyses and 
annotation”. Evidences from biological replicates were combined using MSPC (Jalili 
et al., 2015), using the following parameters -r biological -s 1E-10 -W 1E-6. The 
confirmed regions were assigned the best p-value (as defined by MACS) among the 
overlapping regions across replicates. Performed by the DBM Bioinformatics Core 
Facility member Florian Geier. 
 
9.3.3. 4C-seq analysis  
 
4C-seq libraries of WT and different Grem1 mutant samples were sequenced with 
Illumina technology according to standard protocols, generating reads of comparable 
lengths (76, 81 or 85bp). To achieve an overall high quality of the raw sequencing 
data, firstly reads from different samples were trimmed to 76bp and subsequently, 
those reads that did not match with the primer sequence were discarded. After clipping 
the primer sequence, cleaned reads were aligned onto the mouse reference genome 
mm10 using Bowtie v 2.2.9. To get the valid restriction fragments, the mouse reference 
genome was in-silico digested using the two restriction enzymes. Restriction 
fragments that did not contain a cutting site of the second restriction enzyme or are 
smaller than 20bp were filtered out (Klein et al. 2015), finally yielding valid restriction 
fragments that were used for the quantification of 4C-seq profiles. Read counts were 
then computed in each valid fragment and subsequently visualized using the UCSC 
genome browser. To visualize the data, bedGraph formatted files containing read 
counts of either each fragment or in a specified window of fragments were generated. 
4C‐seq contacts were analyzed in the mouse region chr2:113326224-113894862. As 
suggested by Lupiáñez, Darío G., et al. (Lupiáñez, Darío G., et al. cell 2015), the 
viewpoint, adjacent undigested fragments and fragments 10 kb up and downstream 
were excluded during the procedure. Finally, a range of 5 informative fragments was 
used to normalize the data per million reads (RPM) over a sliding window using custom 
scripts and the continuous‐valued data was displayed in the figures as well as onto 
the UCSC genome browser tracks. The differences track was calculated by 
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subtracting fragment reads between different samples (Klein et al., 2015; Lupianez et 
al., 2015) 
 
9.4. Cell proliferation analysis by fluorescence-activated cell 
sorting (FACS) 
 
 
The flow cell analysis was performed by Dr. Robert Reinhardt and this part is adapted 
from Reinhardt et al., 2019.  
Forelimb buds were dissected and pools of 4 limbs per replicates at E11.0 (39ss to 
43ss) were dissociated using collagenase D. Following the exclusion of lineage-
positive cells (ectodermal cells, erythrocytes, endothelial cells, hematopoietic cells, 
macrophages, dendritic cells, myeloid lineage, see Table 9.5.11) all cells were fixed 
in 70% ethanol at -20°C O/N. Phospho-histone H3 antibodies (BD Biosciences, clone 
HTA28 Alexa Fluor 647) were used to detect mitotic cells. Cells were also incubated 
with 50µl.ml-1 propidium iodide (Sigma) and 50µl.ml-1 RNase A (Sigma) to measure 
their DNA content. FACS was used to determine the fractions of cells in the different 
phases of the cell cycle and the fraction of phospho-histone H3-positive mitotic cells 
among the lineage-negative (Lin−) limb bud mesenchymal cells. FACS was used to 
determine the fractions of cells in the different phases of the cell cycle and the fraction 
of phospho-histone H3-positive mitotic cells among the Lin− limb bud mesenchymal 
cells. FACS analysis was carried out using a BD FACS Aria III machine. After 
exclusion of lineage-positive cells, the numbers of cells in different phases of the cell 
cycle and mitotic cells were determined and fractions calculated using the FlowJo 
10.5.3 software. 
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9.5. Tables  
 
9.5.1. Table 1: Summary of transgenic collections for CRM 
screening  
 
CONSTRUCTS Embryo collected 
% 
Transgenic 
embryos 
Expresser 
embryos 
Limb 
expresser 
embryos 
CRM1 76 22.4% (n=17/76) 9 (52.9%) 9/9 (100%) 
CRM2 59 6.8% (n=4/59) 4 (100%) 4/4 (100%) 
CRM3 73 19% (n=14/73) 11 (78%) 8/11 (73%) 
CRM4 113 15.9% (n=18/113) 15 (83%) 10/15 (70%) 
CRM5 15 40% (n=6/15) 4 (67%) 3/4 (75%) 
CRM6 17 17.65% (n=3/17) 3 (100%) 2/3 (66.7%) 
CRM7 47 12.7% (n=6/47) 6 (100%) 6/6 
CRM8 26 15.4% (n=4/26) 3 (75%) 0/3 
CRM9 26 19.2% (n=5/26) 1 (20%) 0/1 
CRM10 42 11.9% (n=5/42) 4 (80%) 4/4 (100%) 
CRM11 46 10.8% (n=5/46) 3 (60%) 1/5 (33%) 
CRM12 36 30.6% (n=11/36) 6 (45.5%) 6/12 (50%) 
CRM13 42 12% (n=5/42) 
12% 
(n=5/42) 2/5 (40%) 
CRM14 74 21.7% (n=5/24) 12 (75%) 
11/12 
(91.7%) 
  136 
CTCF-V 67 7.5% (n=5/67) 5 (100%) 0 
CRM2_delAB 118 5.9% (n=7/118) 5 (71.4%) 0 
Exon9 51 9.8% (n=5/51) 4 (100%) 0 
Grem1 promoter 
_GRE1 89 
12.4% 
(n=11/89) 0 0 
Grem1_promoter_2.1k
b 66 
7.6% 
(n=5/66) 2 (40%) 1/2 (50%) 
Grem1ORF_700bp 65 20% (n=13/65) 8 (61.5%) 2/8 (25%) 
Grem1PromlacZ 52 9.6% (n=5/52) 60%(n=3/5) 0 
HMCO2_700bp 75 13% (n=10/75) 6 (60%) 3/6 (50%) 
HMCO3 49 16.3% (n=8/49) 6 (75%) 1/6 (16.7%) 
 
9.5.2. Table 2: Reporter assay primers  
 
Target Coordinates 
(mm10) 
Size 
(bp) 
  Sequence (5’ to 3’) 
CRM1 chr2:113,724,49
1-113,724,715 
225 F CACTAAAGGGAACAAAAGCTGGTAC
CGCATGTTTTTGGCCTTCATT 
R TTTGGATGTTCCTGGAGCTCGGTAC
CTGAATCCCGCTATTGGTAGG 
CRM2 chr2:113,689,75
2-113,693,024 
3262 F CACTAAAGGGAACAAAAGCTGGTAC
CTCAGATCTCATCTTTAATGTAGAAA
CC 
R CACTGTTGTTTCAAAACTGCAGAAG
GTAGGGGGAAAC 
chr2:113,692,99
6-113,696,244 
3249 F CTACCTTCTGCAGTTTTGAAACAACA
GTGGGATATTTTG 
R GTTAAAACAAACAACATTTACCTTTG
GGTCTTTCTCTTTG 
chr2:113,696,21
6-113,699,421 
3206 F ACCCAAAGGTAAATGTTGTTTGTTTT
AACCCCACTTC 
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R TCACACAGGTAAGATGGGCCGGGC
CCAGTAGCTTTCGCA TCATGATG 
CRM3 chr2:113,674,07
4-113,675,273 
1246 F CACTAAAGGGAACAAAAGCTGGTAC
CCCGCGTAGTTTCCATTCAAC 
R TTTGGATGTTCCTGGAGCTCGGTAC
CGCAACTGCCTTGAAGGTGAT 
CRM4 chr2:113,640,37
6-113,641,758 
1389 F CACTAAAGGGAACAAAAGCTGGTAC
CTTCCTCAGAGCAGCTGAGTGT 
R TTTGGATGTTCCTGGAGCTCGGTAC
CAGCGCTGAGAATTATAGGCTGA 
CRM5 chr2:113,605,54
2-113,606,069 
528 F CACTAAAGGGAACAAAAGCTGGTAC
CGAAGTCCCTCGAACACCAAG 
R TTTGGATGTTCCTGGAGCTCGGTAC
CCTTTTCCAGCAAGGTGTGGT 
CRM6 chr2:113,595,44
4-113,596,148 
705 F CACTAAAGGGAACAAAAGCTGGTAC
CAGGTGTTGAGCCACTACTGC 
R TTTGGATGTTCCTGGAGCTCGGTAC
CTCATCTTTTGTGAGGGGAAAA 
CRM7 chr2:113,581,14
0-113,581,955 
1029 F CACTAAAGGGAACAAAAGCTGGTAC
CGGTGCTCGAGAGCAGAAGTT 
R TTTGGATGTTCCTGGAGCTCGGTAC
CATACCAGGTGTGGTGGGTGT  
CRM8 chr2:113,575,88
9-113,576,624 
736 F CACTAAAGGGAACAAAAGCTGGTAC
CGGGATGAAAGAACGCCTGTA 
R TTTGGATGTTCCTGGAGCTCGGTAC
CTGTCACTCTCCTGTCCTCCA 
CRM9 chr2:113,537,70
1-113,538,435 
735 F CACTAAAGGGAACAAAAGCTGGTAC
CTCATTCACCGTTGTCCATGT 
R TTTGGATGTTCCTGGAGCTCGGTAC
CTGCATCTTCTGACGCTTGAC 
CRM10 chr2:113,497,60
8-113,498,439 
832 F CACTAAAGGGAACAAAAGCTGGTA 
CCATGGTGTGGAACAAGGCTTC 
R TTTGGATGTTCCTGGAGCTCGGTAC
CTGCATCTTCTGACGCTTGAC 
CRM11 chr2:113,460,27
1-113,461,676 
1406 F GGAACAAAAGCTGGTACCACCTAAG
CCCGTGGGTAC 
R CCTGGAGCTCGGTACCGACAGACA
GACAAGAAAACACTATG 
CRM12 chr2:113,439,96
4-113,441,240 
1277 F GGAACAAAAGCTGGTACCTCTTTCT
CTGTCCCTTCC 
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R CCTGGAGCTCGGTACCGCTCTCTCA
GTTTATCCGC 
CRM13 chr2:113,427,75
5-113,429,093 
1339 F GGAACAAAAGCTGGTACCTTTATGA
GGGTCTGTCTCCTC 
R CCTGGAGCTCGGTACCAGGGACTG
AGGCACAGAG 
CRM14 chr2:113,397,27
2-113,398,270 
999 F GGAACAAAAGCTGGTACCAAGGAAA
TCTGTGGTTGGATAATG 
R CCTGGAGCTCGGTACCAAGGGCAC
ATGATTGTACAG 
CTCF-V chr2:113,648,02
0-113,648,733 
714 F CACTAAAGGGAACAAAAGCTGGTAC
CGTGATGGCCCCAGTTTCTAA 
R TTTGGATGTTCC TGGAGCTCGGTA 
CCTGAGTGGAGTTGACCAGAGC 
Grem1 
ORF 
chr2:113,749,49
0-113,750,190 
701 F CACTAAAGGGAACAAAAGCTGGTAC
CAAGCAACTGCTGGTTCTTCTG 
R TTTGGATGTTCCTGGAGCTCGGTA 
CCTTGTCTGTGTCCCCCTCTCT 
RYR3 chr2:113215912
-113217517 
1606 F AAGGGAACAAAGCTGGTACCTTAAA
AAGGACAGTGCAA G 
R TTTGGATGTTCCTGGAGCTCGGTAC
GGTACCACATGCACCGTGCAA 
Grem1 
Promoter 
chr2:113,757,06
3-113,759,318 
2256 F AACTGAGCAGCCGGGACCGGTGGC 
AAACACTAAGCTGAAG 
R TCATCGCGAGCCATGACCGGTAGAG
GGTATCCTTTTGCAG 
 
 
9.5.3. Table 3: CRISPR/Cas9 deletions coordinates and guides  
 
Deletion Coordinates (mm10)   sgRNa sequence 
Size 
(kb) 
∆CRM2 chr2:113,689,603-113,699,473 
5' AGCGGCAGTTCGGCTTCCGG 
9.9 
3' TCTCATACGATCCAGGAGAA 
∆CRM3 chr2:113,672,786-113,681,077 
5' CACCGCCTGTGATCCATCGAATGCC 
8.6 
3' AAACGGCATTCGATGGATCACAGGC 
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∆CRM4 chr2:113,640,518-113,641,588 
5' CACCGCAGCCTATAATTCTCAGCGC 
1.3 
3' AAACGCGCTGAGAATTATAGGCTGC 
∆CRM5 chr2:113,603,760-113,606,572 
5' CTTGTAATGCTAGGACGGCC  
2.8 
3' AGTCAAGGACACACCTGTA  
∆EC1 chr2:113,636,776-113,707,974 
5' CACCGTGGCTTACCAGACTAGCGGT 
71.2 
3' CACCGAATGGTCTGATCGCCA 
∆EC2 chr2:113,572,310-113,606,574 
5' TTCAGCTGCATTGCGTCCTA 
34 
3' AGTCAAGGACACACGCTGTA 
F1∆1019 chr2:113,528,475 -113,636,771 
5' CACCGGTCTTTCAGGAACTCCCCGG 
108 
3' CCAGAAAGTCCTTGAGGGGC 
 
9.5.4. Table 4: Genotyping Primers  
 
Locus Forward Reverse Size (bp) Allele 
Cis 
GGGCGGATCTCAAACT
C TCCTC  
CTGCATTCTAGTTGTGGT
TTGTCC  350 ∆ 
GAAAGACTGCTGCAGAA
GGAAGC 
TCC AAA GAA GGC ACA 
GGG GAC TT 200 WT 
CRM12 
CTCCCATATGCTCACCG
GTTT 
GGAAAATCCCTGCCCAA
GAGA 908 ∆ 
CTCCCATATGCTCACCG
GTTT 
GGTGGGAGTGGAGTTTG
ACC 429 WT 
CRM2 
AACAAACAGTGCAATTC
TGAAGAG 
AGGAAGCCAGTGATCTC
AAATATC 605 ∆ 
GACTGGGATACATGTGA
TGGTAAA 
AGGAAGCCAGTGATCTC
AAATATC 932 WT 
CRM3 
CCTTTACATGCACACTC
ACACA 
TGCTTTGGATGTCTACAA
GTGG  
2.4k
b ∆ 
AGCAGTGTGTCCCCCTA
ATGAGC 
GAGCCTGGAGCTTACTG
AGCAAC 389 WT 
  140 
CRM4 
AATTGAAGGAACAAAAG
GCTCA 
GGCTGACAGTAGTTTGC
TGTTG 205 ∆ 
GGCCTTCGAAACCATGA
TGC 
GGGAGGTGCTGGAATTA
GGG 513 WT 
EC1 
GGGACAAGTCACAGAT
CTTTTTG  
TCCTTCATGTCTCGTTTT
GTTTT 439 ∆ 
TCCAGTTAAATGCAAAA
AGGAAA 
CTCTTCCTTCATCTCTCC
TAGCC  593 WT 
EC2 
AGAAGCACTTGGCATGT
GATG 
GGAAATTCAGAGCCATC
CAA 750 ∆ 
AGAAGCACTTGGCATGT
GATG 
TGAAAGAGTCGGCAACT
GTG 500 WT 
F1∆10
19 
TCCTCAGCAGTCACCTC
CTG 
AGGTCATCTCAGTCCAG
GGG 569 ∆ 
TCCTCAGCAGTCACCTC
CTG 
GAG GGA GGG AGG GAA 
GGA AT 609 WT 
Grem1 
ATGAATCGCACCGCATA
CACTG 
TCCAAGTCGATGGATATG
CAACG 600 ∆ 
CCCAGGAGGCACATGG
AACACAA 
GGCACATGGCTGAATAT
CGACGG 700 WT 
Tg-
GLE 
AATTCCTTACTGGCTCC
TGACAC 
CCAGAGAAATTAAAGACC
TACCTGG 542 lacZ 
CAACGGGTTCTTCTGTT
AGTCC 
CCAGAGAAATTAAAGACC
TACCTGG 570 WT 
 
 
9.5.5.  Table 5: Software and algorithms table 
 
Software / 
Algorithms Provider website 
Adobe 
Illustrator CS6 Adobe System 
https://www.adobe.com/products/illustra
tor.html 
Adobe 
photoshop 
CS6 
Adobe System https://www.adobe.com/products/photoshop.html 
CRISPOR Maximilian Haeussle et al., 2016 http://crispor.tefor.net/ 
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Galaxy 
CyVerse, Advanced 
Computing Center 
Texas 
https://usegalaxy.org/ 
GraphPad 
Prism 7 
GraphPad Software, 
Inc 
https://www.graphpad.com/scientific-
software/prism/ 
HOMER 4.8.1 Heinz et al., 2010 N/A 
Leica 
Application 
Suite V3 
software 
Leica Microsystems 
https://www.leica-
microsystems.com/products/microscop
e-software/details/product/leica-
application-suite/ 
liftOver Hinrichs et al., 2006 N/A 
NIS Elements 
Basic 
Research 
Nikon 
https://www.microscope.healthcare.niko
n.com/products/software/nis-
elements/nis-elements-basic-research 
UCSC Kent et al., 2002 http://genome.ucsc.edu/cite.html 
3D Genome 
Browser Yue Lab 
http://promoter.bx.psu.edu/hi-
c/view.php 
Universal 
ProbeLibrary 
Assay Design 
Center 
ROCHE 
https://lifescience.roche.com/en_ch/bra
nds/universal-probe-library.html#assay-
design-center 
 
9.5.6. Table 6: RT-qPCR Primers table 
 
Target Forward Reverse Size (bp) 
Gli1 CAAGTGCACGTTTGAAG CAACCTTCTTGCTCACACATGTAAG 76 
Rpl19 ACCCTGGCCCGACGG TACCCTTTCCTCTTCCCTATGCC  53 
BMP4 AGCCGAGCCAACACT GTGA 
GTTCTCCAGATGTTCTTCGT
G 51 
Grem1  CCCACGGAAGTGACAGAA TGA 
AAGCAACGCTCCCACAGTG
TA 53 
HMBS TCTAGATGGCTCAGATAGCATGCA 
TGGACCATCTTCTTGCTGAA
CA 76 
ID1 GCGAGATCAGTGCCTTGG CTCCTGAAGGGCTGGAGT 111 
  142 
Shh GAGGTGCAAAGACAAGTT AAATGC 
GGCCACTGGTTCATCACAG
AG 57 
SMOC1 GATAAGGTCATCTCACTGCCTGA AAGCTGCCAAGGCTACCAC 74 
 
9.5.7. Table 7: ChIP-qPCR Primers table 
 
Primer 
Name 
Coordinates 
(mm10) Forward Reverse 
% 
Eff.  
Size 
(bp) 
CRM1 chr2:113724513-113724657  
ACCACCCCAGTC
GCCTATAT 
TGTCCCCTCCCC
TTTGATCT 88.3 145 
CRM12 chr2:113440509-113440601 
TCCAGATGAAAC
CTGCCAGC 
GAGTGCCCACAA
CTCTGAGA 98.1 93 
CRM14 chr2:113397688-113397758  
TCCCAAGGTTTC
AAAGCCAGA 
GCAGGGCCATG
AAACTTGAA 88.0 71 
CRM2 
A Bcat 
chr2:1136919
21-113692000 
TAATAGTCACAG
GGCTTCGGG 
TGTGGCCATCCT
GAATACTGAG 97.0 80 
CRM2 
A GLI 
chr2:1135322
91-113532421  
GAAGCTTGGAGT
GGGTGAGG 
TGAAGGCATGCT
GTCCACTT 84.3 131 
CRM2 
B 
chr2:1136934
79-113693578 
TGG CAG ACA 
GTA CAG ACA AA 
TGTGTGAAGTGT 
GGCCTGAG 
104.
8 100 
CRM2 
D 
chr2:1136934
71-113693578 
CCTTGCTGTGGC
AGACAGTA 
TGTGTGAAGTGT
GGCCTGAG 86.9 108 
CRM2 
Neg 
chr2:1136907
22-113690834  
CCCCTTGAAAAC
ACACACACA 
TGGCCTGGGGAT
TTCTCTTTC 
100.
0 113 
CRM3 chr2:113674690-113674805 
GAATAAAGTTAG 
TGACCC GCCA 
GCAAAGCCCAGA
TTAATTCCCC 99.5 116 
CRM4 chr2:113640898-113640993 
CCTGTGCAGCC
ATTTGTGTG 
GCATCATGGTTT
CGAAGGCC 
102.
3 96 
CRM5 chr2:113605801-113605890 
TAAGGCCTTGGT
GTGAACCC 
ACCTCAAAGCCT
CATCAAATCTT 95.4 90 
CRM6 chr2:113595746-113595859  
GGGAAGGGAAA
TACACAGGCA 
GCCAAGCTACTT
TATGACCCTG 91.0 114 
CRM7 chr2:113581322-113581412  
GGCCCGGCTAA
TTTCAAACAC 
TCCTTCCCAGAT
ACGTTCGGA 97.0 91 
CRM7 chr2:113581688-113581768 
CCCTTCCTGGTA
ATGGGCAA 
AAGTCTTTCTTCC
CGGCTGG 95.7 81 
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CRM8 chr2:113576238-113576348 
ACCCAATAAAGT
TCCCGGCT 
TAGTTGTTCCCG
CCTCACAC 95.3 111 
CRM9 chr2:113538009-113538078 
TGCATGGCTGTA
AACACGAG 
GGGGTCTCAGGT
TTCTTTTGC 86.1 70 
CTCF V chr2:113648274-113648362 
CAGTGACAGAG
GAGACGTTCA 
GTGACGTTGTGG
ATTTTGGCA 
103.
0 89 
Fmn1 chr2:113573195-113573335 
AGCATGTTGTCT
TTCCTCCCA 
TGAAGGGCGGT
GTAAGGAAG 93.6 141 
Grem1 
int GLI3 
chr2:1137580
14-113758094  
AGCCCTGTACCC
AACTCTCA 
GGAGCTGGCATC
TCTGTGAG 97.6 81 
Grem1 
exon2 
chr2:1137492
07-113749297 
TTCCGAGTCTAA
TGCAGCCC 
TGTGTTCCATGT
GCC CCTG 87.4 91 
HMCO3 chr2:113618867-113618997  
AGCATCCCATTG
TACAGCGA 
GGGCCACATTGT
CAATTCGC 98.8 131 
KP*-
Ptch 
chr13:635628
38-63562988 
CCCCTCCCATCA
AACTTGCT 
GCACAAACTGGA
ACGCATGT 85.5 151 
KP*-
Ptch1-p7 
chr13:637196
77-63719827 
TATCTTGCAAAT
TGGAGGCTTTCG 
ACATCTGATAAG
CAGCCCCAGAAC 80.4 150 
KP*-
Ptch1-p9 
chr13:639804
51-63980649 
GGTCCTGCCTTG
ATTGCTAA 
GGGAGTGGAGA
TGACTGGGA 89.9 199 
Neg 
LRM 
chr2:1136950
93-113695179 
TGATCTAATGCG
AACTTGTGGT 
TGTATGGATGTT 
CAGAA TGCCT 80.2 87 
*: designed by dr. Kevin Peterson 
 
9.5.8. Table 8: 4C-seq primers table 
 
Name Sequence 
Grem1_C
1_TUA 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGA
CGCTCTTCCGATCTCTTCCGTAGATGCTGGCCGAT  
Grem1_C
6_index12 
CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTC
AGACGTGTGCTCTTCCGATCTAAGCACCAGGACCGAGTTTG 
Grem1_C
6_index2  
CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTC
AGACGTGTGCTCTTCCGATCTAAGCACCAGGACCGAGTTTG 
Grem1_C
6_index4  
CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATCTAAGCACCAGGACCGAGTTTG 
Grem1_C
6_index5  
CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATCTAAGCACCAGGACCGAGTTTG 
  144 
Grem1_C
6_index6 
CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATCTAAGCACCAGGACCGAGTTTG 
Grem1_C
6_index7 
CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATCTAAGCACCAGGACCGAGTTTG 
Grem1_C
6_index9 
CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATCTAAGCACCAGGACCGAGTTTG 
 
9.5.9.  Table 9: 4C-seq qPCR primers   
 
Primer 
Name 
Coordinates 
(mm10) Forward Reverse 
% 
Eff.  
Size 
(bp) 
4CqPC
R 
chr2:11372451
3-113724657  
TTGGACCAATTA
GTGCATCTGT 
AACCTAGCCTCT
CAGGTCTCG 111 64 
 
9.5.10. Table 10: WISH probes  
 
Gene Forward Reverse Size (bp) 
ID1 CTCAGGAGACAGCTCAGTGTACC 
CTAACTCAAGCCAGACCCC
CTAC 71 
Grem1 ATGAATCGCACCGCATACACTG 
TCCAAGTCGATGGATATGCA
ACG 500 
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9.5.11. Table 11: Antibodies   
 
Antibody Catalogue number Manufacturer 
Monoclonal ANTI-FLAG® AN F1804 Sigma 
Anti-Digoxigenin-AP, Fab fragments 11093274910 Sigma 
Beta catenin polyclonal antibody 71-2700 Thermofisher 
Biotin Ep-CAM  
  
clone G8.8 
ref.118204 BioLegend 
Biotin TER-119 clone TER-119 ref.116204 BioLegend 
Biotin CD31  clone 390 ref.102404 BioLegend 
Biotin CD45  clone 30-F11 ref.103104 BioLegend 
Biotin CD11b  clone M1/70 ref.101204 BioLegend 
Biotin Gr-1 clone RB6-8C5 ref.108403 BioLegend 
APC/Cy7 Streptavidin 405208 BioLegend 
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12.  Appendixes 
 
 
 
Appendixes Figure 1. Identification Grem1 topologically-associated domain. 
Upper panel: Hi-C map (Barutcu et al., 2018) obtained from mouse embryonic 
fibroblasts with a 10kb resolution show the distribution of TADs on either side of Grem1 
gene in black, other genes are represented in dark grey lines, dashed lines indicate 
TADs, E10.5 mouse forelimb bud CTCF ChIP-Seq (Andrey et al., 2017) identify CTCF 
binding sites, their orientation are represented with orange and green arrowheads. 
Blue and grey dashed lines unveil a potential Grem1 TAD and a potential Fmn1 TAD 
respectively. E10.5 mouse forelimb bud RNA-Seq (Andrey et al., 2017) shows the 
transcriptional activity of Grem1 neighboring genes. Lower panel: WISH performed by 
Victorio Palacio and Laurène Ramos Martins showing the limb expression of Grem1 
TAD genes (n=3). Scale bar: 250µm 
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Appendixes Figure 2. LacZ expression in the Grem1-promoter lacZ transgenic 
embryos forelimb at E11.5. (a): E11.5 forelimb bud ATAC-seq profile, ChIP-seq 
profiles obtain from E11.5 mouse forelimb bud tissue targeting the promoter histone 
mark H3K4me3 (Sheth et al., 2016) on a 60kb region centered on Grem1, the red 
dashed box highlight Grem1 promoter. (b) Grem1_promoter_lacZ plasmid transgenic 
embryos collected at E11.5, blue numbers show limb expressers. Scale bar: 500µm 
 
 
 
Appendixes Figure 3. Grem1 WISH at early developmental stage E9.75 (26-28ss) 
stage is quite variable. Grem1 WISH on 4 forelimbs buds at 26-28ss. Scale bar: 
250µm 
 
 
 
Appendixes Figure 4. Grem1 WISH at developmental stage E10.75 (39ss) for 
CRM2∆/∆ mutants. Grem1 WISH on 2 wild-type forelimbs buds at 26-28ss in 
comparison with two CRM2∆/∆ forelimb buds at the same stage. Scale bar: 250µm 
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Appendixes Figure 5. Grem1 WISH on E10.5 WT and CRM2CRM3∆/∆ mutants 
forelimb buds Grem1 WISH on wild-type forelimbs buds at 35-36ss in comparison 
with CRM2CRM3∆/∆ forelimbs at the same stage Scale bar: 250µm 
 
 
 
 
Appendixes Figure 6. Identification of cohesin binding site in the Grem1/Fmn1 
landscape. Peak calling from ChIP-seq experiments targeting cohesin subunit 
SMC1a (Demare et al., 2013) compared to CTCF binding sites at E11.5 in mouse FL 
(Andrey et al., 2017). Orange and green arrowheads represent CTCF motifs 
orientation.  
 
 
 
Appendixes Figure 7. ChIP-seq revealing cohesin binding at CRM9 in mouse 
forelimb at E11.5 SMC1 (Demare et al., 2013) is a subunit of cohesin, ChIP-seq peak 
calling of SMC1 reveal cohesin binding site. CTCF ChIP-seq Andrey et al., 2017) on 
the lower track shows no overlapping with CRM9 locus. (coordinates mm10 
chr2:113,529,824-113,542,826)  
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Appendixes Figure 8. Grem1 WISH at E10.5 in WT and SMAD4 depleted forelimb 
(Gamart et al., manuscript in preparation). Comparison of Grem1 expression 
domain in WT versus SMAD4 depleted forelimb bud at E10.5 (n=3). Scale bar: 250µm 
 
 
Appendixes Figure 9. CRM5 at E10.5 did not bind GLI proteins. Alignment of GLI3 
ChIP-seq (in collaboration with Dr. Kevin Peterson) with the CRM5 locus in wild-type 
forelimb buds at E10.5. 
 
 
 
Appendixes Figure 10. Tbx2 WISH at E11 in WT, CRM2, EC1 and Cis 
homozygous forelimb buds. From left to right: Tbx2 territory is broad in the anterior 
and posterior proximal wild-type limb bud at E11.0, in comparison, its territory is 
reduced in CRM2∆/∆ and EC1∆/∆ Scale bar: 250µm 
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Appendixes Figure 11. RT-qPCR analyses of the BMP pathway antagonist 
Smoc1 transcription in our homozygous mutant’s forelimb buds at E11.0. WT 
and homozygous mutant handpates at E11.0 were dissected from littermates 
embryos. Red dotted boxes highlight mutants with significant changes (n=7; mean ± 
SEM, two-tailed Mann-Whitney test), p-values are indicated on top. 
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Genotype Sample size  Forelimb phenotype 
Cis∆/∆ 9 100% oligosyndactyly (3 digits) 
CRM2CRM3∆/∆ 4 100% soft-tissue syndactyly 
CRM2CRM4∆/∆ 3 100% soft-tissue syndactyly 
CRM2CRM5∆/∆ 3 no phenotype 
CRM5∆/∆ 10 no phenotype 
EC1∆/∆ 12 
20% C-L type syndactyly (4 
digits)- 80% soft-tissue syndactyly 
(digits 2-3)  
EC1CRM5∆/∆ 10 100% (4 digits)  
EC1EC2∆/∆ 7 100% oligosyndactyly (3 digits) 
EC2∆/∆ 9 no phenotype 
Grem1∆/∆ 2 100% oligosyndactyly (3 digits) 
 
Appendixes Table 1. Skeletal phenotype scoring. List of each homozygous 
mutants generated in this study and their associated limb phenotype 
